Compounds and methods for treatment and diagnosis of chlamydial infection

ABSTRACT

Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a  Chlamydia  antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.10/872,155 filed Jun. 18, 2004; which is a continuation of U.S. patentapplication Ser. No. 09/841,132 filed Apr. 23, 2001 (now abandoned);which is a continuation-in-part of U.S. patent application Ser. No.09/620,412, filed Jul. 20, 2000 (now U.S. Pat. No. 6,448,234); which isa continuation-in-part of 09/598,419, filed Jun. 20, 2000 (now U.S. Pat.No. 6,565,856); which is a continuation-in-part of U.S. patentapplication Ser. No. 09/556,877, filed Apr. 19, 2000 (now U.S. Pat. No.6,432,916); which is a continuation-in-part of U.S. patent applicationSer. No. 09/454,684, filed Dec. 3, 1999 (now abandoned); which is acontinuation-in-part of U.S. patent application Ser. No. 09/426,571,filed Oct. 22, 1999 (now abandoned); which is a continuation-in-part ofU.S. patent application Ser. No. 09/410,568, filed Oct. 1, 1999 (nowU.S. Pat. No. 6,555,115); which is a continuation-in-part of U.S. patentapplication Ser. No. 09/288,594, filed Apr. 8, 1999 (now U.S. Pat. No.6,447,779); which is a continuation-in-part of U.S. patent applicationSer. No. 09/208,277, filed Dec. 8, 1998 (now U.S. Pat. No. 6,166,177),which applications are incorporated herein by reference in theirentireties.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy, and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is 210121_(—)469C17—SEQUENCE_LISTING.txt. The textfile is 1120 KB, was created on Oct. 30, 2007, and is being submittedelectronically via EFS-Web, concurrent with the filing of thespecification.

TECHNICAL FIELD

The present invention relates generally to the detection and treatmentof Chlamydial infection. In particular, the invention is related topolypeptides comprising a Chlamydia antigen and the use of suchpolypeptides for the serodiagnosis and treatment of Chlamydialinfection.

BACKGROUND OF THE INVENTION

Chlamydiae are intracellular bacterial pathogens that are responsiblefor a wide variety of important human and animal infections. Chlamydiatrachomatis is one of the most common causes of sexually transmitteddiseases and can lead to pelvic inflammatory disease (PID), resulting intubal obstruction and infertility. Chlamydia trachomatis may also play arole in male infertility. In 1990, the cost of treating PID in the USwas estimated to be $4 billion. Trachoma, due to ocular infection withChlamydia trachomatis, is the leading cause of preventable blindnessworldwide. Chlamydia pneumonia is a major cause of acute respiratorytract infections in humans and is also believed to play a role in thepathogenesis of atherosclerosis and, in particular, coronary heartdisease. Individuals with a high titer of antibodies to Chlamydiapneumonia have been shown to be at least twice as likely to suffer fromcoronary heart disease as seronegative individuals. Chlamydialinfections thus constitute a significant health problem both in the USand worldwide.

Chlamydial infection is often asymptomatic. For example, by the time awoman seeks medical attention for PID, irreversible damage may havealready occurred resulting in infertility. There thus remains a need inthe art for improved vaccines and pharmaceutical compositions for theprevention and treatment of Chlamydia infections. The present inventionfulfills this need and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for thediagnosis and therapy of Chlamydia infection. In one aspect, the presentinvention provides polypeptides comprising an immunogenic portion of aChlamydia antigen, or a variant of such an antigen. Certain portions andother variants are immunogenic, such that the ability of the variant toreact with antigen-specific antisera is not substantially diminished.Within certain embodiments, the polypeptide comprises an amino acidsequence encoded by a polynucleotide sequence selected from the groupconsisting of (a) a sequence of SEQ ID NO: 358-361; (b) the complementsof said sequences; and (c) sequences that hybridize to a sequence of (a)or (b) under moderate to highly stringent conditions. In specificembodiments, the polypeptides of the present invention comprise at leasta portion of a Chlamydial protein that includes an amino acid sequenceselected from the group consisting of sequences recited in SEQ IDNO:362-365 and variants thereof.

The present invention further provides polynucleotides that encode apolypeptide as described above, or a portion thereof (such as a portionencoding at least 15 amino acid residues of a Chlamydial protein),expression vectors comprising such polynucleotides and host cellstransformed or transfected with such expression vectors.

In a related aspect, polynucleotide sequences encoding the abovepolypeptides, recombinant expression vectors comprising one or more ofthese polynucleotide sequences and host cells transformed or transfectedwith such expression vectors are also provided.

In another aspect, the present invention provides fusion proteinscomprising an inventive polypeptide, or, alternatively, an inventivepolypeptide and a known Chlamydia antigen, as well as polynucleotidesencoding such fusion proteins, in combination with a physiologicallyacceptable carrier or immunostimulant for use as pharmaceuticalcompositions and vaccines thereof.

The present invention further provides pharmaceutical compositions thatcomprise: (a) an antibody, both polyclonal and monoclonal, orantigen-binding fragment thereof that specifically binds to a Chlamydialprotein; and (b) a physiologically acceptable carrier. Within otheraspects, the present invention provides pharmaceutical compositions thatcomprise one or more Chlamydia polypeptides disclosed herein, e.g., apolypeptide according to SEQ ID NO:362-365, 431-454 and 560-581, or apolynucleotide molecule encoding such a polypeptide, such as apolynucleotide according to SEQ ID NO:358-361, 407-430, 525-559 and582-598, and a physiologically acceptable carrier. The invention alsoprovides vaccines for prophylactic and therapeutic purposes comprisingone or more of the disclosed polypeptides and an immunostimulant, asdefined herein, together with vaccines comprising one or morepolynucleotide sequences encoding such polypeptides and animmunostimulant.

In yet another aspect, methods are provided for inducing protectiveimmunity in a patient, comprising administering to a patient aneffective amount of one or more of the above pharmaceutical compositionsor vaccines.

In yet a further aspect, methods for the treatment of Chlamydiainfection in a patient are provided, the methods comprising obtainingperipheral blood mononuclear cells (PBMC) from the patient, incubatingthe PBMC with a polypeptide of the present invention (or apolynucleotide that encodes such a polypeptide) to provide incubated Tcells and administering the incubated T cells to the patient. Thepresent invention additionally provides methods for the treatment ofChlamydia infection that comprise incubating antigen presenting cellswith a polypeptide of the present invention (or a polynucleotide thatencodes such a polypeptide) to provide incubated antigen presentingcells and administering the incubated antigen presenting cells to thepatient. Proliferated cells may, but need not, be cloned prior toadministration to the patient. In certain embodiments, the antigenpresenting cells are selected from the group consisting of dendriticcells, macrophages, monocytes, B-cells, and fibroblasts. Compositionsfor the treatment of Chlamydia infection comprising T cells or antigenpresenting cells that have been incubated with a polypeptide orpolynucleotide of the present invention are also provided. Withinrelated aspects, vaccines are provided that comprise: (a) an antigenpresenting cell that expresses a polypeptide as described above and (b)an immunostimulant.

The present invention further provides, within other aspects, methodsfor removing Chlamydial-infected cells from a biological sample,comprising contacting a biological sample with T cells that specificallyreact with a Chlamydial protein, wherein the step of contacting isperformed under conditions and for a time sufficient to permit theremoval of cells expressing the protein from the sample.

Within related aspects, methods are provided for inhibiting thedevelopment of Chlamydial infection in a patient, comprisingadministering to a patient a biological sample treated as describedabove. In further aspects of the subject invention, methods anddiagnostic kits are provided for detecting Chlamydia infection in apatient. In one embodiment, the method comprises: (a) contacting abiological sample with at least one of the polypeptides or fusionproteins disclosed herein; and (b) detecting in the sample the presenceof binding agents that bind to the polypeptide or fusion protein,thereby detecting Chlamydia infection in the biological sample. Suitablebiological samples include whole blood, sputum, serum, plasma, saliva,cerebrospinal fluid and urine. In one embodiment, the diagnostic kitscomprise one or more of the polypeptides or fusion proteins disclosedherein in combination with a detection reagent. In yet anotherembodiment, the diagnostic kits comprise either a monoclonal antibody ora polyclonal antibody that binds with a polypeptide of the presentinvention.

The present invention also provides methods for detecting Chlamydiainfection comprising: (a) obtaining a biological sample from a patient;(b) contacting the sample with at least two oligonucleotide primers in apolymerase chain reaction, at least one of the oligonucleotide primersbeing specific for a polynucleotide sequence disclosed herein; and (c)detecting in the sample a polynucleotide sequence that amplifies in thepresence of the oligonucleotide primers. In one embodiment, theoligonucleotide primer comprises at least about 10 contiguousnucleotides of a polynucleotide sequence peptide disclosed herein, or ofa sequence that hybridizes thereto.

In a further aspect, the present invention provides a method fordetecting Chlamydia infection in a patient comprising: (a) obtaining abiological sample from the patient; (b) contacting the sample with anoligonucleotide probe specific for a polynucleotide sequence disclosedherein; and (c) detecting in the sample a polynucleotide sequence thathybridizes to the oligonucleotide probe. In one embodiment, theoligonucleotide probe comprises at least about 15 contiguous nucleotidesof a polynucleotide sequence disclosed herein, or a sequence thathybridizes thereto.

These and other aspects of the present invention will become apparentupon reference to the following detailed description.

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in the Application Data Sheet, are incorporated herein byreference, in their entirety.

Sequence Identifiers

SEQ ID NO: 1 is the determined DNA sequence for the C. trachomatis clone1-B1-66.

SEQ ID NO: 2 is the determined DNA sequence for the C. trachomatis clone4-D7-28.

SEQ ID NO: 3 is the determined DNA sequence for the C. trachomatis clone3-G3-10.

SEQ ID NO: 4 is the determined DNA sequence for the C. trachomatis clone10-C10-31.

SEQ ID NO: 5 is the predicted amino acid sequence for 1-B1-66.

SEQ ID NO: 6 is the predicted amino acid sequence for 4-D7-28.

SEQ ID NO: 7 is a first predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 8 is a second predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 9 is a third predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 10 is a fourth predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 11 is a fifth predicted amino acid sequence for 3-G3-10.

SEQ ID NO: 12 is the predicted amino acid sequence for 10-C10-31.

SEQ ID NO: 13 is the amino acid sequence of the synthetic peptide1-B1-66/48-67.

SEQ ID NO: 14 is the amino acid sequence of the synthetic peptide1-B1-66/58-77.

SEQ ID NO: 15 is the determined DNA sequence for the C. trachomatisserovar LGV II clone 2C7-8

SEQ ID NO: 16 is a DNA sequence of a putative open reading frame from aregion of the C. trachomatis serovar D genome to which 2C7-8 maps

SEQ ID NO: 17 is the predicted amino acid sequence encoded by the DNAsequence of SEQ ID NO: 16

SEQ ID NO: 18 is the amino acid sequence of the synthetic peptideCtC7.8-12

SEQ ID NO: 19 is the amino acid sequence of the synthetic peptideCtC7.8-13

SEQ ID NO: 20 is the predicted amino acid sequence encoded by a secondputative open reading from C. trachomatis serovar D

SEQ ID NO: 21 is the determined DNA sequence for clone 4C9-18 from C.trachomatis LGV II

SEQ ID NO: 22 is the determined DNA sequence homologous to LipoamideDehydrogenase from C. trachomatis LGV II

SEQ ID NO: 23 is the determined DNA sequence homologous to Hypotheticalprotein from C. trachomatis LGV II

SEQ ID NO: 24 is the determined DNA sequence homologous to UbiquinoneMethyltransferase from C. trachomatis LGV II

SEQ ID NO: 25 is the determined DNA sequence for clone 4C9-18#2 BL21pLysS from C. trachomatis LGV II

SEQ ID NO: 26 is the predicted amino acid sequence for 4C9-18#2 from C.trachomatis LGV II

SEQ ID NO: 27 is the determined DNA sequence for Cp-SWIB from C.pneumonia strain TWAR

SEQ ID NO: 28 is the predicted amino acid sequence for Cp-SWIB from C.pneumonia strain TWAR

SEQ ID NO: 29 is the determined DNA sequence for Cp-S13 (CT509) from C.pneumonia strain TWAR

SEQ ID NO: 30 is the predicted amino acid sequence for Cp-S13 from C.pneumonia strain TWAR

SEQ ID NO: 31 is the amino acid sequence for a 10 mer consensus peptidefrom CtC7.8-12 and CtC7.8-13

SEQ ID NO: 32 is the predicted amino acid sequence for clone 2C7-8 fromC. trachomatis LGV II

SEQ ID NO: 33 is the DNA sequence corresponding to nucleotides597304-597145 of the C. trachomatis serovar D genome (NCBI, BLASTNsearch), which shows homology to clone 2C7-8

SEQ ID NO: 34 is the predicted amino acid sequence encoded by thesequence of SEQ ID NO: 33 SEQ ID NO: 35 is the DNA sequence for C.p.SWIB Nde (5′ primer) from C. pneumonia

SEQ ID NO: 36 is the DNA sequence for C.p. SWIB EcoRI (3′ primer) fromC. pneumonia

SEQ ID NO: 37 is the DNA sequence for C.p. S13 Nde (5′ primer) from C.pneumonia

SEQ ID NO: 38 is the DNA sequence for C.p. S13 EcoRI (3′ primer) from C.pneumonia

SEQ ID NO: 39 is the amino acid sequence for CtSwib 52-67 peptide fromC. trachomatis LGV II

SEQ ID NO: 40 is the amino acid sequence for CpSwib 53-68 peptide fromC. pneumonia

SEQ ID NO: 41 is the amino acid sequence for HuSwib 288-302 peptide fromHuman SWI domain

SEQ ID NO: 42 is the amino acid sequence for CtSWI-T 822-837 peptidefrom the topoisomerase-SWIB fusion of C. trachomatis

SEQ ID NO: 43 is the amino acid sequence for CpSWI-T 828-842 peptidefrom the topoisomerase-SWIB fusion of C. pneumonia

SEQ ID NO: 44 is a first determined DNA sequence for the C. trachomatisLGV II clone 19783.3,jen.seq(1>509)CTL2#11-3′, representing the 3′ end.

SEQ ID NO: 45 is a second determined DNA sequence for the C. trachomatisLGV II clone 19783.4,jen.seq(1>481)CTL2#11-5′, representing the 5′ end.

SEQ ID NO: 46 is the determined DNA sequence for the C. trachomatis LGVII clone 19784CTL2_(—)12consensus.seq(1>427)CTL2#12.

SEQ ID NO: 47 is the determined DNA sequence for the C. trachomatis LGVII clone 19785.4,jen.seq(1>600)CTL2#16-5′, representing the 5′ end.

SEQ ID NO: 48 is a first determined DNA sequence for the C. trachomatisLGV II clone 19786.3,jen.seq(1>600)CTL2#18-3′, representing the 3′ end.

SEQ ID NO: 49 is a second determined DNA sequence for the C. trachomatisLGV II clone 19786.4,jen.seq(1>600)CTL2#18-5′, representing the 5′ end.

SEQ ID NO: 50 is the determined DNA sequence for the C. trachomatis LGVII clone 19788CTL2_(—)21consensus.seq(1>406)CTL2#21.

SEQ ID NO: 51 is the determined DNA sequence for the C. trachomatis LGVII clone 19790CTL2_(—)23consensus.seq(1>602)CTL2#23.

SEQ ID NO: 52 is the determined DNA sequence for the C. trachomatis LGVII clone 19791CTL2_(—)24consensus.seq(1>145)CTL2#24.

SEQ ID NO: 53 is the determined DNA sequence for the C. trachomatis LGVII clone CTL2#4.

SEQ ID NO: 54 is the determined DNA sequence for the C. trachomatis LGVII clone CTL2#8b.

SEQ ID NO: 55 is the determined DNA sequence for the C. trachomatis LGVII clone 15-G1-89, sharing homology to the lipoamide dehydrogenase geneCT557.

SEQ ID NO: 56 is the determined DNA sequence for the C. trachomatis LGVII clone 14-H1-4, sharing homology to the thiol specific antioxidantgene CT603.

SEQ ID NO: 57 is the determined DNA sequence for the C. trachomatis LGVII clone 12-G3-83, sharing homology to the hypothetical protein CT622.

SEQ ID NO: 58 is the determined DNA sequence for the C. trachomatis LGVII clone 12-B3-95, sharing homology to the lipoamide dehydrogenase geneCT557.

SEQ ID NO: 59 is the determined DNA sequence for the C. trachomatis LGVII clone 11-H4-28, sharing homology to the dnaK gene CT396.

SEQ ID NO: 60 is the determined DNA sequence for the C. trachomatis LGVII clone 11-H3-68, sharing partial homology to the PGP6-D virulenceprotein and L1 ribosomal gene CT318.

SEQ ID NO: 61 is the determined DNA sequence for the C. trachomatis LGVII clone 11-G1-34, sharing partial homology to the malate dehydrogenasegene CT376 and to the glycogen hydrolase gene CT042.

SEQ ID NO: 62 is the determined DNA sequence for the C. trachomatis LGVII clone 11-G10-46, sharing homology to the hypothetical protein CT610.

SEQ ID NO: 63 is the determined DNA sequence for the C. trachomatis LGVII clone 11-C12-91, sharing homology to the OMP2 gene CT443.

SEQ ID NO: 64 is the determined DNA sequence for the C. trachomatis LGVII clone 11-A3-93, sharing homology to the HAD superfamily gene CT103.

SEQ ID NO: 65 is the determined amino acid sequence for the C.trachomatis LGV II clone 14-H1-4, sharing homology to the thiol specificantioxidant gene CT603.

SEQ ID NO: 66 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#9.

SEQ ID NO: 67 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#7.

SEQ ID NO: 68 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#6.

SEQ ID NO: 69 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#5.

SEQ ID NO: 70 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#2.

SEQ ID NO: 71 is the determined DNA sequence for the C. trachomatis LGVII clone CtL2#1.

SEQ ID NO: 72 is a first determined DNA sequence for the C. trachomatisLGV II clone 23509.2CtL2#3-5′, representing the 5′ end.

SEQ ID NO: 73 is a second determined DNA sequence for the C. trachomatisLGV II clone 23509.1CtL2#3-3′, representing the 3′ end.

SEQ ID NO: 74 is a first determined DNA sequence for the C. trachomatisLGV II clone 22121.2CtL2#10-5′, representing the 5′ end.

SEQ ID NO: 75 is a second determined DNA sequence for the C. trachomatisLGV II clone 22121.1CtL2#10-3′, representing the 3′ end.

SEQ ID NO: 76 is the determined DNA sequence for the C. trachomatis LGVII clone 19787.6CtL2#19-5′, representing the 5′ end.

SEQ ID NO: 77 is the determined DNA sequence for the C. pneumoniae LGVII clone CpS13-His.

SEQ ID NO: 78 is the determined DNA sequence for the C. pneumoniae LGVII clone Cp_SWIB-His.

SEQ ID NO: 79 is the determined DNA sequence for the C. trachomatis LGVII clone 23-G7-68, sharing partial homology to the L11, L10 and L1ribosomal protein.

SEQ ID NO: 80 is the determined DNA sequence for the C. trachomatis LGVII clone 22-F8-91, sharing homology to the pmpC gene.

SEQ ID NO: 81 is the determined DNA sequence for the C. trachomatis LGVII clone 21-E8-95, sharing homology to the CT610-CT613 genes.

SEQ ID NO: 82 is the determined DNA sequence for the C. trachomatis LGVII clone 19-F12-57, sharing homology to the CT858 and recA genes.

SEQ ID NO: 83 is the determined DNA sequence for the C. trachomatis LGVII clone 19-F12-53, sharing homology to the CT445 gene encoding glutamyltRNA synthetase.

SEQ ID NO: 84 is the determined DNA sequence for the C. trachomatis LGVII clone 19-A5-54, sharing homology to the cryptic plasmid gene.

SEQ ID NO: 85 is the determined DNA sequence for the C. trachomatis LGVII clone 17-E11-72, sharing partial homology to the OppC_(—)2 and pmpDgenes.

SEQ ID NO: 86 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C1-77, sharing partial homology to the CT857 and CT858 openreading frames.

SEQ ID NO: 87 is the determined DNA sequence for the C. trachomatis LGVII clone 15-H2-76, sharing partial homology to the pmpD and SycE genes,and to the CT089 ORF.

SEQ ID NO: 88 is the determined DNA sequence for the C. trachomatis LGVII clone 15-A3-26, sharing homology to the CT858 ORF.

SEQ ID NO: 89 is the determined amino acid sequence for the C.pneumoniae clone Cp_SWIB-His.

SEQ ID NO: 90 is the determined amino acid sequence for the C.trachomatis LGV II clone CtL2_LPDA_FL.

SEQ ID NO: 91 is the determined amino acid sequence for the C.pneumoniae clone CpS13-His.

SEQ ID NO: 92 is the determined amino acid sequence for the C.trachomatis LGV II clone CtL2_TSA_FL.

SEQ ID NO: 93 is the amino acid sequence for Ct-Swib 43-61 peptide fromC. trachomatis LGV II.

SEQ ID NO: 94 is the amino acid sequence for Ct-Swib 48-67 peptide fromC. trachomatis LGV II.

SEQ ID NO: 95 is the amino acid sequence for Ct-Swib 52-71 peptide fromC. trachomatis LGV II.

SEQ ID NO: 96 is the amino acid sequence for Ct-Swib 58-77 peptide fromC. trachomatis LGV II.

SEQ ID NO: 97 is the amino acid sequence for Ct-Swib 63-82 peptide fromC. trachomatis LGV II.

SEQ ID NO: 98 is the amino acid sequence for Ct-Swib 51-66 peptide fromC. trachomatis LGV II.

SEQ ID NO: 99 is the amino acid sequence for Cp-Swib 52-67 peptide fromC. pneumonia.

SEQ ID NO: 100 is the amino acid sequence for Cp-Swib 37-51 peptide fromC. pneumonia.

SEQ ID NO: 101 is the amino acid sequence for Cp-Swib 32-51 peptide fromC. pneumonia.

SEQ ID NO: 102 is the amino acid sequence for Cp-Swib 37-56 peptide fromC. pneumonia.

SEQ ID NO: 103 is the amino acid sequence for Ct-Swib 36-50 peptide fromC. trachomatis.

SEQ ID NO: 104 is the amino acid sequence for Ct-S13 46-65 peptide fromC. trachomatis.

SEQ ID NO: 105 is the amino acid sequence for Ct-S13 60-80 peptide fromC. trachomatis.

SEQ ID NO: 106 is the amino acid sequence for Ct-S13 1-20 peptide fromC. trachomatis.

SEQ ID NO: 107 is the amino acid sequence for Ct-S13 46-65 peptide fromC. trachomatis.

SEQ ID NO: 108 is the amino acid sequence for Ct-S13 56-75 peptide fromC. trachomatis.

SEQ ID NO: 109 is the amino acid sequence for Cp-S13 56-75 peptide fromC. pneumoniae.

SEQ ID NO: 110 is the determined DNA sequence for the C. trachomatis LGVII clone 21-G12-60, containing partial open reading frames forhypothetical proteins CT875, CT229 and CT228.

SEQ ID NO: 111 is the determined DNA sequence for the C. trachomatis LGVII clone 22-B3-53, sharing homology to the CT110ORF of GroEL.

SEQ ID NO: 112 is the determined DNA sequence for the C. trachomatis LGVII clone 22-A1-49, sharing partial homology to the CT660 and CT659 ORFs.

SEQ ID NO: 113 is the determined DNA sequence for the C. trachomatis LGVII clone 17-E2-9, sharing partial homology to the CT611 and CT 610 ORFs.

SEQ ID NO: 114 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C10-31, sharing partial homology to the CT858 ORF.

SEQ ID NO: 115 is the determined DNA sequence for the C. trachomatis LGVII clone 21-C7-8, sharing homology to the dnaK-like gene.

SEQ ID NO: 116 is the determined DNA sequence for the C. trachomatis LGVII clone 20-G3-45, containing part of the pmpB gene CT413.

SEQ ID NO: 117 is the determined DNA sequence for the C. trachomatis LGVII clone 18-C5-2, sharing homology to the SI ribosomal protein ORF.

SEQ ID NO: 118 is the determined DNA sequence for the C. trachomatis LGVII clone 17-C5-19, containing part of the ORFs for CT431 and CT430.

SEQ ID NO: 119 is the determined DNA sequence for the C. trachomatis LGVII clone 16-D4-22, contains partial sequences of ORF3 and ORF4 of theplasmid for growth within mammalian cells.

SEQ ID NO: 120 is the determined full-length DNA sequence for the C.trachomatis serovar LGV II Cap1 gene CT529.

SEQ ID NO: 121 is the predicted full-length amino acid sequence for theC. trachomatis serovar LGV II Cap1 gene CT529.

SEQ ID NO: 122 is the determined full-length DNA sequence for the C.trachomatis serovar E Cap1 gene CT529.

SEQ ID NO: 123 is the predicted full-length amino acid sequence for theC. trachomatis serovar E Cap1 gene CT529.

SEQ ID NO: 124 is the determined full-length DNA sequence for the C.trachomatis serovar 1A Cap1 gene CT529.

SEQ ID NO: 125 is the predicted full-length amino acid sequence for theC. trachomatis serovar 1A Cap1 gene CT529.

SEQ ID NO: 126 is the determined full-length DNA sequence for the C.trachomatis serovar G Cap1 gene CT529.

SEQ ID NO: 127 is the predicted full-length amino acid sequence for theC. trachomatis serovar G Cap1 gene CT529.

SEQ ID NO: 128 is the determined full-length DNA sequence for the C.trachomatis serovar FI NII Cap1 gene CT529.

SEQ ID NO: 129 is the predicted full-length amino acid sequence for theC. trachomatis serovar FI NII Cap1 gene CT529.

SEQ ID NO: 130 is the determined full-length DNA sequence for the C.trachomatis serovar L1 Cap1 gene CT529.

SEQ ID NO: 131 is the predicted full-length amino acid sequence for theC. trachomatis serovar L1 Cap1 gene CT529.

SEQ ID NO: 132 is the determined full-length DNA sequence for the C.trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 133 is the predicted full-length amino acid sequence for theC. trachomatis serovar L3 Cap1 gene CT529.

SEQ ID NO: 134 is the determined full-length DNA sequence for the C.trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 135 is the predicted full-length amino acid sequence for theC. trachomatis serovar Ba Cap1 gene CT529.

SEQ ID NO: 136 is the determined full-length DNA sequence for the C.trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 137 is the predicted full-length amino acid sequence for theC. trachomatis serovar MOPN Cap1 gene CT529.

SEQ ID NO: 138 is the determined amino acid sequence for the Cap1 CT529ORF peptide #124-139 of C. trachomatis serovar L2.

SEQ ID NO: 139 is the determined amino acid sequence for the Cap1 CT529ORF peptide #132-147 of C. trachomatis serovar L2.

SEQ ID NO: 140 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-155 of C. trachomatis serovar L2.

SEQ ID NO: 141 is the determined amino acid sequence for the Cap1 CT529ORF peptide #146-163 of C. trachomatis serovar L2.

SEQ ID NO: 142 is the determined amino acid sequence for the Cap1 CT529ORF peptide #154-171 of C. trachomatis serovar L2.

SEQ ID NO: 143 is the determined amino acid sequence for the Cap1 CT529ORF peptide #162-178 of C. trachomatis serovar L2.

SEQ ID NO: 144 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-147 of C. trachomatis serovar L2.

SEQ ID NO: 145 is the determined amino acid sequence for the Cap1 CT529ORF peptide #139-147 of C. trachomatis serovar L2.

SEQ ID NO: 146 is the determined amino acid sequence for the Cap1 CT529ORF peptide #140-147 of C. trachomatis serovar L2.

SEQ ID NO: 147 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-146 of C. trachomatis serovar L2.

SEQ ID NO: 148 is the determined amino acid sequence for the Cap1 CT529ORF peptide #138-145 of C. trachomatis serovar L2.

SEQ ID NO: 149 is the determined amino acid sequence for the Cap1 CT529ORF peptide # F140->I of C. trachomatis serovar L2.

SEQ ID NO: 150 is the determined amino acid sequence for the Cap1 CT529ORF peptide # #S139>Ga of C. trachomatis serovar L2.

SEQ ID NO: 151 is the determined amino acid sequence for the Cap1 CT529ORF peptide # #S139>Gb of C. trachomatis serovar L2.

SEQ ID NO: 152 is the determined amino acid sequence for the peptide #2C7.8-6 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 153 is the determined amino acid sequence for the peptide #2C7.8-7 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 154 is the determined amino acid sequence for the peptide #2C7.8-8 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 155 is the determined amino acid sequence for the peptide #2C7.8-9 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 156 is the determined amino acid sequence for the peptide #2C7.8-10 of the 216aa ORF of C. trachomatis serovar L2.

SEQ ID NO: 157 is the determined amino acid sequence for the 53 aminoacid residue peptide of the 216aa ORF within clone 2C7.8 of C.trachomatis serovar L2.

SEQ ID NO: 158 is the determined amino acid sequence for the 52 aminoacid residue peptide of the CT529 ORF within clone 2C7.8 of C.trachomatis serovar L2.

SEQ ID NO: 159 is the determined DNA sequence for the 5′ (forward)primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 160 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovar L2.

SEQ ID NO: 161 is the determined DNA sequence for the 5′ (forward)primer for cloning full-length CT529 for serovars other than L2 andMOPN.

SEQ ID NO: 162 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovars other than L2 and MOPN.

SEQ ID NO: 163 is the determined DNA sequence for the 5′ (forward)primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 164 is the determined DNA sequence for the 5′ (reverse)primer for cloning full-length CT529 serovar MOPN.

SEQ ID NO: 165 is the determined DNA sequence for the 5′ (forward)primer for pBIB-KS.

SEQ ID NO: 166 is the determined DNA sequence for the 5′ (reverse)primer for pBIB-KS.

SEQ ID NO: 167 is the determined amino acid sequence for the 9-merepitope peptide Cap1#139-147 from serovar L2.

SEQ ID NO: 168 is the determined amino acid sequence for the 9-merepitope peptide Cap1#139-147 from serovar D.

SEQ ID NO: 169 is the determined full-length DNA sequence for the C.trachomatis pmpI (CT874) gene.

SEQ ID NO: 170 is the determined full-length DNA sequence for the C.trachomatis pmpG gene.

SEQ ID NO: 171 is the determined full-length DNA sequence for the C.trachomatis pmpE gene.

SEQ ID NO: 172 is the determined full-length DNA sequence for the C.trachomatis pmpD gene.

SEQ ID NO: 173 is the determined full-length DNA sequence for the C.trachomatis pmpC gene.

SEQ ID NO: 174 is the determined full-length DNA sequence for the C.trachomatis pmpB gene.

SEQ ID NO: 175 is the predicted full-length amino acid sequence for theC. trachomatis pmpI gene.

SEQ ID NO: 176 is the predicted full-length amino acid sequence for theC. trachomatis pmpG gene.

SEQ ID NO: 177 is the predicted full-length amino acid sequence for theC. trachomatis pmpE gene.

SEQ ID NO: 178 is the predicted full-length amino acid sequence for theC. trachomatis pmpD gene.

SEQ ID NO: 179 is the predicted full-length amino acid sequence for theC. trachomatis pmpC gene.

SEQ ID NO: 180 is the predicted full-length amino acid sequence for theC. trachomatis pmpB gene.

SEQ ID NO: 181 is the determined DNA sequence minus the signal sequencefor the C. trachomatis pmpI gene.

SEQ ID NO: 182 is a subsequently determined full-length DNA sequence forthe C. trachomatis pmpG gene.

SEQ ID NO: 183 is the determined DNA sequence minus the signal sequencefor the C. trachomatis pmpE gene.

SEQ ID NO: 184 is a first determined DNA sequence representing thecarboxy terminus for the C. trachomatis pmpD gene.

SEQ ID NO: 185 is a second determined DNA sequence representing theamino terminus minus the signal sequence for the C. trachomatis pmpDgene.

SEQ ID NO: 186 is a first determined DNA sequence representing thecarboxy terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 187 is a second determined DNA sequence representing theamino terminus minus the signal sequence for the C. trachomatis pmpCgene.

SEQ ID NO: 188 is the determined DNA sequence representing the C.pneumoniae serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 189 is the predicted amino acid sequence minus the signalsequence for the C. trachomatis pmpI gene.

SEQ ID NO: 190 is subsequently predicted amino acid sequence for the C.trachomatis pmpG gene.

SEQ ID NO: 191 is the predicted amino acid sequence minus the signalsequence for the C. trachomatis pmpE gene.

SEQ ID NO: 192 is a first predicted amino acid sequence representing thecarboxy terminus for the C. trachomatis pmpD gene.

SEQ ID NO: 193 is a second predicted amino acid sequence representingthe Amino terminus minus the signal sequence for the C. trachomatis pmpDgene.

SEQ ID NO: 194 is a first predicted amino acid sequence representing theCarboxy terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 195 is a second predicted amino acid sequence representingthe Amino terminus for the C. trachomatis pmpC gene.

SEQ ID NO: 196 is the predicted amino acid sequence representing the C.pneumoniae serovar MOMPS pmp gene in a fusion molecule with Ra12.

SEQ ID NO: 197 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 198 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 199 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpC gene in the SKB vaccine vector.

SEQ ID NO: 200 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 201 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 202 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpD gene in the SKB vaccine vector.

SEQ ID NO: 203 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpE gene in the SKB vaccine vector.

SEQ ID NO: 204 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpE gene in the SKB vaccine vector.

SEQ ID NO: 205 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 206 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 207 is the determined DNA sequence for the 5′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 208 is the determined DNA sequence for the 3′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 209 is the determined DNA sequence for the 5′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 210 is the determined DNA sequence for the 3′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpC genein the pET17b vector.

SEQ ID NO: 211 is the determined DNA sequence for the 5′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 212 is the determined DNA sequence for the 3′ oligo primerfor cloning the amino terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 213 is the determined DNA sequence for the 5′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 214 is the determined DNA sequence for the 3′ oligo primerfor cloning the carboxy terminus portion of the C. trachomatis pmpD genein the pET17b vector.

SEQ ID NO: 215 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 216 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 217 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 218 is the amino acid sequence for the insertion sequence forcloning the C. trachomatis pmpE gene in the pET17b vector.

SEQ ID NO: 219 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 220 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 221 is the amino acid sequence for the insertion sequence forcloning the C. trachomatis pmpG gene in the pET17b vector.

SEQ ID NO: 222 is the determined DNA sequence for the 5′ oligo primerfor cloning the C. trachomatis pmpI gene in the pET17b vector.

SEQ ID NO: 223 is the determined DNA sequence for the 3′ oligo primerfor cloning the C. trachomatis pmpI gene in the pET17b vector.

SEQ ID NO: 224 is the determined amino acid sequence for the C.pneumoniae Swib peptide 1-20.

SEQ ID NO: 225 is the determined amino acid sequence for the C.pneumoniae Swib peptide 6-25.

SEQ ID NO: 226 is the determined amino acid sequence for the C.pneumoniae Swib peptide 12-31.

SEQ ID NO: 227 is the determined amino acid sequence for the C.pneumoniae Swib peptide 17-36.

SEQ ID NO: 228 is the determined amino acid sequence for the C.pneumoniae Swib peptide 22-41.

SEQ ID NO: 229 is the determined amino acid sequence for the C.pneumoniae Swib peptide 27-46.

SEQ ID NO: 230 is the determined amino acid sequence for the C.pneumoniae Swib peptide 42-61.

SEQ ID NO: 231 is the determined amino acid sequence for the C.pneumoniae Swib peptide 46-65.

SEQ ID NO: 232 is the determined amino acid sequence for the C.pneumoniae Swib peptide 51-70.

SEQ ID NO: 233 is the determined amino acid sequence for the C.pneumoniae Swib peptide 56-75.

SEQ ID NO: 234 is the determined amino acid sequence for the C.pneumoniae Swib peptide 61-80.

SEQ ID NO: 235 is the determined amino acid sequence for the C.pneumoniae Swib peptide 66-87.

SEQ ID NO: 236 is the determined amino acid sequence for the C.trachomatis OMCB peptide 103-122.

SEQ ID NO: 237 is the determined amino acid sequence for the C.trachomatis OMCB peptide 108-127.

SEQ ID NO: 238 is the determined amino acid sequence for the C.trachomatis OMCB peptide 113-132.

SEQ ID NO: 239 is the determined amino acid sequence for the C.trachomatis OMCB peptide 118-137.

SEQ ID NO: 240 is the determined amino acid sequence for the C.trachomatis OMCB peptide 123-143.

SEQ ID NO: 241 is the determined amino acid sequence for the C.trachomatis OMCB peptide 128-147.

SEQ ID NO: 242 is the determined amino acid sequence for the C.trachomatis OMCB peptide 133-152.

SEQ ID NO: 243 is the determined amino acid sequence for the C.trachomatis OMCB peptide 137-156.

SEQ ID NO: 244 is the determined amino acid sequence for the C.trachomatis OMCB peptide 142-161.

SEQ ID NO: 245 is the determined amino acid sequence for the C.trachomatis OMCB peptide 147-166.

SEQ ID NO: 246 is the determined amino acid sequence for the C.trachomatis OMCB peptide 152-171.

SEQ ID NO: 247 is the determined amino acid sequence for the C.trachomatis OMCB peptide 157-176.

SEQ ID NO: 248 is the determined amino acid sequence for the C.trachomatis OMCB peptide 162-181.

SEQ ID NO: 249 is the determined amino acid sequence for the C.trachomatis OMCB peptide 167-186.

SEQ ID NO: 250 is the determined amino acid sequence for the C.trachomatis OMCB peptide 171-190.

SEQ ID NO: 251 is the determined amino acid sequence for the C.trachomatis OMCB peptide 171-186.

SEQ ID NO: 252 is the determined amino acid sequence for the C.trachomatis OMCB peptide 175-186.

SEQ ID NO: 252 is the determined amino acid sequence for the C.trachomatis OMCB peptide 175-186.

SEQ ID NO: 253 is the determined amino acid sequence for the C.pneumoniae OMCB peptide 185-198.

SEQ ID NO: 254 is the determined amino acid sequence for the C.trachomatis TSA peptide 96-115.

SEQ ID NO: 255 is the determined amino acid sequence for the C.trachomatis TSA peptide 101-120.

SEQ ID NO: 256 is the determined amino acid sequence for the C.trachomatis TSA peptide 106-125.

SEQ ID NO: 257 is the determined amino acid sequence for the C.trachomatis TSA peptide 111-130.

SEQ ID NO: 258 is the determined amino acid sequence for the C.trachomatis TSA peptide 116-135.

SEQ ID NO: 259 is the determined amino acid sequence for the C.trachomatis TSA peptide 121-140.

SEQ ID NO: 260 is the determined amino acid sequence for the C.trachomatis TSA peptide 126-145.

SEQ ID NO: 261 is the determined amino acid sequence for the C.trachomatis TSA peptide 131-150.

SEQ ID NO: 262 is the determined amino acid sequence for the C.trachomatis TSA peptide 136-155.

SEQ ID NO: 263 is the determined full-length DNA sequence for the C.trachomatis CT529/Cap 1 gene serovar I.

SEQ ID NO: 264 is the predicted full-length amino sequence for the C.trachomatis CT529/Cap 1 gene serovar I.

SEQ ID NO: 265 is the determined full-length DNA sequence for the C.trachomatis CT529/Cap 1 gene serovar K.

SEQ ID NO: 266 is the predicted full-length amino sequence for the C.trachomatis CT529/Cap 1 gene serovar K.

SEQ ID NO: 267 is the determined DNA sequence for the C. trachomatisclone 17-G4-36 sharing homology to part of the ORF of DNA-directed RNApolymerase beta subunit-CT315 in serD.

SEQ ID NO: 268 is the determined DNA sequence for the partial sequenceof the C. trachomatis CT016 gene in clone 2E10.

SEQ ID NO: 269 is the determined DNA sequence for the partial sequenceof the C. trachomatis tRNA syntase gene in clone 2E10.

SEQ ID NO: 270 is the determined DNA sequence for the partial sequencefor the C. trachomatis clpX gene in clone 2E10.

SEQ ID NO: 271 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-30 representing the 5′ end.

SEQ ID NO: 272 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-30 representing the 3′ end.

SEQ ID NO: 273 is the determined DNA sequence for the C. trachomatisclone CtL2gam-28.

SEQ ID NO: 274 is the determined DNA sequence for the C. trachomatisclone CtL2gam-27.

SEQ ID NO: 275 is the determined DNA sequence for the C. trachomatisclone CtL2gam-26.

SEQ ID NO: 276 is the determined DNA sequence for the C. trachomatisclone CtL2gam-24.

SEQ ID NO: 277 is the determined DNA sequence for the C. trachomatisclone CtL2gam-23.

SEQ ID NO: 278 is the determined DNA sequence for the C. trachomatisclone CtL2gam-21.

SEQ ID NO: 279 is the determined DNA sequence for the C. trachomatisclone CtL2gam-18.

SEQ ID NO: 280 is the determined DNA sequence for the C. trachomatisclone CtL2gam-17.

SEQ ID NO: 281 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-15 representing the 5′ end.

SEQ ID NO: 282 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-15 representing the 3′ end.

SEQ ID NO: 283 is the determined DNA sequence for the C. trachomatisclone CtL2gam-13.

SEQ ID NO: 284 is the determined DNA sequence for the C. trachomatisclone CtL2gam-10.

SEQ ID NO: 285 is the determined DNA sequence for the C. trachomatisclone CtL2gam-8.

SEQ ID NO: 286 is a first determined DNA sequence for the C. trachomatisclone CtL2gam-6 representing the 5′ end.

SEQ ID NO: 287 is a second determined DNA sequence for the C.trachomatis clone CtL2gam-6 representing the 3′ end.

SEQ ID NO: 288 is the determined DNA sequence for the C. trachomatisclone CtL2gam-5.

SEQ ID NO: 289 is the determined DNA sequence for the C. trachomatisclone CtL2gam-2.

SEQ ID NO: 290 is the determined DNA sequence for the C. trachomatisclone CtL2gam-1.

SEQ ID NO: 291 is the determined full-length DNA sequence for the C.pneumoniae homologue of the CT529 gene.

SEQ ID NO: 292 is the predicted full-length amino acid sequence for theC. pneumoniae homologue of the CT529 gene.

SEQ ID NO: 293 is the determined DNA sequence for the insertion sequencefor cloning the C. trachomatis pmpG gene in the SKB vaccine vector.

SEQ ID NO: 294 is the amino acid sequence of an open reading frame ofclone CT603.

SEQ ID NO: 295 is the amino acid sequence of a first open reading frameof clone CT875.

SEQ ID NO: 296 is the amino acid sequence of a second open reading frameof clone CT875.

SEQ ID NO: 297 is the amino acid sequence of a first open reading frameof clone CT858.

SEQ ID NO: 298 is the amino acid sequence of a second open reading frameof clone CT858.

SEQ ID NO: 299 is the amino acid sequence of an open reading frame ofclone CT622.

SEQ ID NO: 300 is the amino acid sequence of an open reading frame ofclone CT610.

SEQ ID NO: 301 is the amino acid sequence of an open reading frame ofclone CT396.

SEQ ID NO: 302 is the amino acid sequence of an open reading frame ofclone CT318.

SEQ ID NO: 304 is the amino acid sequence for C. trachomatis, serovar L2rCt529c1-125 having a modified N-terminal sequence (6-His tag).

SEQ ID NO: 305 is the amino acid sequence for C. trachomatis, serovar L2rCt529c1-125.

SEQ ID NO: 306 is the sense primer used in the synthesis of thePmpA(N-term) fusion protein.

SEQ ID NO: 307 is the antisense primer used in the synthesis of thePmpA(N-term) fusion protein.

SEQ ID NO: 308 is the DNA sequence encoding the PmpA(N-term) fusionprotein.

SEQ ID NO: 309 is the amino acid sequence of the PmpA(N-term) fusionprotein.

SEQ ID NO: 310 is the sense primer used in the synthesis of thePmpA(C-term) fusion protein.

SEQ ID NO: 311 is the antisense primer used in the synthesis of thePmpA(C-term) fusion protein.

SEQ ID NO: 312 is the DNA sequence encoding the PmpA(C-term) fusionprotein.

SEQ ID NO: 313 is the amino acid sequence of the PmpA(C-term) fusionprotein.

SEQ ID NO: 314 is the sense primer used in the synthesis of thePmpF(N-term) fusion protein.

SEQ ID NO: 315 is the antisense primer used in the synthesis of thePmpF(N-term) fusion protein.

SEQ ID NO: 316 is the DNA sequence encoding the PmpF(N-term) fusionprotein.

SEQ ID NO: 317 is the amino acid sequence of the PmpF(N-term) fusionprotein.

SEQ ID NO: 318 is the sense primer used in the synthesis of thePmpF(C-term) fusion protein.

SEQ ID NO: 319 is the antisense primer used in the synthesis of thePmpF(C-term) fusion protein.

SEQ ID NO: 320 is the DNA sequence encoding the PmpF(C-term) fusionprotein.

SEQ ID NO: 321 is the amino acid sequence of the PmpF(C-term) fusionprotein.

SEQ ID NO: 322 is the sense primer used in the synthesis of the PmpH(CT412) (N-term) fusion protein.

SEQ ID NO: 323 is the antisense primer used in the synthesis of thePmpH(N-term) fusion protein.

SEQ ID NO: 324 is the DNA sequence encoding the PmpH(N-term) fusionprotein.

SEQ ID NO: 325 is the amino acid sequence of the PmpH(N-term) fusionprotein.

SEQ ID NO: 326 is the sense primer used in the synthesis of thePmpH(C-term) fusion protein.

SEQ ID NO: 327 is the antisense primer used in the synthesis of thePmpH(C-term) fusion protein.

SEQ ID NO: 328 is the DNA sequence encoding the PmpH(C-term) fusionprotein.

SEQ ID NO: 329 is the amino acid sequence of the PmpH(C-term) fusionprotein.

SEQ ID NO: 330 is the sense primer used in the synthesis of the PmpB(1)fusion protein.

SEQ ID NO: 331 is the antisense primer used in the synthesis of thePmpB(1) fusion protein.

SEQ ID NO: 332 is the DNA sequence encoding the PmpB(1) fusion protein.

SEQ ID NO: 333 is the amino acid sequence of the PmpB(1) fusion protein.

SEQ ID NO: 334 is the sense primer used in the synthesis of the PmpB(2)fusion protein.

SEQ ID NO: 335 is the antisense primer used in the synthesis of thePmpB(2) fusion protein.

SEQ ID NO: 336 is the DNA sequence encoding the PmpB(2) fusion protein.

SEQ ID NO: 337 is the amino acid sequence of the PmpB(2) fusion protein.

SEQ ID NO: 338 is the sense primer used in the synthesis of the PmpB(3)fusion protein.

SEQ ID NO: 339 is the antisense primer used in the synthesis of thePmpB(3) fusion protein.

SEQ ID NO: 340 is the DNA sequence encoding the PmpB(3) fusion protein.

SEQ ID NO: 341 is the amino acid sequence of the PmpB(3) fusion protein.

SEQ ID NO: 342 is the sense primer used in the synthesis of the PmpB(4)fusion protein.

SEQ ID NO: 343 is the antisense primer used in the synthesis of thePmpB(4) fusion protein.

SEQ ID NO: 344 is the DNA sequence encoding the PmpB(4) fusion protein.

SEQ ID NO: 345 is the amino acid sequence of the PmpB(4) fusion protein.

SEQ ID NO: 346 is the sense primer used in the synthesis of the PmpC(1)fusion protein.

SEQ ID NO: 347 is the antisense primer used in the synthesis of thePmpC(1) fusion protein.

SEQ ID NO: 348 is the DNA sequence encoding the PmpC(1) fusion protein.

SEQ ID NO: 349 is the amino acid sequence of the PmpC(1) fusion protein.

SEQ ID NO: 350 is the sense primer used in the synthesis of the PmpC(2)fusion protein.

SEQ ID NO: 351 is the antisense primer used in the synthesis of thePmpC(2) fusion protein.

SEQ ID NO: 352 is the DNA sequence encoding the PmpC(2) fusion protein.

SEQ ID NO: 353 is the amino acid sequence of the PmpC(2) fusion protein.

SEQ ID NO: 354 is the sense primer used in the synthesis of the PmpC(3)fusion protein.

SEQ ID NO: 355 is the antisense primer used in the synthesis of thePmpC(3) fusion protein.

SEQ ID NO: 356 is the DNA sequence encoding the PmpC(3) fusion protein.

SEQ ID NO: 357 is the amino acid sequence of the PmpC(3) fusion protein.

SEQ ID NO: 358 is the DNA sequence of the oppA1 protein, devoid of thefirst trans-membrane domain.

SEQ ID NO: 359 is the full length DNA sequence of CT139.

SEQ ID NO: 360 is the full length DNA sequence of ORF-3.

SEQ ID NO: 361 is the full length DNA sequence of CT611.

SEQ ID NO: 362 is the amino acid sequence of oppA1 starting from aminoacid 22.

SEQ ID NO: 363 is the amino acid sequence of CT139.

SEQ ID NO: 364 is the amino acid sequence of ORF-3.

SEQ ID NO: 365 is the amino acid sequence of CT611.

SEQ ID NO: 366 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0275, of the Chlamydia trachomatis gene CT190.

SEQ ID NO: 367 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0407, of the Chlamydia trachomatis gene CT103.

SEQ ID NO: 368 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0720, of the Chlamydia trachomatis gene CT659.

SEQ ID NO: 369 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0716, of the Chlamydia trachomatis gene CT660.

SEQ ID NO: 370 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0519, of the Chlamydia trachomatis gene CT430.

SEQ ID NO: 371 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0520, of the Chlamydia trachomatis gene CT431.

SEQ ID NO: 372 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0078, of the Chlamydia trachomatis gene CT318.

SEQ ID NO: 373 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0628, of the Chlamydia trachomatis gene CT509.

SEQ ID NO: 374 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0540, of the Chlamydia trachomatis gene CT414.

SEQ ID NO: 375 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, pmp20, of the Chlamydia trachomatis gene CT413.

SEQ ID NO: 376 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0081, of the Chlamydia trachomatis gene CT315.

SEQ ID NO: 377 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0761, of the Chlamydia trachomatis gene CT610.

SEQ ID NO: 378 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0557, of the Chlamydia trachomatis gene CT443.

SEQ ID NO: 379 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0833, of the Chlamydia trachomatis gene CT557.

SEQ ID NO: 380 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0134, of the Chlamydia trachomatis gene CT604.

SEQ ID NO: 381 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0388, of the Chlamydia trachomatis gene CT042.

SEQ ID NO: 382 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn1028, of the Chlamydia trachomatis gene CT376.

SEQ ID NO: 383 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0875, of the Chlamydia trachomatis gene CT734.

SEQ ID NO: 384 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0908, of the Chlamydia trachomatis gene CT764.

SEQ ID NO: 385 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0728, of the Chlamydia trachomatis gene CT622.

SEQ ID NO: 386 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0275, of the Chlamydia trachomatis gene CT190.

SEQ ID NO: 387 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0407, of the Chlamydia trachomatis gene CT103.

SEQ ID NO: 388 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0720, of the Chlamydia trachomatis gene CT659.

SEQ ID NO: 389 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0716, of the Chlamydia trachomatis gene CT660.

SEQ ID NO: 390 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0519, of the Chlamydia trachomatis gene CT430.

SEQ ID NO: 391 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0520, of the Chlamydia trachomatis gene CT431.

SEQ ID NO: 392 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0078, of the Chlamydia trachomatis gene CT318.

SEQ ID NO: 393 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0628, of the Chlamydia trachomatis gene CT509.

SEQ ID NO: 394 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0540, of the Chlamydia trachomatis gene CT414.

SEQ ID NO: 395 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, pmp20, of the Chlamydia trachomatis gene CT413.

SEQ ID NO: 396 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0081, of the Chlamydia trachomatis gene CT315.

SEQ ID NO: 397 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0761, of the Chlamydia trachomatis gene CT610.

SEQ ID NO: 398 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0557, of the Chlamydia trachomatis gene CT443.

SEQ ID NO: 399 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0833, of the Chlamydia trachomatis gene CT557.

SEQ ID NO: 400 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0134, of the Chlamydia trachomatis gene CT604.

SEQ ID NO: 401 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0388, of the Chlamydia trachomatis gene CT042.

SEQ ID NO: 402 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn1028, of the Chlamydia trachomatis gene CT376.

SEQ ID NO: 403 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0875, of the Chlamydia trachomatis gene CT734.

SEQ ID NO: 404 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0908, of the Chlamydia trachomatis gene CT764.

SEQ ID NO: 405 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0728, of the Chlamydia trachomatis gene CT622.

SEQ ID NO: 406 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT287.

SEQ ID NO: 407 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT858.

SEQ ID NO: 408 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT764.

SEQ ID NO: 409 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT734.

SEQ ID NO: 410 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT660.

SEQ ID NO: 411 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT659.

SEQ ID NO: 412 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT622.

SEQ ID NO: 413 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT610.

SEQ ID NO: 414 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT604.

SEQ ID NO: 415 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT557.

SEQ ID NO: 416 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT509.

SEQ ID NO: 417 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT443.

SEQ ID NO: 418 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT431.

SEQ ID NO: 419 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT430.

SEQ ID NO: 420 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT414.

SEQ ID NO: 421 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT413.

SEQ ID NO: 422 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT396.

SEQ ID NO: 423 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT376.

SEQ ID NO: 424 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT318.

SEQ ID NO: 425 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT315.

SEQ ID NO: 426 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT104.

SEQ ID NO: 427 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT103.

SEQ ID NO: 428 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT102.

SEQ ID NO: 429 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT098.

SEQ ID NO: 430 sets forth the full-length serovar D DNA sequence of theChlamydia trachomatis gene CT042.

SEQ ID NO: 431 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT858.

SEQ ID NO: 432 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT764.

SEQ ID NO: 433 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT734.

SEQ ID NO: 434 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT660.

SEQ ID NO: 435 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT659.

SEQ ID NO: 436 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT622.

SEQ ID NO: 437 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT610.

SEQ ID NO: 438 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT604.

SEQ ID NO: 439 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT557.

SEQ ID NO: 440 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT509.

SEQ ID NO: 441 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT443.

SEQ ID NO: 442 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT431.

SEQ ID NO: 443 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT430.

SEQ ID NO: 444 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT414.

SEQ ID NO: 445 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT413.

SEQ ID NO: 446 sets forth the full-length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT396.

SEQ ID NO: 447 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT376.

SEQ ID NO: 448 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT318.

SEQ ID NO: 449 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT315.

SEQ ID NO: 450 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT104.

SEQ ID NO: 451 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT103.

SEQ ID NO: 452 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT102.

SEQ ID NO: 453 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT098.

SEQ ID NO: 454 sets forth the full length serovar D amino acid sequenceof the Chlamydia trachomatis gene CT042.

SEQ ID NO: 455 corresponds to the DNA sequence of CPn0894, which is theCP homologue of CT751 (amn), which was identified in clones CTL2-1, andCTL2-5.

SEQ ID NO: 456 corresponds to the DNA sequence of CPn0074, which is theCP homologue of CT322 (tuf), which was identified in clone CTL2-2.

SEQ ID NO: 457 corresponds to the DNA sequence of CPn0122, which is theCP homologue of CT032 (metG), which was identified in clones CTL2gam2,CTL2-3(5′) and CTL2-4.

SEQ ID NO: 458 corresponds to the DNA sequence of CPn0121, which is theCP homologue of CT031, which was identified in clone CTL2-3(5′)(3′).

SEQ ID NO: 459 corresponds to the DNA sequence of CPn0120, which is theCP homologue of CT030 (gmK), which was identified in clones CTL2-3(3′)and CTL2-21.

SEQ ID NO: 460 corresponds to the DNA sequence of CPn0359, which is theCP homologue of CT064 (lepA), which was identified in clone CTL2gam5.

SEQ ID NO: 461 corresponds to the DNA sequence of CPn0414, which is theCP homologue of CT265 (accA), which was identified in clone CTL2-6.

SEQ ID NO: 462 corresponds to the DNA sequence of CPn0413, which is theCP homologue of CT264 (msbA), which was identified in clone CTL2-6.

SEQ ID NO: 463 corresponds to the DNA sequence of CPn0394, which is theCP homologue of CT256 which was identified in clones CTL2gam6(5′) andCTL2-11(5′).

SEQ ID NO: 464 corresponds to the DNA sequence of CPn0395, which is theCP homologue of CT257 which was identified in clones CTL2gam6(5′) andCTL2-11(5′).

SEQ ID NO: 465 corresponds to the DNA sequence of CPn0487, which is theCP homologue of CT384 which was identified in clones CTL2gam6(3′) andCTL2-11(3′).

SEQ ID NO: 466 corresponds to the DNA sequence of CPn0592, which is theCP homologue of CT473, which was identified in clone CTL2-8b.

SEQ ID NO: 467 corresponds to the DNA sequence of CPn0593, which is theCP homologue of CT474, which was identified in clone CTL2-8b.

SEQ ID NO: 468 corresponds to the DNA sequence of CPn0197, which is theCP homologue of CT139 (oppA1), which was identified in clone CTL2-8b.

SEQ ID NO: 469 corresponds to the DNA sequence of CPn0363, which is theCP homologue of CT060 (flhA), which was identified in clone CTL2-8b.

SEQ ID NO: 470 corresponds to the DNA sequence of CPn0301, which is theCP homologue of CT242, which was identified in clone CTL2gam8.

SEQ ID NO: 471 corresponds to the DNA sequence of CPn0302, which is theCP homologue of CT243 (lpxD), which was identified in clone CTL2gam8.

SEQ ID NO: 472 corresponds to the DNA sequence of CPn0324, which is theCP homologue of CT089 (lcrE), which was identified in clones CTL2-9,CTL2gam1, CTL2gam17 and CTL2-19(5′).

SEQ ID NO: 473 corresponds to the DNA sequence of CPn0761, which is theCP homologue of CT610, which was identified in clone CTL2-10(5′)(3′).

SEQ ID NO: 474 corresponds to the DNA sequence of CPn0760, which is theCP homologue of CT611, which was identified in clone CTL2-10(5′).

SEQ ID NO: 475 corresponds to the DNA sequence of CPn0329, which is theCP homologue of CT154, which was identified in clones CTL2gam10 andCTL2gam21.

SEQ ID NO: 476 corresponds to the DNA sequence of CPn0990, which is theCP homologue of CT833 (infC), which was identified in clone CTL2-12.

SEQ ID NO: 477 corresponds to the DNA sequence of CPn0984, which is theCP homologue of CT827 (nrdA), which was identified in clones CTL2-16(3′)and CTL2gam15(3′).

SEQ ID NO: 478 corresponds to the DNA sequence of CPn0985 which is theCP homologue of CT828 (nrdB) which was identified in clones CTL2-16(3′)CTL2gam15(3′).

SEQ ID NO: 479 corresponds to the DNA sequence of CPn0349, which is theCP homologue of CT067 (ytgA), which was identified in clone CTL2gam18.

SEQ ID NO: 480 corresponds to the DNA sequence of CPn0325, which is theCP homologue of CT088 (sycE), which was identified in clone CTL2-19(5′).

SEQ ID NO: 481 corresponds to the DNA sequence of CPn0326, which is theCP homologue of CT087 (malQ), which was identified in clone CTL2-19(5′).

SEQ ID NO: 482 corresponds to the DNA sequence of CPn0793, which is theCP homologue of CT588 (rbsu), which was identified in clone CTL2gam23.

SEQ ID NO: 483 corresponds to the DNA sequence of CPn0199, which is theCP homologue of CT199 (oppB1), which was identified in clone CTL2gam24.

SEQ ID NO: 484 corresponds to the DNA sequence of CPn0666, which is theCP homologue of CT545 (dnaE), which was identified in clone CTL2-24.

SEQ ID NO: 485 corresponds to the DNA sequence of CPn0065, which is theCP homologue of CT288, which was identified in clone CTL2gam27.

SEQ ID NO: 486 corresponds to the DNA sequence of CPn0444, which is theCP homologue of CT413 (pmpB), which was identified in cloneCTL2gam30(5′)(3′).

SEQ ID NO: 487 corresponds to the DNA sequence of CPn-ORF5, which is theCP homologue of CT-ORF3, which was identified in clones CTL2gam15(5′),CTL2-16(5′), CTL2-18(5′), and CTL2-23.

SEQ ID NO: 488 corresponds to the DNA sequence of CPn-ORF6, which is theCP homologue of CT-ORF4, which was identified in clone CTL2-18(3′).

SEQ ID NO: 489 corresponds to the DNA sequence of CP-ORF7, which is theCP homologue of CT-ORF5, which was identified in clone CTL2-18(3′).

SEQ ID NO: 490 corresponds to the amino acid sequence of CPn0894, whichis the CP homologue of CT751 (amn), which was identified in clonesCTL2-1 and CTL2-5.

SEQ ID NO: 491 corresponds to the amino acid sequence of CPn0074, whichis the CP homologue of CT332 (tuf), which was identified in cloneCTL2-2.

SEQ ID NO: 492 corresponds to the amino acid sequence of CPn0122, whichis the CP homologue of CT032 (metG), which was identified in clones

CTL2gam2, CTL2-3(5′) and CTL2-4.

SEQ ID NO: 493 corresponds to the amino acid sequence of CPn0121, whichis the CP homologue of CT031, which was identified in cloneCTL2-3(5′)(3′).

SEQ ID NO: 494 corresponds to the amino acid sequence of CPn0120 whichis the CP homologue of CT030 (gmK) which was identified in clones CTL2-3(3′) and CTL2-21.

SEQ ID NO: 495 corresponds to the amino acid sequence of CPn0359, whichis the CP homologue of CT064 (lepA), which was identified in cloneCTL2gam5.

SEQ ID NO: 496 corresponds to the amino acid sequence of CPn0414, whichis the CP homologue of CT265 (accA), which was identified in cloneCTL2-6.

SEQ ID NO: 497 corresponds to the amino acid sequence of CPn0413, whichis the CP homologue of CT264 (msbA), which was identified in cloneCTL2-6.

SEQ ID NO: 498 corresponds to the amino acid sequence of CPn0394, whichis the CP homologue of CT256, which was identified in clonesCTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 499 corresponds to the amino acid sequence of CPn0395, whichis the CP homologue of CT257, which was identified in clonesCTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 500 corresponds to the amino acid sequence of CPn0487, whichis the CP homologue of CT384, which was identified in clonesCTL2gam6(3′) and CTL2-11(3′).

SEQ ID NO: 501 corresponds to the amino acid sequence of CPn0592, whichis the CP homologue of CT473, which was identified in clone CTL2-8b.

SEQ ID NO: 502 corresponds to the amino acid sequence of CPn0593, whichis the CP homologue of CT474, which was identified in clone CTL2-8b.

SEQ ID NO: 503 corresponds to the amino acid sequence of CPn0197, whichis the CP homologue of CT139 (oppA1), which was identified in clone

CTL2-8b.

SEQ ID NO: 504 corresponds to the amino acid sequence of CPn0363, whichis the CP homologue of CT060 (flhA), which was identified in cloneCTL2-8b.

SEQ ID NO: 505 corresponds to the amino acid sequence of CPn0301, whichis the CP homologue of CT242, which was identified in clone CTL2gam8.

SEQ ID NO: 506 corresponds to the amino acid sequence of CPn0302, whichis the CP homologue of CT243 (lpxD), which was identified in cloneCTL2gam8.

SEQ ID NO: 507 corresponds to the amino acid sequence of CPn0324, whichis the CP homologue of CT089 (lcrE), which was identified in clonesCTL2-9, CTL2gam1, CTL2gam17 and CTL2-19(5′).

SEQ ID NO: 508 corresponds to the amino acid sequence of CPn0761, whichis the CP homologue of CT610, which was identified in cloneCTL2-10(5′)(3′).

SEQ ID NO: 509 corresponds to the amino acid sequence of CPn0760, whichis the CP homologue of CT611, which was identified in clone CTL2-10(5′).

SEQ ID NO: 510 corresponds to the amino acid sequence of CPn0329, whichis the CP homologue of CT154, which was identified in clones CTL2gam10and CTL2gam21.

SEQ ID NO: 511 corresponds to the amino acid sequence of CPn0990, whichis the CP homologue of CT833 (infC), which was identified in cloneCTL2-12.

SEQ ID NO: 512 corresponds to the amino acid sequence of CPn-ORF5, whichis the CP homologue of CT ORF3, which was identified in clonesCTL2gam15(5′), CTL2-16(5′), CTL2-18(5′), and CTL2-23.

SEQ ID NO: 513 corresponds to the amino acid sequence of CPn0984, whichis the CP homologue of CT827 (nrdA) which was identified in clonesCTL2-16(3′) and CTL2gam15(3′).

SEQ ID NO: 514 corresponds to the amino acid sequence of CPn0985, whichis the CP homologue of CT828 (nrdB) which was identified in clonesCTL2-16(3′) CTL2gam15(3′).

SEQ ID NO: 515 corresponds to the amino acid sequence of CPn0349, whichis the CP homologue of CT067 (ytgA), which was identified in cloneCTL2gam18.

SEQ ID NO: 516 corresponds to the DNA sequence of CPn-ORF6, which is theCP homologue of CT-ORF4, which was identified in clone CTL2-18(3′).

SEQ ID NO: 517 corresponds to the DNA sequence of CP-ORF7, which is theCP homologue of CT-ORF5, which was identified in clone CTL2-18(3′).

SEQ ID NO: 518 corresponds to the amino acid sequence of CPn0326, whichis the CP homologue of CT087 (malQ), which was identified in cloneCTL2-19(5′).

SEQ ID NO: 519 corresponds to the amino acid sequence of CPn0325, whichis the CP homologue of CT088 (sycE), which was identified in cloneCTL2-19(5′).

SEQ ID NO: 520 corresponds to the amino acid sequence of CPn0793, whichis the CP homologue of CT588 (rbsu), which was identified in cloneCTL2gam23.

SEQ ID NO: 521 corresponds to the amino acid sequence of CPn0199, whichis the CP homologue of CT199 (oppB1), which was identified in cloneCTL2gam24.

SEQ ID NO: 522 corresponds to the amino acid sequence of CPn0666, whichis the CP homologue of CT545 (dnaE), which was identified in cloneCTL2-24.

SEQ ID NO: 523 corresponds to the DNA sequence of CPn0065, which is theCP homologue of CT288, which was identified in clone CTL2gam27.

SEQ ID NO: 524 corresponds to the DNA sequence of CPn0444, which is theCP homologue of CT413 (pmpB), which was identified in cloneCTL2gam30(5′)(3′).

SEQ ID NO: 525 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT751(amn) identified from the clones CTL2-1 and CTL2-5.

SEQ ID NO: 526 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT322(tuff) identified from the clone CTL2-2.

SEQ ID NO: 527 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT032(metG) identified from the clones CTL2gam2, CTL2-3(5′) and CTL2-4.

SEQ ID NO: 528 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT031identified from the clone CTL2-3(5′)(3′).

SEQ ID NO: 529 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT030(gmK) identified from the clones CTL2-3(3′) and CTL2-21.

SEQ ID NO: 530 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT064(lepA) identified from the clone CTL2gam5.

SEQ ID NO: 531 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT265(accA) identified from the clone CTL2-6.

SEQ ID NO: 532 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT624(msbA) identified from the clones CTL2-6.

SEQ ID NO: 533 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT256identified from the clones CTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 534 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT257identified from the clones CTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 535 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT384identified from the clones CTL2gam6(3′) and CTL2-11(3′).

SEQ ID NO: 536 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT473identified from the clone CTL2-8b.

SEQ ID NO: 537 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT474identified from the clones CTL2-8b.

SEQ ID NO: 538 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT139(oppA1) identified from the clones CTL2-8b.

SEQ ID NO: 539 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT060(flhA) identified from the clone CTL2-8b.

SEQ ID NO: 540 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT242identified from the clone CTL2gam8.

SEQ ID NO: 541 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT243(lpxD) identified from the clone CTL2gam8.

SEQ ID NO: 542 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT089identified from the clones CTL2-9, CTL2gam1, CTL2gam17, and CTL2-19(5′).

SEQ ID NO: 543 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT610identified from the clone CTL2-10 (5′)(3′).

SEQ ID NO: 544 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT611identified from the clone CTL2-10(5′).

SEQ ID NO: 545 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT154identified from the clones CTL2gam10 and CTL2gam21.

SEQ ID NO: 546 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT833(infC) identified from the clone CTL2-12.

SEQ ID NO: 547 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT827(nrdA) identified from the clones CTL2-16(3′) and CTL2gam15(3′).

SEQ ID NO: 548 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT828(nrdB) identified from the clones CTL2-16(3′) and CTL2gam15(3′).

SEQ ID NO: 549 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT067(ytgA) identified from the clone CTL2gam18.

SEQ ID NO: 550 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT088(sycE) identified from the clones CTL2-19(5′).

SEQ ID NO: 551 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT087identified from the clone CTL2-19(5′).

SEQ ID NO: 552 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT588(rsbu) identified from the clone CTL2gam23.

SEQ ID NO: 553 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT199(oppB1) identified from the clone CTL2gam24.

SEQ ID NO: 554 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT545(dnaE) identified from the clone CTL2-4.

SEQ ID NO: 555 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT288identified from the clones CTL2gam27.

SEQ ID NO: 556 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT413(pmpB) identified from the clone CTL2gam30(5′)(3′).

SEQ ID NO: 557 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT-ORF3identified from the clones CTL2gam15(5′), CTL2-16(5′), CTL2-18(5′) andCTL2-23.

SEQ ID NO: 558 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for pCT-ORF4identified from the clone CTL2-18(3′).

SEQ ID NO: 559 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT-ORF5identified from the clones CTL2-18(3′).

SEQ ID NO: 560 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT751(amn) identified from the clones CTL2-1 and CTL2-5.

SEQ ID NO: 561 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT322(tuff) identified from the clone CTL2-2.

SEQ ID NO: 562 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT032(metG) identified from the clones CTL2gam2, CTL2-3(5′) and CTL2-4.

SEQ ID NO: 563 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT031identified from the clone CTL2-3(5′)(3′).

SEQ ID NO: 564 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT030(gmK) identified from the clones CTL2-3(3′) and CTL2-21.

SEQ ID NO: 565 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT064(lepA) identified from the clone CTL2gam5.

SEQ ID NO: 566 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT265(accA) identified from the clone CTL2-6.

SEQ ID NO: 567 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT624(msbA) identified from the clones CTL2-6.

SEQ ID NO: 568 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT256identified from the clones CTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 569 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT257identified from the clones CTL2gam6(5′) and CTL2-11(5′).

SEQ ID NO: 570 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT384identified from the clones CTL2gam6(3′) and CTL2-11(3′).

SEQ ID NO: 571 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT473identified from the clone CTL2-8b.

SEQ ID NO: 572 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT474identified from the clones CTL2-8b.

SEQ ID NO: 573 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT139(oppA1) identified from the clones CTL2-8b.

SEQ ID NO: 574 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT060(flhA) identified from the clone CTL2-8b.

SEQ ID NO: 575 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT242identified from the clone CTL2gam8.

SEQ ID NO: 576 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT243(lpxD) identified from the clone CTL2gam8.

SEQ ID NO: 577 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT089identified from the clones CTL2-9, CTL2gam1, CTL2gam17, and CTL2-19(5′).

SEQ ID NO: 578 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT610identified from the clone CTL2-10 (5′)(3′).

SEQ ID NO: 579 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT611identified from the clone CTL2-10(5′).

SEQ ID NO: 580 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT154identified from the clones CTL2gam10 and CTL2gam21.

SEQ ID NO: 581 sets forth the full-length C. trachomatis serovar D aminoacid sequence homologous to the C. trachomatis LGV II sequence for CT833(infC) identified from the clone CTL2-12.

SEQ ID NO: 582 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT-ORF3identified from the clones CTL2gam15(5′), CTL2-16(5′), CTL2-18(5′) andCTL2-23.

SEQ ID NO: 583 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT827(nrdA) identified from the clones CTL2-16(3′) and CTL2gam15(3′).

SEQ ID NO: 584 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT828(nrdB) identified from the clones CTL2-16(3′) and CTL2gam15(3′).

SEQ ID NO: 585 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT067(ytgA) identified from the clone CTL2gam18.

SEQ ID NO: 586 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for pCT-ORF4identified from the clone CTL2-18(3′)

SEQ ID NO: 587 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT-ORF5identified from the clones CTL2-18(3′).

SEQ ID NO: 588 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT087identified from the clone CTL2-19(5′).

SEQ ID NO: 589 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT088(sycE) identified from the clones CTL2-19(5′).

SEQ ID NO: 590 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT588(rsbu) identified from the clone CTL2gam23.

SEQ ID NO: 591 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT199(oppB1) identified from the clone CTL2gam24.

SEQ ID NO: 592 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT545(dnaE) identified from the clone CTL2-4.

SEQ ID NO: 593 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT288identified from the clones CTL2gam27.

SEQ ID NO: 594 sets forth the full-length C. trachomatis serovar D DNAsequence homologous to the C. trachomatis LGV II sequence for CT413(pmpB) identified from the clone CTL2gam30(5′)(3′).

SEQ ID NO: 595 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0406, of the Chlamydia trachomatis gene CT102.

SEQ ID NO: 596 sets forth the DNA sequence for the Chlamydia pneumoniaehomologue, CPn0315, of the Chlamydia trachomatis gene CT098.

SEQ ID NO: 597 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0406, of the Chlamydia trachomatis gene CT102.

SEQ ID NO: 598 sets forth the amino acid sequence for the Chlamydiapneumoniae homologue, CPn0315, of the Chlamydia trachomatis gene CT098.

SEQ ID NO: 599 sets forth the amino acid sequence for Chlamydiatrachomatis serovar D CT287 protein.

DESCRIPTION OF THE FIGURES

FIG. 1 illustrates induction of INF-γ from a Chlamydia-specific T cellline activated by target cells expressing clone 4C9-18#2.

FIG. 2 illustrates retroviral vectors pBIB-KS1,2,3 modified to contain aKosak translation initiation site and stop codons.

FIG. 3 shows specific lysis in a chromium release assay of P815 cellspulsed with Chlamydia peptides CtC7.8-12 (SEQ ID NO: 18) and CtC7.8-13(SEQ ID NO: 19).

FIG. 4 shows antibody isotype titers in C57B1/6 mice immunized with C.trachomatis SWIB protein.

FIG. 5 shows Chlamydia-specific T-cell proliferative responses insplenocytes from C3H mice immunized with C. trachomatis SWIB protein.

FIG. 6 illustrates the 5′ and 3′ primer sequences designed from C.pneumoniae which were used to isolate the SWIB and S13 genes from C.pneumoniae.

FIGS. 7A and 7B show induction of IFN-γ from a human anti-chlamydiaT-cell line (TCL-8) capable of cross-reacting to C. trachomatis and C.pneumonia upon activation by monocyte-derived dendritic cells expressingchlamydial proteins.

FIG. 8 shows the identification of T cell epitopes in Chlamydialribosomal S13 protein with T-cell line TCL 8 EB/DC.

FIG. 9 illustrates the proliferative response of CP-21 T-cells generatedagainst C. pneumoniae-infected dendritic cells to recombinant C.pneumonia-SWIBprotein, but not C. trachomatis SWIB protein.

FIG. 10 shows the C. trachomatis-specific SWIB proliferative responsesof a primary T-cell line (TCT-10 EB) from an asymptomatic donor.

FIG. 11 illustrates the identification of T-cell epitope in C.trachomatis SWIB with an antigen specific T-cell line (TCL-10 EB).

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed tocompositions and methods for the diagnosis and treatment of Chlamydialinfection. In one aspect, the compositions of the subject inventioninclude polypeptides that comprise at least one immunogenic portion of aChlamydia antigen, or a variant thereof.

In specific embodiments, the subject invention discloses polypeptidescomprising an immunogenic portion of a Chlamydia antigen, wherein theChlamydia antigen comprises an amino acid sequence encoded by apolynucleotide molecule disclosed herein, the complements of saidnucleotide sequences, and variants of such sequences.

As used herein, the term “polypeptide” encompasses amino acid chains ofany length, including full length proteins (i.e., antigens), wherein theamino acid residues are linked by covalent peptide bonds. Thus, apolypeptide comprising an immunogenic portion of one of the inventiveantigens may consist entirely of the immunogenic portion, or may containadditional sequences. The additional sequences may be derived from thenative Chlamydia antigen or may be heterologous, and such sequences may(but need not) be immunogenic.

The term “polynucleotide(s),” as used herein, means a single ordouble-stranded polymer of deoxyribonucleotide or ribonucleotide basesand includes DNA and corresponding RNA molecules, including HnRNA andmRNA molecules, both sense and anti-sense strands, and comprehends cDNA,genomic DNA and recombinant DNA, as well as wholly or partiallysynthesized polynucleotides. An HnRNA molecule contains introns andcorresponds to a DNA molecule in a generally one-to-one manner. An mRNAmolecule corresponds to an HnRNA and DNA molecule from which the intronshave been excised. A polynucleotide may consist of an entire gene, orany portion thereof. Operable anti-sense polynucleotides may comprise afragment of the corresponding polynucleotide, and the definition of“polynucleotide” therefore includes all such operable anti-sensefragments.

An “immunogenic portion” of an antigen is a portion that is capable ofreacting with sera obtained from a Chlamydia-infected individual (i.e.,generates an absorbance reading with sera from infected individuals thatis at least three standard deviations above the absorbance obtained withsera from uninfected individuals, in a representative ELISA assaydescribed herein). Such immunogenic portions generally comprise at leastabout 5 amino acid residues, more preferably at least about 10, and mostpreferably at least about 20 amino acid residues. Methods for preparingand identifying immunogenic portions of antigens of known sequence arewell known in the art and include those summarized in Paul, FundamentalImmunology, 3^(rd) ed., Raven Press, 1993, pp. 243-247 and referencescited therein. Such techniques include screening polypeptides for theability to react with antigen-specific antibodies, antisera and/orT-cell lines or clones. As used herein, antisera and antibodies are“antigen-specific” if they specifically bind to an antigen (i.e., theyreact with the protein in an ELISA or other immunoassay, and do notreact detectably with unrelated proteins). Such antisera and antibodiesmay be prepared as described herein, and using well known techniques. Animmunogenic portion of a native Chlamydia protein is a portion thatreacts with such antisera and/or T-cells at a level that is notsubstantially less than the reactivity of the full length polypeptide(e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenicportions may react within such assays at a level that is similar to orgreater than the reactivity of the full length polypeptide. Such screensmay generally be performed using methods well known to those of ordinaryskill in the art, such as those described in Harlow and Lane,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.For example, a polypeptide may be immobilized on a solid support andcontacted with patient sera to allow binding of antibodies within thesera to the immobilized polypeptide. Unbound sera may then be removedand bound antibodies detected using, for example, ¹²⁵I-labeled ProteinA.

Examples of immunogenic portions of antigens contemplated by the presentinvention include, for example, the T cell stimulating epitopes providedin SEQ ID NO: 9, 10, 18, 19, 31, 39, 93-96, 98, 100-102, 106, 108,138-140, 158, 167, 168, 246, 247 and 254-256. Polypeptides comprising atleast an immunogenic portion of one or more Chlamydia antigens asdescribed herein may generally be used, alone or in combination, todetect Chlamydial infection in a patient.

The compositions and methods of the present invention also encompassvariants of the above polypeptides and polynucleotide molecules. Suchvariants include, but are not limited to, naturally occurring allelicvariants of the inventive sequences. In particular, variants includeother Chlamydiae serovars, such as serovars D, E and F, as well as theseveral LGV serovars which share homology to the inventive polypeptideand polynucleotide molecules described herein. Preferably, the serovarhomologues show 95-99% homology to the corresponding polypeptidesequence(s) described herein.

A polypeptide “variant,” as used herein, is a polypeptide that differsfrom the recited polypeptide only in conservative substitutions and/ormodifications, such that the antigenic properties of the polypeptide areretained. In a preferred embodiment, variant polypeptides differ from anidentified sequence by substitution, deletion or addition of five aminoacids or fewer. Such variants may generally be identified by modifyingone of the above polypeptide sequences, and evaluating the antigenicproperties of the modified polypeptide using, for example, therepresentative procedures described herein. In other words, the abilityof a variant to react with antigen-specific antisera may be enhanced orunchanged, relative to the native protein, or may be diminished by lessthan 50%, and preferably less than 20%, relative to the native protein.Such variants may generally be identified by modifying one of the abovepolypeptide sequences and evaluating the reactivity of the modifiedpolypeptide with antigen-specific antibodies or antisera as describedherein. Preferred variants include those in which one or more portions,such as an N-terminal leader sequence or transmembrane domain, have beenremoved. Other preferred variants include variants in which a smallportion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has beenremoved from the N- and/or C-terminal of the mature protein.

As used herein, a “conservative substitution” is one in which an aminoacid is substituted for another amino acid that has similar properties,such that one skilled in the art of peptide chemistry would expect thesecondary structure and hydropathic nature of the polypeptide to besubstantially unchanged. Amino acid substitutions may generally be madeon the basis of similarity in polarity, charge, solubility,hydrophobicity, hydrophilicity and/or the amphipathic nature of theresidues. For example, negatively charged amino acids include asparticacid and glutamic acid; positively charged amino acids include lysineand arginine; and amino acids with uncharged polar head groups havingsimilar hydrophilicity values include leucine, isoleucine and valine;glycine and alanine; asparagine and glutamine; and serine, threonine,phenylalanine and tyrosine. Other groups of amino acids that mayrepresent conservative changes include: (1) ala, pro, gly, glu, asp,gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala,phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also,or alternatively, contain nonconservative changes. In a preferredembodiment, variant polypeptides differ from a native sequence bysubstitution, deletion or addition of five amino acids or fewer.Variants may also (or alternatively) be modified by, for example, thedeletion or addition of amino acids that have minimal influence on theimmunogenicity, secondary structure and hydropathic nature of thepolypeptide. Variants may also, or alternatively, contain othermodifications, including the deletion or addition of amino acids thathave minimal influence on the antigenic properties, secondary structureand hydropathic nature of the polypeptide. For example, a polypeptidemay be conjugated to a signal (or leader) sequence at the N-terminal endof the protein which co-translationally or post-translationally directstransfer of the protein. The polypeptide may also be conjugated to alinker or other sequence for ease of synthesis, purification oridentification of the polypeptide (e.g., poly-His), or to enhancebinding of the polypeptide to a solid support. For example, apolypeptide may be conjugated to an immunoglobulin Fc region.

A polynucleotide “variant” is a sequence that differs from the recitednucleotide sequence in having one or more nucleotide deletions,substitutions or additions such that the immunogenicity of the encodedpolypeptide is not diminished, relative to the native protein. Theeffect on the immunogenicity of the encoded polypeptide may generally beassessed as described herein. Such modifications may be readilyintroduced using standard mutagenesis techniques, such asoligonucleotide-directed site-specific mutagenesis as taught, forexample, by Adelman et al. (DNA, 2:183, 1983). Nucleotide variants maybe naturally occurring allelic variants as discussed below, ornon-naturally occurring variants. The polypeptides provided by thepresent invention include variants that are encoded by polynucleotidesequences which are substantially homologous to one or more of thepolynucleotide sequences specifically recited herein. “Substantialhomology,” as used herein, refers to polynucleotide sequences that arecapable of hybridizing under moderately stringent conditions. Suitablemoderately stringent conditions include prewashing in a solution of5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-65° C.,5×SSC, overnight or, in the event of cross-species homology, at 45° C.with 0.5×SSC; followed by washing twice at 65° C. for 20 minutes witheach of 2×, 0.5× and 0.2×SSC containing 0.1% SDS. Such hybridizingpolynucleotide sequences are also within the scope of this invention, asare nucleotide sequences that, due to code degeneracy, encode apolypeptide that is the same as a polypeptide of the present invention.

Two nucleotide or polypeptide sequences are said to be “identical” ifthe sequence of nucleotides or amino acid residues in the two sequencesis the same when aligned for maximum correspondence as described below.Comparisons between two sequences are typically performed by comparingthe sequences over a comparison window to identify and compare localregions of sequence similarity. A “comparison window” as used herein,refers to a segment of at least about 20 contiguous positions, usually30 to about 75, 40 to about 50, in which a sequence may be compared to areference sequence of the same number of contiguous positions after thetwo sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted using theMegalign program in the Lasergene suite of bioinformatics software(DNASTAR, Inc., Madison, Wis.), using default parameters. This programembodies several alignment schemes described in the followingreferences: Dayhoff, M. O. (1978) A model of evolutionary change inproteins—Matrices for detecting distant relationships. In Dayhoff, M. O.(ed.) Atlas of Protein Sequence and Structure, National BiomedicalResearch Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; HeinJ. (1990) Unified Approach to Alignment and Phylogenes pp. 626-645Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.;Higgins, D. G. and Sharp, P. M. (1989) Fast and sensitive multiplesequence alignments on a microcomputer CABIOS 5:151-153; Myers, E. W.and Muller W. (1988) Optimal alignments in linear space CABIOS 4:11-17;Robinson, E. D. (1971) Comb. Theor 11:105; Santou, N. Nes, M. (1987) Theneighbor joining method. A new method for reconstructing phylogenetictrees Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R.(1973) Numerical Taxonomy—the Principles and Practice of NumericalTaxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W. J. andLipman, D. J. (1983) Rapid similarity searches of nucleic acid andprotein data banks Proc. Natl. Acad., Sci. USA 80:726-730.

Alternatively, optimal alignment of sequences for comparison may beconducted by the local identity algorithm of Smith and Waterman (1981)Add. APL. Math 2:482, by the identity alignment algorithm of Needlemanand Wunsch (1970) J. Mol. Biol. 48:443, by the search for similaritymethods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (U.S.A.) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT,BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package,Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or byinspection.

One illustrative example of algorithms that are suitable for determiningpercent sequence identity and sequence similarity are the BLAST andBLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc.Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol.215:403-410, respectively. BLAST and BLAST 2.0 can be used, for examplewith the parameters described herein, to determine percent sequenceidentity for the polynucleotides and polypeptides of the invention.Software for performing BLAST analyses is publicly available through theNational Center for Biotechnology Information(http://www.ncbi.nlm.nih.gov/) In one illustrative example, cumulativescores can be calculated using, for nucleotide sequences, the parametersM (reward score for a pair of matching residues; always >0) and N(penalty score for mismatching residues; always <0). For amino acidsequences, a scoring matrix can be used to calculate the cumulativescore. Extension of the word hits in each direction are halted when: thecumulative alignment score falls off by the quantity X from its maximumachieved value; the cumulative score goes to zero or below, due to theaccumulation of one or more negative-scoring residue alignments; or theend of either sequence is reached. The BLAST algorithm parameters W, Tand X determine the sensitivity and speed of the alignment. The BLASTNprogram (for nucleotide sequences) uses as defaults a wordlength (W) of11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (seeHenikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915)alignments, (B) of 50, expectation (E) of 10, M=5, N=−4 and a comparisonof both strands.

Preferably, the “percentage of sequence identity” is determined bycomparing two optimally aligned sequences over a window of comparison ofat least 20 positions, wherein the portion of the polynucleotide oramino acid sequence in the comparison window may comprise additions ordeletions (i.e. gaps) of 20 percent or less, usually 5 to 15 percent, or10 to 12 percent, as compared to the reference sequences (which does notcomprise additions or deletions) for optimal alignment of the twosequences. The percentage is calculated by determining the number ofpositions at which the identical nucleic acid bases or amino acidresidue occurs in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the reference sequence (i.e. the window size) andmultiplying the results by 100 to yield the percentage of sequenceidentity.

Therefore, the present invention provides polynucleotide and polypeptidesequences having substantial identity to the sequences disclosed herein,for example those comprising at least 50% or more sequence identity,preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, or 99% or higher, sequence identity compared to apolynucleotide or polypeptide sequence of this invention using themethods described herein, (e.g., BLAST analysis using standardparameters, as described below). One skilled in this art will recognizethat these values can be appropriately adjusted to determinecorresponding identity of proteins encoded by two polynucleotidesequences by taking into account codon degeneracy, amino acidsimilarity, reading frame positioning and the like.

In additional embodiments, the present invention provides isolatedpolynucleotides or polypeptides comprising various lengths of contiguousstretches of sequence identical to or complementary to one or more ofthe sequences disclosed herein. For example, polynucleotides andpolypeptides encompassed by this invention may comprise at least about15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or morecontiguous nucleotides of one or more of the disclosed sequences, aswell as all intermediate lengths therebetween. It will be readilyunderstood that “intermediate lengths”, in this context, means anylength between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22,23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103,etc.; 150, 151, 152, 153, etc.; including all integers through the200-500; 500-1,000, and the like.

The polynucleotides of the present invention, or fragments thereof,regardless of the length of the coding sequence itself, may be combinedwith other DNA sequences, such as promoters, polyadenylation signals,additional restriction enzyme sites, multiple cloning sites, othercoding segments, and the like, such that their overall length may varyconsiderably. It is therefore contemplated that a nucleic acid fragmentof almost any length may be employed, with the total length preferablybeing limited by the ease of preparation and use in the intendedrecombinant DNA protocol. For example, illustrative DNA segments withtotal lengths of about 10,000, about 5000, about 3000, about 2,000,about 1,000, about 500, about 200, about 100, about 50 base pairs inlength, and the like, (including all intermediate lengths) arecontemplated to be useful in many implementations of this invention.

Also included in the scope of the present invention are alleles of thegenes encoding the nucleotide sequences recited in herein. As usedherein, an “allele” or “allellic sequence” is an alternative form of thegene which may result from at least one mutation in the nucleic acidsequence. Alleles may result in altered mRNAs or polypeptides whosestructure or function may or may not be altered. Any given gene may havenone, one, or many allelic forms. Common mutational changes which giverise to alleles are generally ascribed to natural deletions, additions,or substitutions of nucleotides. Each of these types of changes mayoccur alone or in combination with the others, one or more times in agiven sequence.

In specific embodiments, the subject invention discloses polypeptidescomprising at least an immunogenic portion of a Chlamydia antigen (or avariant of such an antigen), that comprises one or more of the aminoacid sequences encoded by (a) a polynucleotide sequence selected fromthe group consisting of SEQ ID NO: 358-361, 407-430, 525-559, 582-598;(b) the complements of such DNA sequences or (c) DNA sequencessubstantially homologous to a sequence in (a) or (b). As discussed inthe Examples below, several of the Chlamydia antigens disclosed hereinrecognize a T cell line that recognizes both Chlamydia trachomatis andChlamydia pneumoniae infected monocyte-derived dendritic cells,indicating that they may represent an immunoreactive epitope shared byChlamydia trachomatis and Chlamydia pneumoniae. The antigens may thus beemployed in a vaccine for both C. trachomatis genital tract infectionsand for C. pneumonia infections. Further characterization of theseChlamydia antigens from Chlamydia trachomatis and Chlamydia pneumonia todetermine the extent of cross-reactivity is provided in Example 6.Additionally, Example 4 describes cDNA fragments (SEQ ID NO: 15, 16 and33) isolated from C. trachomatis which encode proteins (SEQ ID NO: 17-19and 32) capable of stimulating a Chlamydia-specific murine CD8+ T cellline.

In general, Chlamydia antigens, and polynucleotide sequences encodingsuch antigens, may be prepared using any of a variety of procedures. Forexample, polynucleotide molecules encoding Chlamydia antigens may beisolated from a Chlamydia genomic or cDNA expression library byscreening with a Chlamydia-specific T cell line as described below, andsequenced using techniques well known to those of skill in the art.Additionally, a polynucleotide may be identified, as described in moredetail below, by screening a microarray of cDNAs forChlamydia-associated expression (i.e., expression that is at least twofold greater in Chlamydia-infected cells than in controls, as determinedusing a representative assay provided herein). Such screens may beperformed using a Synteni microarray (Palo Alto, Calif.) according tothe manufacturer's instructions (and essentially as described by Schenaet al., Proc. Natl. Acad. Sci. USA 93:10614-10619, 1996 and Heller etal., Proc. Natl. Acad. Sci. USA 94:2150-2155, 1997). Alternatively,polypeptides may be amplified from cDNA prepared from cells expressingthe proteins described herein. Such polynucleotides may be amplified viapolymerase chain reaction (PCR). For this approach, sequence-specificprimers may be designed based on the sequences provided herein, and maybe purchased or synthesized.

Antigens may be produced recombinantly, as described below, by insertinga polynucleotide sequence that encodes the antigen into an expressionvector and expressing the antigen in an appropriate host. Antigens maybe evaluated for a desired property, such as the ability to react withsera obtained from a Chlamydia-infected individual as described herein,and may be sequenced using, for example, traditional Edman chemistry.See Edman and Berg, Eur. J. Biochem. 80:116-132, 1967.

Polynucleotide sequences encoding antigens may also be obtained byscreening an appropriate Chlamydia cDNA or genomic DNA library forpolynucleotide sequences that hybridize to degenerate oligonucleotidesderived from partial amino acid sequences of isolated antigens.Degenerate oligonucleotide sequences for use in such a screen may bedesigned and synthesized, and the screen may be performed, as described(for example) in Sambrook et al., Molecular Cloning: A LaboratoryManual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (andreferences cited therein). Polymerase chain reaction (PCR) may also beemployed, using the above oligonucleotides in methods well known in theart, to isolate a nucleic acid probe from a cDNA or genomic library. Thelibrary screen may then be performed using the isolated probe.

An amplified portion may be used to isolate a full length gene from asuitable library (e.g., a Chlamydia cDNA library) using well knowntechniques. Within such techniques, a library (cDNA or genomic) isscreened using one or more polynucleotide probes or primers suitable foramplification. Preferably, a library is size-selected to include largermolecules. Random primed libraries may also be preferred for identifying5′ and upstream regions of genes. Genomic libraries are preferred forobtaining introns and extending 5′ sequences.

For hybridization techniques, a partial sequence may be labeled (e.g.,by nick-translation or end-labeling with ³²P) using well knowntechniques. A bacterial or bacteriophage library is then screened byhybridizing filters containing denatured bacterial colonies (or lawnscontaining phage plaques) with the labeled probe (see Sambrook et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories,Cold Spring Harbor, N.Y., 1989). Hybridizing colonies or plaques areselected and expanded, and the DNA is isolated for further analysis.cDNA clones may be analyzed to determine the amount of additionalsequence by, for example, PCR using a primer from the partial sequenceand a primer from the vector. Restriction maps and partial sequences maybe generated to identify one or more overlapping clones. The completesequence may then be determined using standard techniques, which mayinvolve generating a series of deletion clones. The resultingoverlapping sequences are then assembled into a single contiguoussequence. A full length cDNA molecule can be generated by ligatingsuitable fragments, using well known techniques.

Alternatively, there are numerous amplification techniques for obtaininga full length coding sequence from a partial cDNA sequence. Within suchtechniques, amplification is generally performed via PCR. Any of avariety of commercially available kits may be used to perform theamplification step. Primers may be designed using techniques well knownin the art (see, for example, Mullis et al., Cold Spring Harbor Symp.Quant. Biol. 51:263, 1987; Erlich ed., PCR Technology, Stockton Press,NY, 1989), and software well known in the art may also be employed.Primers are preferably 22-30 nucleotides in length, have a GC content ofat least 50% and anneal to the target sequence at temperatures of about68° C. to 72° C. The amplified region may be sequenced as describedabove, and overlapping sequences assembled into a contiguous sequence.

One such amplification technique is inverse PCR (see Triglia et al.,Nucl. Acids Res. 16:8186, 1988), which uses restriction enzymes togenerate a fragment in the known region of the gene. The fragment isthen circularized by intramolecular ligation and used as a template forPCR with divergent primers derived from the known region. Within analternative approach, sequences adjacent to a partial sequence may beretrieved by amplification with a primer to a linker sequence and aprimer specific to a known region. The amplified sequences are typicallysubjected to a second round of amplification with the same linker primerand a second primer specific to the known region. A variation on thisprocedure, which employs two primers that initiate extension in oppositedirections from the known sequence, is described in WO 96/38591.Additional techniques include capture PCR (Lagerstrom et al., PCRMethods Applic. 1:111-19, 1991) and walking PCR (Parker et al., Nucl.Acids. Res. 19:3055-60, 1991). Transcription-Mediated Amplification, orTMA is another method that may be utilized for the amplification of DNA,rRNA, or mRNA, as described in Patent No. PCT/US91/03184. Thisautocatalytic and isothermic non-PCR based method utilizes two primersand two enzymes: RNA polymerase and reverse transcriptase. One primercontains a promoter sequence for RNA polymerase. In the firstamplification, the promoter-primer hybridizes to the target rRNA at adefined site. Reverse transcriptase creates a DNA copy of the targetrRNA by extension from the 3′ end of the promoter-primer. The RNA in theresulting complex is degraded and a second primer binds to the DNA copy.A new strand of DNA is synthesized from the end of the primer by reversetranscriptase creating double stranded DNA. RNA polymerase recognizesthe promoter sequence in the DNA template and initiates transcription.Each of the newly synthesized RNA amplicons re-enters the TMA processand serves as a template for a new round of replication leading to theexpotential expansion of the RNA amplicon. Other methods employingamplification may also be employed to obtain a full length cDNAsequence.

In certain instances, it is possible to obtain a full length cDNAsequence by analysis of sequences provided in an expressed sequence tag(EST) database, such as that available from GenBank. Searches foroverlapping ESTs may generally be performed using well known programs(e.g., NCBI BLAST searches), and such ESTs may be used to generate acontiguous full length sequence. Full length cDNA sequences may also beobtained by analysis of genomic fragments.

Polynucleotide variants may generally be prepared by any method known inthe art, including chemical synthesis by, for example, solid phasephosphoramidite chemical synthesis. Modifications in a polynucleotidesequence may also be introduced using standard mutagenesis techniques,such as oligonucleotide-directed site-specific mutagenesis (see Adelmanet al., DNA 2:183, 1983). Alternatively, RNA molecules may be generatedby in vitro or in vivo transcription of DNA sequences encoding aChlamydial protein, or portion thereof, provided that the DNA isincorporated into a vector with a suitable RNA polymerase promoter (suchas T7 or SP6). Certain portions may be used to prepare an encodedpolypeptide, as described herein. In addition, or alternatively, aportion may be administered to a patient such that the encodedpolypeptide is generated in vivo (e.g., by transfectingantigen-presenting cells, such as dendritic cells, with a cDNA constructencoding a Chlamydial polypeptide, and administering the transfectedcells to the patient).

A portion of a sequence complementary to a coding sequence (i.e., anantisense polynucleotide) may also be used as a probe or to modulategene expression. cDNA constructs that can be transcribed into antisenseRNA may also be introduced into cells of tissues to facilitate theproduction of antisense RNA. An antisense polynucleotide may be used, asdescribed herein, to inhibit expression of a Chlamydial protein.Antisense technology can be used to control gene expression throughtriple-helix formation, which compromises the ability of the doublehelix to open sufficiently for the binding of polymerases, transcriptionfactors or regulatory molecules (see Gee et al., In Huber and Carr,Molecular and Immunologic Approaches, Futura Publishing Co. (Mt. Kisco,N.Y.; 1994)). Alternatively, an antisense molecule may be designed tohybridize with a control region of a gene (e.g., promoter, enhancer ortranscription initiation site), and block transcription of the gene; orto block translation by inhibiting binding of a transcript to ribosomes.

A portion of a coding sequence, or of a complementary sequence, may alsobe designed as a probe or primer to detect gene expression. Probes maybe labeled with a variety of reporter groups, such as radionuclides andenzymes, and are preferably at least 10 nucleotides in length, morepreferably at least 20 nucleotides in length and still more preferablyat least 30 nucleotides in length. Primers, as noted above, arepreferably 22-30 nucleotides in length.

Any polynucleotide may be further modified to increase stability invivo. Possible modifications include, but are not limited to, theaddition of flanking sequences at the 5′ and/or 3′ ends; the use ofphosphorothioate or 2′ O-methyl rather than phosphodiesterase linkagesin the backbone; and/or the inclusion of nontraditional bases such asinosine, queosine and wybutosine, as well as acetyl- methyl-, thio- andother modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety ofother nucleotide sequences using established recombinant DNA techniques.For example, a polynucleotide may be cloned into any of a variety ofcloning vectors, including plasmids, phagemids, lambda phage derivativesand cosmids. Vectors of particular interest include expression vectors,replication vectors, probe generation vectors and sequencing vectors. Ingeneral, a vector will contain an origin of replication functional in atleast one organism, convenient restriction endonuclease sites and one ormore selectable markers. Other elements will depend upon the desireduse, and will be apparent to those of ordinary skill in the art.

Synthetic polypeptides having fewer than about 100 amino acids, andgenerally fewer than about 50 amino acids, may be generated usingtechniques well known in the art. For example, such polypeptides may besynthesized using any of the commercially available solid-phasetechniques, such as the Merrifield solid-phase synthesis method, whereamino acids are sequentially added to a growing amino acid chain. See

Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963. Equipment forautomated synthesis of polypeptides is commercially available fromsuppliers such as Perkin Elmer/Applied BioSystems Division, Foster City,Calif., and may be operated according to the manufacturer'sinstructions.

As noted above, immunogenic portions of Chlamydia antigens may beprepared and identified using well known techniques, such as thosesummarized in Paul, Fundamental Immunology, 3d ed., Raven Press, 1993,pp. 243-247 and references cited therein. Such techniques includescreening polypeptide portions of the native antigen for immunogenicproperties. The representative ELISAs described herein may generally beemployed in these screens. An immunogenic portion of a polypeptide is aportion that, within such representative assays, generates a signal insuch assays that is substantially similar to that generated by the fulllength antigen. In other words, an immunogenic portion of a Chlamydiaantigen generates at least about 20%, and preferably about 100%, of thesignal induced by the full length antigen in a model ELISA as describedherein.

Portions and other variants of Chlamydia antigens may be generated bysynthetic or recombinant means. Variants of a native antigen maygenerally be prepared using standard mutagenesis techniques, such asoligonucleotide-directed site-specific mutagenesis. Sections of thepolynucleotide sequence may also be removed using standard techniques topermit preparation of truncated polypeptides.

Recombinant polypeptides containing portions and/or variants of a nativeantigen may be readily prepared from a polynucleotide sequence encodingthe polypeptide using a variety of techniques well known to those ofordinary skill in the art. For example, supernatants from suitablehost/vector systems which secrete recombinant protein into culture mediamay be first concentrated using a commercially available filter.Following concentration, the concentrate may be applied to a suitablepurification matrix such as an affinity matrix or an ion exchange resin.Finally, one or more reverse phase HPLC steps can be employed to furtherpurify a recombinant protein.

Any of a variety of expression vectors known to those of ordinary skillin the art may be employed to express recombinant polypeptides asdescribed herein. Expression may be achieved in any appropriate hostcell that has been transformed or transfected with an expression vectorcontaining a polynucleotide molecule that encodes a recombinantpolypeptide. Suitable host cells include prokaryotes, yeast and highereukaryotic cells. Preferably, the host cells employed are E. coli, yeastor a mammalian cell line, such as COS or CHO. The DNA sequencesexpressed in this manner may encode naturally occurring antigens,portions of naturally occurring antigens, or other variants thereof.

In general, regardless of the method of preparation, the polypeptidesdisclosed herein are prepared in an isolated, substantially pure, form.Preferably, the polypeptides are at least about 80% pure, morepreferably at least about 90% pure and most preferably at least about99% pure.

Within certain specific embodiments, a polypeptide may be a fusionprotein that comprises multiple polypeptides as described herein, orthat comprises at least one polypeptide as described herein and anunrelated sequence, such as a known Chlamydial protein. A fusion partnermay, for example, assist in providing T helper epitopes (animmunological fusion partner), preferably T helper epitopes recognizedby humans, or may assist in expressing the protein (an expressionenhancer) at higher yields than the native recombinant protein. Certainpreferred fusion partners are both immunological and expressionenhancing fusion partners. Other fusion partners may be selected so asto increase the solubility of the protein or to enable the protein to betargeted to desired intracellular compartments. Still further fusionpartners include affinity tags, which facilitate purification of theprotein. A DNA sequence encoding a fusion protein of the presentinvention may be constructed using known recombinant DNA techniques toassemble separate DNA sequences encoding, for example, the first andsecond polypeptides, into an appropriate expression vector. The 3′ endof a DNA sequence encoding the first polypeptide is ligated, with orwithout a peptide linker, to the 5′ end of a DNA sequence encoding thesecond polypeptide so that the reading frames of the sequences are inphase to permit mRNA translation of the two DNA sequences into a singlefusion protein that retains the biological activity of both the firstand the second polypeptides.

A peptide linker sequence may be employed to separate the first and thesecond polypeptides by a distance sufficient to ensure that eachpolypeptide folds into its secondary and tertiary structures. Such apeptide linker sequence is incorporated into the fusion protein usingstandard techniques well known in the art. Suitable peptide linkersequences may be chosen based on the following factors: (1) theirability to adopt a flexible extended conformation; (2) their inabilityto adopt a secondary structure that could interact with functionalepitopes on the first and second polypeptides; and (3) the lack ofhydrophobic or charged residues that might react with the polypeptidefunctional epitopes. Preferred peptide linker sequences contain Gly, Asnand Ser residues. Other near neutral amino acids, such as Thr and Alamay also be used in the linker sequence. Amino acid sequences which maybe usefully employed as linkers include those disclosed in Maratea etal., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA83:8258-8562, 1986; U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180.The linker sequence may be from 1 to about 50 amino acids in length. Asan alternative to the use of a peptide linker sequence (when desired),one can utilize non-essential N-terminal amino acid regions (whenpresent) on the first and second polypeptides to separate the functionaldomains and prevent steric hindrance.

The ligated DNA sequences are operably linked to suitabletranscriptional or translational regulatory elements. The regulatoryelements responsible for expression of DNA are located only 5′ to theDNA sequence encoding the first polypeptides. Similarly, stop codonsrequired to end translation and transcription termination signals areonly present 3′ to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of thepresent invention together with an unrelated immunogenic protein.Preferably the immunogenic protein is capable of eliciting a recallresponse. Examples of such proteins include tetanus, tuberculosis andhepatitis proteins (see, for example, Stoute et al. New Engl. J. Med.,336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derivedfrom protein D, a surface protein of the gram-negative bacteriumHaemophilus influenza B (WO 91/18926). Preferably, a protein Dderivative comprises approximately the first third of the protein (e.g.,the first N-terminal 100-110 amino acids), and a protein D derivativemay be lipidated. Within certain preferred embodiments, the first 109residues of a Lipoprotein D fusion partner is included on the N-terminusto provide the polypeptide with additional exogenous T-cell epitopes andto increase the expression level in E. coli (thus functioning as anexpression enhancer). The lipid tail ensures optimal presentation of theantigen to antigen presenting cells. Other fusion partners include thenon-structural protein from influenzae virus, NS1 (hemaglutinin).Typically, the N-terminal 81 amino acids are used, although differentfragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the proteinknown as LYTA, or a portion thereof (preferably a C-terminal portion).LYTA is derived from Streptococcus pneumoniae, which synthesizes anN-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytAgene; Gene 43:265-292, 1986). LYTA is an autolysin that specificallydegrades certain bonds in the peptidoglycan backbone. The C-terminaldomain of the LYTA protein is responsible for the affinity to thecholine or to some choline analogues such as DEAE. This property hasbeen exploited for the development of E. coli C-LYTA expressing plasmidsuseful for expression of fusion proteins. Purification of hybridproteins containing the C-LYTA fragment at the amino terminus has beendescribed (see Biotechnology 10:795-798, 1992). Within a preferredembodiment, a repeat portion of LYTA may be incorporated into a fusionprotein. A repeat portion is found in the C-terminal region starting atresidue 178. A particularly preferred repeat portion incorporatesresidues 188-305.

In another embodiment, a Mycobacterium tuberculosis-derived Ra12polynucleotide is linked to at least an immunogenic portion of apolynucleotide of this invention. Ra12 compositions and methods fortheir use in enhancing expression of heterologous polynucleotidesequences is described in U.S. Patent Application 60/158,585, thedisclosure of which is incorporated herein by reference in its entirety.Briefly, Ra12 refers to a polynucleotide region that is a subsequence ofa Mycobacterium tuberculosis MTB32A nucleic acid. MTB32A is a serineprotease of 32 KD molecular weight encoded by a gene in virulent andavirulent strains of M. tuberculosis. The nucleotide sequence and aminoacid sequence of MTB32A have been described (U.S. Patent Application60/158,585; see also, Skeiky et al., Infection and Immun. (1999)67:3998-4007, incorporated herein by reference. In one embodiment, theRa12 polypeptide used in the production of fusion polypeptides comprisesa C-terminal fragment of the MTB32A coding sequence that is effectivefor enhancing the expression and/or immunogenicity of heterologousChlamydial antigenic polypeptides with which it is fused. In anotherembodiment, the Ra12 polypeptide corresponds to an approximately 14 kDC-terminal fragment of MTB32A comprising some or all of amino acidresidues 192 to 323 of MTB32A.

Recombinant nucleic acids, which encode a fusion polypeptide comprisinga Ra12 polypeptide and a heterologous Chlamydia polypeptide of interest,can be readily constructed by conventional genetic engineeringtechniques. Recombinant nucleic acids are constructed so that,preferably, a Ra12 polynucleotide sequence is located 5′ to a selectedheterologous Chlamydia polynucleotide sequence. It may also beappropriate to place a Ra12 polynucleotide sequence 3′ to a selectedheterologous polynucleotide sequence or to insert a heterologouspolynucleotide sequence into a site within a Ra12 polynucleotidesequence.

In addition, any suitable polynucleotide that encodes a Ra12 or aportion or other variant thereof can be used in constructing recombinantfusion polynucleotides comprising Ra12 and one or more Chlamydiapolynucleotides disclosed herein. Preferred Ra12 polynucleotidesgenerally comprise at least about 15 consecutive nucleotides, at leastabout 30 nucleotides, at least about 60 nucleotides, at least about 100nucleotides, at least about 200 nucleotides, or at least about 300nucleotides that encode a portion of a Ra12 polypeptide.

Ra12 polynucleotides may comprise a native sequence (i.e., an endogenoussequence that encodes a Ra12 polypeptide or a portion thereof) or maycomprise a variant of such a sequence. Ra12 polynucleotide variants maycontain one or more substitutions, additions, deletions and/orinsertions such that the biological activity of the encoded fusionpolypeptide is not substantially diminished, relative to a fusionpolypeptide comprising a native Ra12 polypeptide. Variants preferablyexhibit at least about 70% identity, more preferably at least about 80%identity and most preferably at least about 90% identity to apolynucleotide sequence that encodes a native Ra12 polypeptide or aportion thereof.

In another aspect, the present invention provides methods for using oneor more of the above polypeptides or fusion proteins (or polynucleotidesencoding such polypeptides or fusion proteins) to induce protectiveimmunity against Chlamydial infection in a patient. As used herein, a“patient” refers to any warm-blooded animal, preferably a human. Apatient may be afflicted with a disease, or may be free of detectabledisease and/or infection. In other words, protective immunity may beinduced to prevent or treat Chlamydial infection.

In this aspect, the polypeptide, fusion protein or polynucleotidemolecule is generally present within a pharmaceutical composition or avaccine. Pharmaceutical compositions may comprise one or morepolypeptides, each of which may contain one or more of the abovesequences (or variants thereof), and a physiologically acceptablecarrier. Vaccines may comprise one or more of the above polypeptides andan immunostimulant, such as an adjuvant or a liposome (into which thepolypeptide is incorporated). Such pharmaceutical compositions andvaccines may also contain other Chlamydia antigens, either incorporatedinto a combination polypeptide or present within a separate polypeptide.

Alternatively, a vaccine may contain polynucleotides encoding one ormore polypeptides or fusion proteins as described above, such that thepolypeptide is generated in situ. In such vaccines, the polynucleotidesmay be present within any of a variety of delivery systems known tothose of ordinary skill in the art, including nucleic acid expressionsystems, bacterial and viral expression systems. Appropriate nucleicacid expression systems contain the necessary polynucleotide sequencesfor expression in the patient (such as a suitable promoter andterminating signal). Bacterial delivery systems involve theadministration of a bacterium (such as Bacillus-Calmette-Guerrin) thatexpresses an immunogenic portion of the polypeptide on its cell surface.In a preferred embodiment, the polynucleotides may be introduced using aviral expression system (e.g., vaccinia or other pox virus, retrovirus,or adenovirus), which may involve the use of a non-pathogenic(defective) virus. Techniques for incorporating polynucleotides intosuch expression systems are well known to those of ordinary skill in theart. The polynucleotides may also be administered as “naked” plasmidvectors as described, for example, in Ulmer et al., Science259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692,1993.Techniques for incorporating DNA into such vectors are well knownto those of ordinary skill in the art. A retroviral vector mayadditionally transfer or incorporate a gene for a selectable marker (toaid in the identification or selection of transduced cells) and/or atargeting moiety, such as a gene that encodes a ligand for a receptor ona specific target cell, to render the vector target specific. Targetingmay also be accomplished using an antibody, by methods known to those ofordinary skill in the art.

Other formulations for therapeutic purposes include colloidal dispersionsystems, such as macromolecule complexes, nanocapsules, microspheres,beads, and lipid-based systems including oil-in-water emulsions,micelles, mixed micelles, and liposomes. A preferred colloidal systemfor use as a delivery vehicle in vitro and in vivo is a liposome (i.e.,an artificial membrane vesicle). The uptake of naked polynucleotides maybe increased by incorporating the polynucleotides into and/or ontobiodegradable beads, which are efficiently transported into the cells.The preparation and use of such systems is well known in the art.

In a related aspect, a polynucleotide vaccine as described above may beadministered simultaneously with or sequentially to either a polypeptideof the present invention or a known Chlamydia antigen. For example,administration of polynucleotides encoding a polypeptide of the presentinvention, either “naked” or in a delivery system as described above,may be followed by administration of an antigen in order to enhance theprotective immune effect of the vaccine.

Polypeptides and polynucleotides disclosed herein may also be employedin adoptive immunotherapy for the treatment of Chlamydial infection.Adoptive immunotherapy may be broadly classified into either active orpassive immunotherapy. In active immunotherapy, treatment relies on thein vivo stimulation of the endogenous host immune system with theadministration of immune response-modifying agents (for example,vaccines, bacterial adjuvants, and/or cytokines).

In passive immunotherapy, treatment involves the delivery of biologicreagents with established immune reactivity (such as effector cells orantibodies) that can directly or indirectly mediate anti-Chlamydiaeffects and does not necessarily depend on an intact host immune system.Examples of effector cells include T lymphocytes (for example, CD8+cytotoxic T-lymphocyte, CD4+ T-helper), killer cells (such as NaturalKiller cells, lymphokine-activated killer cells), B cells, or antigenpresenting cells (such as dendritic cells and macrophages) expressingthe disclosed antigens. The polypeptides disclosed herein may also beused to generate antibodies or anti-idiotypic antibodies (as in U.S.Pat. No. 4,918,164), for passive immunotherapy.

The predominant method of procuring adequate numbers of T-cells foradoptive immunotherapy is to grow immune T-cells in vitro. Cultureconditions for expanding single antigen-specific T-cells to severalbillion in number with retention of antigen recognition in vivo are wellknown in the art. These in vitro culture conditions typically utilizeintermittent stimulation with antigen, often in the presence ofcytokines, such as IL-2, and non-dividing feeder cells. As noted above,the immunoreactive polypeptides described herein may be used to rapidlyexpand antigen-specific T cell cultures in order to generate sufficientnumber of cells for immunotherapy. In particular, antigen-presentingcells, such as dendritic, macrophage, monocyte, fibroblast, or B-cells,may be pulsed with immunoreactive polypeptides, or polynucleotidesequence(s) may be introduced into antigen presenting cells, using avariety of standard techniques well known in the art. For example,antigen presenting cells may be transfected or transduced with apolynucleotide sequence, wherein said sequence contains a promoterregion appropriate for increasing expression, and can be expressed aspart of a recombinant virus or other expression system. Several viralvectors may be used to transduce an antigen presenting cell, includingpox virus, vaccinia virus, and adenovirus; also, antigen presentingcells may be transfected with polynucleotide sequences disclosed hereinby a variety of means, including gene-gun technology, lipid-mediateddelivery, electroporation, osmotic shock, and particulate deliverymechanisms, resulting in efficient and acceptable expression levels asdetermined by one of ordinary skill in the art. For cultured T-cells tobe effective in therapy, the cultured T-cells must be able to grow anddistribute widely and to survive long term in vivo. Studies havedemonstrated that cultured T-cells can be induced to grow in vivo and tosurvive long term in substantial numbers by repeated stimulation withantigen supplemented with IL-2 (see, for example, Cheever, M., et al,“Therapy With Cultured T Cells: Principles Revisited,” ImmunologicalReviews, 157:177, 1997).

The polypeptides disclosed herein may also be employed to generateand/or isolate chlamydial-reactive T-cells, which can then beadministered to the patient. In one technique, antigen-specific T-celllines may be generated by in vivo immunization with short peptidescorresponding to immunogenic portions of the disclosed polypeptides. Theresulting antigen specific CD8+ or CD4+ T-cell clones may be isolatedfrom the patient, expanded using standard tissue culture techniques, andreturned to the patient.

Alternatively, peptides corresponding to immunogenic portions of thepolypeptides may be employed to generate Chlamydia reactive T cellsubsets by selective in vitro stimulation and expansion of autologous Tcells to provide antigen-specific T cells which may be subsequentlytransferred to the patient as described, for example, by Chang et al,(Crit. Rev. Oncol. Hematol., 22(3), 213, 1996). Cells of the immunesystem, such as T cells, may be isolated from the peripheral blood of apatient, using a commercially available cell separation system, such asIsolex™ System, available from Nexell Therapeutics, Inc. Irvine, Calif.The separated cells are stimulated with one or more of theimmunoreactive polypeptides contained within a delivery vehicle, such asa microsphere, to provide antigen-specific T cells. The population ofantigen-specific T cells is then expanded using standard techniques andthe cells are administered back to the patient.

In other embodiments, T-cell and/or antibody receptors specific for thepolypeptides disclosed herein can be cloned, expanded, and transferredinto other vectors or effector cells for use in adoptive immunotherapy.In particular, T cells may be transfected with the appropriate genes toexpress the variable domains from chlamydia specific monoclonalantibodies as the extracellular recognition elements and joined to the Tcell receptor signaling chains, resulting in T cell activation, specificlysis, and cytokine release. This enables the T cell to redirect itsspecificity in an MHC-independent manner. See for example, Eshhar, Z.,Cancer Immunol Immunother, 45(3-4):131-6, 1997 and Hwu, P., et al,Cancer Res, 55(15):3369-73, 1995. Another embodiment may include thetransfection of chlamydia antigen specific alpha and beta T cellreceptor chains into alternate T cells, as in Cole, D J, et al, CancerRes, 55(4):748-52, 1995.

In a further embodiment, syngeneic or autologous dendritic cells may bepulsed with peptides corresponding to at least an immunogenic portion ofa polypeptide disclosed herein. The resulting antigen-specific dendriticcells may either be transferred into a patient, or employed to stimulateT cells to provide antigen-specific T cells which may, in turn, beadministered to a patient. The use of peptide-pulsed dendritic cells togenerate antigen-specific T cells and the subsequent use of suchantigen-specific T cells to eradicate disease in a murine model has beendemonstrated by Cheever et al, Immunological Reviews, 157:177, 1997).Additionally, vectors expressing the disclosed polynucleotides may beintroduced into stem cells taken from the patient and clonallypropagated in vitro for autologous transplant back into the samepatient.

Within certain aspects, polypeptides, polynucleotides, T cells and/orbinding agents disclosed herein may be incorporated into pharmaceuticalcompositions or immunogenic compositions (i.e., vaccines).Alternatively, a pharmaceutical composition may comprise anantigen-presenting cell (e.g. a dendritic cell) transfected with aChlamydial polynucleotide such that the antigen presenting cellexpresses a Chlamydial polypeptide. Pharmaceutical compositions compriseone or more such compounds and a physiologically acceptable carrier.Vaccines may comprise one or more such compounds and an immunostimulant.An immunostimulant may be any substance that enhances or potentiates animmune response to an exogenous antigen. Examples of immunostimulantsinclude adjuvants, biodegradable microspheres (e.g., polylacticgalactide) and liposomes (into which the compound is incorporated; seee.g., Fullerton, U.S. Pat. No. 4,235,877). Vaccine preparation isgenerally described in, for example, M. F. Powell and M. J. Newman,eds., “Vaccine Design (the subunit and adjuvant approach),” Plenum Press(NY, 1995). Pharmaceutical compositions and vaccines within the scope ofthe present invention may also contain other compounds, which may bebiologically active or inactive. For example, one or more immunogenicportions of other Chlamydial antigens may be present, eitherincorporated into a fusion polypeptide or as a separate compound, withinthe composition or vaccine.

A pharmaceutical composition or vaccine may contain DNA encoding one ormore of the polypeptides as described above, such that the polypeptideis generated in situ. As noted above, the DNA may be present within anyof a variety of delivery systems known to those of ordinary skill in theart, including nucleic acid expression systems, bacteria and viralexpression systems. Numerous gene delivery techniques are well known inthe art, such as those described by Rolland, Crit. Rev. Therap. DrugCarrier Systems 15:143-198, 1998, and references cited therein.Appropriate nucleic acid expression systems contain the necessary DNAsequences for expression in the patient (such as a suitable promoter andterminating signal). Bacterial delivery systems involve theadministration of a bacterium (such as Bacillus-Calmette-Guerrin) thatexpresses an immunogenic portion of the polypeptide on its cell surfaceor secretes such an epitope.

In a preferred embodiment, the DNA may be introduced using a viralexpression system (e.g., vaccinia or other pox virus, retrovirus,adenovirus, baculovirus, togavirus, bacteriophage, and the like), whichoften involves the use of a non-pathogenic (defective), replicationcompetent virus.

For example, many viral expression vectors are derived from viruses ofthe retroviridae family. This family includes the murine leukemiaviruses, the mouse mammary tumor viruses, the human foamy viruses, Roussarcoma virus, and the immunodeficiency viruses, including human,simian, and feline. Considerations when designing retroviral expressionvectors are discussed in Comstock et al. (1997).

Excellent murine leukemia virus (MLV)-based viral expression vectorshave been developed by Kim et al. (1998). In creating the MLV vectors,Kim et al. found that the entire gag sequence, together with theimmediate upstream region, could be deleted without significantlyaffecting viral packaging or gene expression. Further, it was found thatnearly the entire U3 region could be replaced with the immediately-earlypromoter of human cytomegalovirus without deleterious effects.Additionally, MCR and internal ribosome entry sites (IRES) could beadded without adverse effects. Based on their observations, Kim et al.have designed a series of MLV-based expression vectors comprising one ormore of the features described above.

As more has been learned about human foamy virus (HFV), characteristicsof HFV that are favorable for its use as an expression vector have beendiscovered. These characteristics include the expression of pol bysplicing and start of translation at a defined initiation codon. Otheraspects of HFV viral expression vectors are reviewed in Bodem et al.(1997).

Murakami et al. (1997) describe a Rous sarcoma virus (RSV)-basedreplication-competent avian retrovirus vectors, IR1 and IR2 to express aheterologous gene at a high level. In these vectors, the IRES derivedfrom encephalomyocarditis virus (EMCV) was inserted between the env geneand the heterologous gene. The IR1 vector retains the splice-acceptorsite that is present downstream of the env gene while the IR2 vectorlacks it. Murakami et al. have shown high level expression of severaldifferent heterologous genes by these vectors.

Recently, a number of lentivirus-based retroviral expression vectorshave been developed. Kafri et al. (1997) have shown sustained expressionof genes delivered directly into liver and muscle by a humanimmunodeficiency virus (HIV)-based expression vector. One benefit of thesystem is the inherent ability of HIV to transduce non-dividing cells.Because the viruses of Kafri et al. are pseudotyped with vesicularstomatitis virus G glycoprotein (VSVG), they can transduce a broad rangeof tissues and cell types.

A large number of adenovirus-based expression vectors have beendeveloped, primarily due to the advantages offered by these vectors ingene therapy applications. Adenovirus expression vectors and methods ofusing such vectors are the subject of a number of United States patents,including U.S. Pat. No. 5,698,202, U.S. Pat. No. 5,616,326, U.S. Pat.No. 5,585,362, and U.S. Pat. No. 5,518,913, all incorporated herein byreference.

Additional adenoviral constructs are described in Khatri et al. (1997)and Tomanin et al. (1997). Khatri et al. describe novel ovine adenovirusexpression vectors and their ability to infect bovine nasal turbinateand rabbit kidney cells as well as a range of human cell type, includinglung and foreskin fibroblasts as well as liver, prostate, breast, colonand retinal lines. Tomanin et al. describe adenoviral expression vectorscontaining the T7 RNA polymerase gene. When introduced into cellscontaining a heterologous gene operably linked to a T7 promoter, thevectors were able to drive gene expression from the T7 promoter. Theauthors suggest that this system may be useful for the cloning andexpression of genes encoding cytotoxic proteins.

Poxviruses are widely used for the expression of heterologous genes inmammalian cells. Over the years, the vectors have been improved to allowhigh expression of the heterologous gene and simplify the integration ofmultiple heterologous genes into a single molecule. In an effort todiminish cytopathic effects and to increase safety, vaccinia virusmutant and other poxviruses that undergo abortive infection in mammaliancells are receiving special attention (Oertli et al., 1997). The use ofpoxviruses as expression vectors is reviewed in Carroll and Moss (1997).

Togaviral expression vectors, which includes alphaviral expressionvectors have been used to study the structure and function of proteinsand for protein production purposes. Attractive features of togaviralexpression vectors are rapid and efficient gene expression, wide hostrange, and RNA genomes (Huang, 1996). Also, recombinant vaccines basedon alphaviral expression vectors have been shown to induce a stronghumoral and cellular immune response with good immunological memory andprotective effects (Tubulekas et al., 1997). Alphaviral expressionvectors and their use are discussed, for example, in Lundstrom (1997).

In one study, L1 and Garoff (1996) used Semliki Forest virus (SFV)expression vectors to express retroviral genes and to produce retroviralparticles in BHK-21 cells. The particles produced by this method hadprotease and reverse transcriptase activity and were infectious.Furthermore, no helper virus could be detected in the virus stocks.Therefore, this system has features that are attractive for its use ingene therapy protocols.

Baculoviral expression vectors have traditionally been used to expressheterologous proteins in insect cells. Examples of proteins includemammalian chemokine receptors (Wang et al., 1997), reporter proteinssuch as green fluorescent protein (Wu et al., 1997), and FLAG fusionproteins (Wu et al., 1997; Koh et al., 1997). Recent advances inbaculoviral expression vector technology, including their use in viriondisplay vectors and expression in mammalian cells is reviewed by Possee(1997). Other reviews on baculoviral expression vectors include Jonesand Morikawa (1996) and O'Reilly (1997).

Other suitable viral expression systems are disclosed, for example, inFisher-Hoch et al., Proc. Natl. Acad. Sci. USA 86:317-321, 1989; Flexneret al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO89/01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO91/02805; Berkner, Biotechniques 6:616-627, 1988; Rosenfeld et al.,Science 252:431-434, 1991; Kolls et al., Proc. Natl. Acad. Sci. USA91:215-219, 1994; Kass-Eisler et al., Proc. Natl. Acad. Sci. USA90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; andGuzman et al., Cir. Res. 73:1202-1207, 1993. Techniques forincorporating DNA into such expression systems are well known to thoseof ordinary skill in the art. In other systems, the DNA may beintroduced as “naked” DNA, as described, for example, in Ulmer et al.,Science 259:1745-1749, 1993 and reviewed by Cohen, Science259:1691-1692, 1993. The uptake of naked DNA may be increased by coatingthe DNA onto biodegradable beads, which are efficiently transported intothe cells.

It will be apparent that a vaccine may comprise a polynucleotide and/ora polypeptide component, as desired. It will also be apparent that avaccine may contain pharmaceutically acceptable salts of thepolynucleotides and/or polypeptides provided herein. Such salts may beprepared from pharmaceutically acceptable non-toxic bases, includingorganic bases (e.g., salts of primary, secondary and tertiary amines andbasic amino acids) and inorganic bases (e.g., sodium, potassium,lithium, ammonium, calcium and magnesium salts). While any suitablecarrier known to those of ordinary skill in the art may be employed inthe pharmaceutical compositions of this invention, the type of carrierwill vary depending on the mode of administration. Compositions of thepresent invention may be formulated for any appropriate manner ofadministration, including for example, topical, oral, nasal,intravenous, intracranial, intraperitoneal, subcutaneous orintramuscular administration. For parenteral administration, such assubcutaneous injection, the carrier preferably comprises water, saline,alcohol, a fat, a wax or a buffer. For oral administration, any of theabove carriers or a solid carrier, such as mannitol, lactose, starch,magnesium stearate, sodium saccharine, talcum, cellulose, glucose,sucrose, and magnesium carbonate, may be employed. Biodegradablemicrospheres (e.g., polylactate polyglycolate) may also be employed ascarriers for the pharmaceutical compositions of this invention. Suitablebiodegradable microspheres are disclosed, for example, in U.S. Pat. Nos.4,897,268 and 5,075,109.

Such compositions may also comprise buffers (e.g., neutral bufferedsaline or phosphate buffered saline), carbohydrates (e.g., glucose,mannose, sucrose or dextrans), mannitol, proteins, polypeptides or aminoacids such as glycine, antioxidants, bacteriostats, chelating agentssuch as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide),solutes that render the formulation isotonic, hypotonic or weaklyhypertonic with the blood of a recipient, suspending agents, thickeningagents and/or preservatives. Alternatively, compositions of the presentinvention may be formulated as a lyophilizate. Compounds may also beencapsulated within liposomes using well known technology.

Any of a variety of immunostimulants may be employed in the vaccines ofthis invention. For example, an adjuvant may be included. Most adjuvantscontain a substance designed to protect the antigen from rapidcatabolism, such as aluminum hydroxide or mineral oil, and a stimulatorof immune responses, such as lipid A, Bortadella pertussis orMycobacterium tuberculosis derived proteins. Suitable adjuvants arecommercially available as, for example, Freund's Incomplete Adjuvant andComplete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant65 (Merck and Company, Inc., Rahway, N.J.); AS-2 (SmithKline Beecham,Philadelphia, Pa.); aluminum salts such as aluminum hydroxide gel (alum)or aluminum phosphate; salts of calcium, iron or zinc; an insolublesuspension of acylated tyrosine; acylated sugars; cationically oranionically derivatized polysaccharides; polyphosphazenes; biodegradablemicrospheres; monophosphoryl lipid A and quil A. Cytokines, such asGM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

Within the vaccines provided herein, under select circumstances, theadjuvant composition may be designed to induce an immune responsepredominantly of the Th1 type or Th2 type. High levels of Th1-typecytokines (e.g., IFN-γ, TNFα, IL-2 and IL-12) tend to favor theinduction of cell mediated immune responses to an administered antigen.In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6and IL-10) tend to favor the induction of humoral immune responses.Following application of a vaccine as provided herein, a patient willsupport an immune response that includes Th1- and Th2-type responses.Within a preferred embodiment, in which a response is predominantlyTh1-type, the level of Th1-type cytokines will increase to a greaterextent than the level of Th2-type cytokines. The levels of thesecytokines may be readily assessed using standard assays. For a review ofthe families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol.7:145-173, 1989.

Preferred adjuvants for use in eliciting a predominantly Th1-typeresponse include, for example, a combination of monophosphoryl lipid A,preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), togetherwith an aluminum salt. MPL adjuvants are available from CorixaCorporation (Seattle, Wash.; see U.S. Pat. Nos. 4,436,727; 4,877,611;4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which theCpG dinucleotide is unmethylated) also induce a predominantly Th1response. Such oligonucleotides are well known and are described, forexample, in WO 96/02555 and WO 99/33488. Immunostimulatory DNA sequencesare also described, for example, by Sato et al., Science 273:352, 1996.Another preferred adjuvant is a saponin, preferably QS21 (AquilaBiopharmaceuticals Inc., Framingham, Mass.), which may be used alone orin combination with other adjuvants. For example, an enhanced systeminvolves the combination of a monophosphoryl lipid A and saponinderivative, such as the combination of QS21 and 3D-MPL as described inWO 94/00153, or a less reactogenic composition where the QS21 isquenched with cholesterol, as described in WO 96/33739. Other preferredformulations comprise an oil-in-water emulsion and tocopherol. Aparticularly potent adjuvant formulation involving QS21, 3D-MPL andtocopherol in an oil-in-water emulsion is described in WO 95/17210.

Other preferred adjuvants include Montanide ISA 720 (Seppic, France),SAF (Chiron, Calif., United States), ISCOMS (CSL), MF-59 (Chiron), theSBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available fromSmithKline Beecham, Rixensart, Belgium), Detox (Corixa Corporation;Seattle, Wash.), RC-529 (Corixa Corporation; Seattle, Wash.) and otheraminoalkyl glucosaminide 4-phosphates (AGPs), such as those described inpending U.S. patent application Ser. Nos. 08/853,826 and 09/074,720, thedisclosures of which are incorporated herein by reference in theirentireties.

Any vaccine provided herein may be prepared using well known methodsthat result in a combination of antigen, immunostimulant and a suitablecarrier or excipient. The compositions described herein may beadministered as part of a sustained release formulation (i.e., aformulation such as a capsule, sponge or gel (composed ofpolysaccharides, for example) that effects a slow release of compoundfollowing administration). Such formulations may generally be preparedusing well known technology (see, e.g., Coombes et al., Vaccine14:1429-1438, 1996) and administered by, for example, oral, rectal orsubcutaneous implantation, or by implantation at the desired targetsite. Sustained-release formulations may contain a polypeptide,polynucleotide or antibody dispersed in a carrier matrix and/orcontained within a reservoir surrounded by a rate controlling membrane.

Carriers for use within such formulations are biocompatible, and mayalso be biodegradable; preferably the formulation provides a relativelyconstant level of active component release. Such carriers includemicroparticles of poly(lactide-co-glycolide), as well as polyacrylate,latex, starch, cellulose and dextran. Other delayed-release carriersinclude supramolecular biovectors, which comprise a non-liquidhydrophilic core (e.g., a cross-linked polysaccharide oroligosaccharide) and, optionally, an external layer comprising anamphiphilic compound, such as a phospholipid (see e.g., U.S. Pat. No.5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO96/06638). The amount of active compound contained within a sustainedrelease formulation depends upon the site of implantation, the rate andexpected duration of release and the nature of the condition to betreated or prevented.

Any of a variety of delivery vehicles may be employed withinpharmaceutical compositions and vaccines to facilitate production of anantigen-specific immune response that targets Chlamydia-infected cells.Delivery vehicles include antigen presenting cells (APCs), such asdendritic cells, macrophages, B cells, monocytes and other cells thatmay be engineered to be efficient APCs. Such cells may, but need not, begenetically modified to increase the capacity for presenting theantigen, to improve activation and/or maintenance of the T cellresponse, to have anti-Chlamydia effects per se and/or to beimmunologically compatible with the receiver (i.e., matched HLAhaplotype). APCs may generally be isolated from any of a variety ofbiological fluids and organs, and may be autologous, allogeneic,syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendriticcells or progenitors thereof as antigen-presenting cells. Dendriticcells are highly potent APCs (Banchereau and Steinman, Nature392:245-251, 1998) and have been shown to be effective as aphysiological adjuvant for eliciting prophylactic or therapeuticimmunity (see Timmerman and Levy, Ann. Rev. Med. 50:507-529, 1999). Ingeneral, dendritic cells may be identified based on their typical shape(stellate in situ, with marked cytoplasmic processes (dendrites) visiblein vitro), their ability to take up, process and present antigens withhigh efficiency, and their ability to activate naïve T cell responses.Dendritic cells may, of course, be engineered to express specificcell-surface receptors or ligands that are not commonly found ondendritic cells in vivo or ex vivo, and such modified dendritic cellsare contemplated by the present invention. As an alternative todendritic cells, secreted vesicles antigen-loaded dendritic cells(called exosomes) may be used within a vaccine (see Zitvogel et al.,Nature Med. 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood,bone marrow, lymph nodes, spleen, skin, umbilical cord blood or anyother suitable tissue or fluid. For example, dendritic cells may bedifferentiated ex vivo by adding a combination of cytokines such asGM-CSF, IL-4, IL-13 and/or TNFα to cultures of monocytes harvested fromperipheral blood. Alternatively, CD34 positive cells harvested fromperipheral blood, umbilical cord blood or bone marrow may bedifferentiated into dendritic cells by adding to the culture mediumcombinations of GM-CSF, IL-3, TNFα, CD40 ligand, LPS, flt3 ligand and/orother compound(s) that induce differentiation, maturation andproliferation of dendritic cells.

Dendritic cells are conveniently categorized as “immature” and “mature”cells, which allows a simple way to discriminate between two wellcharacterized phenotypes. However, this nomenclature should not beconstrued to exclude all possible intermediate stages ofdifferentiation. Immature dendritic cells are characterized as APC witha high capacity for antigen uptake and processing, which correlates withthe high expression of Fcγ receptor and mannose receptor. The maturephenotype is typically characterized by a lower expression of thesemarkers, but a high expression of cell surface molecules responsible forT cell activation such as class I and class II MHC, adhesion molecules(e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80,CD86 and 4-1 BB).

APCs may generally be transfected with a polynucleotide encoding aChlamydial protein (or portion or other variant thereof) such that theChlamydial polypeptide, or an immunogenic portion thereof, is expressedon the cell surface. Such transfection may take place ex vivo, and acomposition or vaccine comprising such transfected cells may then beused for therapeutic purposes, as described herein. Alternatively, agene delivery vehicle that targets a dendritic or other antigenpresenting cell may be administered to a patient, resulting intransfection that occurs in vivo. In vivo and ex vivo transfection ofdendritic cells, for example, may generally be performed using anymethods known in the art, such as those described in WO 97/24447, or thegene gun approach described by Mahvi et al., Immunology and cell Biology75:456-460, 1997. Antigen loading of dendritic cells may be achieved byincubating dendritic cells or progenitor cells with the Chlamydialpolypeptide, DNA (naked or within a plasmid vector) or RNA; or withantigen-expressing recombinant bacterium or viruses (e.g., vaccinia,fowlpox, adenovirus or lentivirus vectors). Prior to loading, thepolypeptide may be covalently conjugated to an immunological partnerthat provides T cell help (e.g., a carrier molecule). Alternatively, adendritic cell may be pulsed with a non-conjugated immunologicalpartner, separately or in the presence of the polypeptide.

Routes and frequency of administration of pharmaceutical compositionsand vaccines, as well as dosage, will vary from individual toindividual. In general, the pharmaceutical compositions and vaccines maybe administered by injection (e.g., intracutaneous, intramuscular,intravenous or subcutaneous), intranasally (e.g., by aspiration) ororally. Between 1 and 3 doses may be administered for a 1-36 weekperiod. Preferably, 3 doses are administered, at intervals of 3-4months, and booster vaccinations may be given periodically thereafter.Alternate protocols may be appropriate for individual patients. Asuitable dose is an amount of polypeptide or DNA that, when administeredas described above, is capable of raising an immune response in animmunized patient sufficient to protect the patient from Chlamydialinfection for at least 1-2 years. In general, the amount of polypeptidepresent in a dose (or produced in situ by the DNA in a dose) ranges fromabout 1 pg to about 100 mg per kg of host, typically from about 10 pg toabout 1 mg, and preferably from about 100 pg to about 1 μg. Suitabledose sizes will vary with the size of the patient, but will typicallyrange from about 0.1 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the artmay be employed in the pharmaceutical compositions of this invention,the type of carrier will vary depending on the mode of administration.For parenteral administration, such as subcutaneous injection, thecarrier preferably comprises water, saline, alcohol, a fat, a wax or abuffer. For oral administration, any of the above carriers or a solidcarrier, such as mannitol, lactose, starch, magnesium stearate, sodiumsaccharine, talcum, cellulose, glucose, sucrose, and magnesiumcarbonate, may be employed. Biodegradable microspheres (e.g., polylacticgalactide) may also be employed as carriers for the pharmaceuticalcompositions of this invention. Suitable biodegradable microspheres aredisclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

In general, an appropriate dosage and treatment regimen provides theactive compound(s) in an amount sufficient to provide therapeutic and/orprophylactic benefit. Such a response can be monitored by establishingan improved clinical outcome in treated patients as compared tonon-treated patients. Increases in preexisting immune responses to aChlamydial protein generally correlate with an improved clinicaloutcome. Such immune responses may generally be evaluated using standardproliferation, cytotoxicity or cytokine assays, which may be performedusing samples obtained from a patient before and after treatment.

In another aspect, the present invention provides methods for using thepolypeptides described above to diagnose Chlamydial infection. In thisaspect, methods are provided for detecting Chlamydial infection in abiological sample, using one or more of the above polypeptides, eitheralone or in combination. For clarity, the term “polypeptide” will beused when describing specific embodiments of the inventive diagnosticmethods. However, it will be clear to one of skill in the art that thefusion proteins of the present invention may also be employed in suchmethods.

As used herein, a “biological sample” is any antibody-containing sampleobtained from a patient. Preferably, the sample is whole blood, sputum,serum, plasma, saliva, cerebrospinal fluid or urine. More preferably,the sample is a blood, serum or plasma sample obtained from a patient.The polypeptides are used in an assay, as described below, to determinethe presence or absence of antibodies to the polypeptide(s) in thesample, relative to a predetermined cut-off value. The presence of suchantibodies indicates previous sensitization to Chlamydia antigens whichmay be indicative of Chlamydia-infection.

In embodiments in which more than one polypeptide is employed, thepolypeptides used are preferably complementary (i.e., one componentpolypeptide will tend to detect infection in samples where the infectionwould not be detected by another component polypeptide). Complementarypolypeptides may generally be identified by using each polypeptideindividually to evaluate serum samples obtained from a series ofpatients known to be infected with Chlamydia. After determining whichsamples test positive (as described below) with each polypeptide,combinations of two or more polypeptides may be formulated that arecapable of detecting infection in most, or all, of the samples tested.

A variety of assay formats are known to those of ordinary skill in theart for using one or more polypeptides to detect antibodies in a sample.See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold SpringHarbor Laboratory, 1988, which is incorporated herein by reference. In apreferred embodiment, the assay involves the use of polypeptideimmobilized on a solid support to bind to and remove the antibody fromthe sample. The bound antibody may then be detected using a detectionreagent that contains a reporter group. Suitable detection reagentsinclude antibodies that bind to the antibody/polypeptide complex andfree polypeptide labeled with a reporter group (e.g., in asemi-competitive assay). Alternatively, a competitive assay may beutilized, in which an antibody that binds to the polypeptide is labeledwith a reporter group and allowed to bind to the immobilized antigenafter incubation of the antigen with the sample. The extent to whichcomponents of the sample inhibit the binding of the labeled antibody tothe polypeptide is indicative of the reactivity of the sample with theimmobilized polypeptide.

The solid support may be any solid material known to those of ordinaryskill in the art to which the antigen may be attached. For example, thesolid support may be a test well in a microtiter plate, or anitrocellulose or other suitable membrane. Alternatively, the supportmay be a bead or disc, such as glass, fiberglass, latex or a plasticmaterial such as polystyrene or polyvinylchloride. The support may alsobe a magnetic particle or a fiber optic sensor, such as those disclosed,for example, in U.S. Pat. No. 5,359,681.

The polypeptides may be bound to the solid support using a variety oftechniques known to those of ordinary skill in the art. In the contextof the present invention, the term “bound” refers to both noncovalentassociation, such as adsorption, and covalent attachment (which may be adirect linkage between the antigen and functional groups on the supportor may be a linkage by way of a cross-linking agent). Binding byadsorption to a well in a microtiter plate or to a membrane ispreferred. In such cases, adsorption may be achieved by contacting thepolypeptide, in a suitable buffer, with the solid support for a suitableamount of time. The contact time varies with temperature, but istypically between about 1 hour and 1 day. In general, contacting a wellof a plastic microtiter plate (such as polystyrene or polyvinylchloride)with an amount of polypeptide ranging from about 10 ng to about 1 μg,and preferably about 100 ng, is sufficient to bind an adequate amount ofantigen.

Covalent attachment of polypeptide to a solid support may generally beachieved by first reacting the support with a bifunctional reagent thatwill react with both the support and a functional group, such as ahydroxyl or amino group, on the polypeptide. For example, thepolypeptide may be bound to supports having an appropriate polymercoating using benzoquinone or by condensation of an aldehyde group onthe support with an amine and an active hydrogen on the polypeptide(see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, atA12-A13).

In certain embodiments, the assay is an enzyme linked immunosorbentassay (ELISA). This assay may be performed by first contacting apolypeptide antigen that has been immobilized on a solid support,commonly the well of a microtiter plate, with the sample, such thatantibodies to the polypeptide within the sample are allowed to bind tothe immobilized polypeptide. Unbound sample is then removed from theimmobilized polypeptide and a detection reagent capable of binding tothe immobilized antibody-polypeptide complex is added. The amount ofdetection reagent that remains bound to the solid support is thendetermined using a method appropriate for the specific detectionreagent.

More specifically, once the polypeptide is immobilized on the support asdescribed above, the remaining protein binding sites on the support aretypically blocked. Any suitable blocking agent known to those ofordinary skill in the art, such as bovine serum albumin (BSA) or Tween20™ (Sigma Chemical Co., St. Louis, Mo.) may be employed. Theimmobilized polypeptide is then incubated with the sample, and antibodyis allowed to bind to the antigen. The sample may be diluted with asuitable dilutent, such as phosphate-buffered saline (PBS) prior toincubation. In general, an appropriate contact time (i.e., incubationtime) is that period of time that is sufficient to detect the presenceof antibody within an HGE-infected sample. Preferably, the contact timeis sufficient to achieve a level of binding that is at least 95% of thatachieved at equilibrium between bound and unbound antibody. Those ofordinary skill in the art will recognize that the time necessary toachieve equilibrium may be readily determined by assaying the level ofbinding that occurs over a period of time. At room temperature, anincubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with anappropriate buffer, such as PBS containing 0.1% Tween 20™. Detectionreagent may then be added to the solid support. An appropriate detectionreagent is any compound that binds to the immobilizedantibody-polypeptide complex and that can be detected by any of avariety of means known to those in the art. Preferably, the detectionreagent contains a binding agent (such as, for example, Protein A,Protein G, immunoglobulin, lectin or free antigen) conjugated to areporter group. Preferred reporter groups include enzymes (such ashorseradish peroxidase), substrates, cofactors, inhibitors, dyes,radionuclides, luminescent groups, fluorescent groups and biotin. Theconjugation of binding agent to reporter group may be achieved usingstandard methods known to those of ordinary skill in the art. Commonbinding agents may also be purchased conjugated to a variety of reportergroups from many commercial sources (e.g., Zymed Laboratories, SanFrancisco, Calif., and Pierce, Rockford, Ill.).

The detection reagent is then incubated with the immobilizedantibody-polypeptide complex for an amount of time sufficient to detectthe bound antibody. An appropriate amount of time may generally bedetermined from the manufacturer's instructions or by assaying the levelof binding that occurs over a period of time. Unbound detection reagentis then removed and bound detection reagent is detected using thereporter group. The method employed for detecting the reporter groupdepends upon the nature of the reporter group. For radioactive groups,scintillation counting or autoradiographic methods are generallyappropriate. Spectroscopic methods may be used to detect dyes,luminescent groups and fluorescent groups. Biotin may be detected usingavidin, coupled to a different reporter group (commonly a radioactive orfluorescent group or an enzyme). Enzyme reporter groups may generally bedetected by the addition of substrate (generally for a specific periodof time), followed by spectroscopic or other analysis of the reactionproducts.

To determine the presence or absence of anti-Chlamydia antibodies in thesample, the signal detected from the reporter group that remains boundto the solid support is generally compared to a signal that correspondsto a predetermined cut-off value. In one preferred embodiment, thecut-off value is the average mean signal obtained when the immobilizedantigen is incubated with samples from an uninfected patient. Ingeneral, a sample generating a signal that is three standard deviationsabove the predetermined cut-off value is considered positive forChlamydia-infection. In an alternate preferred embodiment, the cut-offvalue is determined using a Receiver Operator Curve, according to themethod of Sackett et al., Clinical Epidemiology: A Basic Science forClinical Medicine, Little Brown and Co., 1985, pp. 106-107. Briefly, inthis embodiment, the cut-off value may be determined from a plot ofpairs of true positive rates (i.e., sensitivity) and false positiverates (100%-specificity) that correspond to each possible cut-off valuefor the diagnostic test result. The cut-off value on the plot that isthe closest to the upper left-hand corner (i.e., the value that enclosesthe largest area) is the most accurate cut-off value, and a samplegenerating a signal that is higher than the cut-off value determined bythis method may be considered positive. Alternatively, the cut-off valuemay be shifted to the left along the plot, to minimize the falsepositive rate, or to the right, to minimize the false negative rate. Ingeneral, a sample generating a signal that is higher than the cut-offvalue determined by this method is considered positive for Chlamydialinfection.

In a related embodiment, the assay is performed in a rapid flow-throughor strip test format, wherein the antigen is immobilized on a membrane,such as nitrocellulose. In the flow-through test, antibodies within thesample bind to the immobilized polypeptide as the sample passes throughthe membrane. A detection reagent (e.g., protein A-colloidal gold) thenbinds to the antibody-polypeptide complex as the solution containing thedetection reagent flows through the membrane. The detection of bounddetection reagent may then be performed as described above. In the striptest format, one end of the membrane to which polypeptide is bound isimmersed in a solution containing the sample. The sample migrates alongthe membrane through a region containing detection reagent and to thearea of immobilized polypeptide. Concentration of detection reagent atthe polypeptide indicates the presence of anti-Chlamydia antibodies inthe sample. Typically, the concentration of detection reagent at thatsite generates a pattern, such as a line, that can be read visually. Theabsence of such a pattern indicates a negative result. In general, theamount of polypeptide immobilized on the membrane is selected togenerate a visually discernible pattern when the biological samplecontains a level of antibodies that would be sufficient to generate apositive signal in an ELISA, as discussed above. Preferably, the amountof polypeptide immobilized on the membrane ranges from about 25 ng toabout 1 μg, and more preferably from about 50 ng to about 500 ng. Suchtests can typically be performed with a very small amount (e.g., onedrop) of patient serum or blood.

Of course, numerous other assay protocols exist that are suitable foruse with the polypeptides of the present invention. The abovedescriptions are intended to be exemplary only. One example of analternative assay protocol which may be usefully employed in suchmethods is a Western blot, wherein the proteins present in a biologicalsample are separated on a gel, prior to exposure to a binding agent.Such techniques are well known to those of skill in the art.

The present invention further provides agents, such as antibodies andantigen-binding fragments thereof, that specifically bind to aChlamydial protein. As used herein, an antibody, or antigen-bindingfragment thereof, is said to “specifically bind” to a Chlamydial proteinif it reacts at a detectable level (within, for example, an ELISA) witha Chlamydial protein, and does not react detectably with unrelatedproteins under similar conditions. As used herein, “binding” refers to anoncovalent association between two separate molecules such that acomplex is formed. The ability to bind may be evaluated by, for example,determining a binding constant for the formation of the complex. Thebinding constant is the value obtained when the concentration of thecomplex is divided by the product of the component concentrations. Ingeneral, two compounds are said to “bind,” in the context of the presentinvention, when the binding constant for complex formation exceeds about10³ L/mol. The binding constant may be determined using methods wellknown in the art.

Binding agents may be further capable of differentiating betweenpatients with and without a Chlamydial infection using therepresentative assays provided herein. In other words, antibodies orother binding agents that bind to a Chlamydial protein will generate asignal indicating the presence of a Chlamydial infection in at leastabout 20% of patients with the disease, and will generate a negativesignal indicating the absence of the disease in at least about 90% ofindividuals without infection. To determine whether a binding agentsatisfies this requirement, biological samples (e.g., blood, sera,sputum urine and/or tissue biopsies) from patients with and withoutChlamydial infection (as determined using standard clinical tests) maybe assayed as described herein for the presence of polypeptides thatbind to the binding agent. It will be apparent that a statisticallysignificant number of samples with and without the disease should beassayed. Each binding agent should satisfy the above criteria; however,those of ordinary skill in the art will recognize that binding agentsmay be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent.For example, a binding agent may be a ribosome, with or without apeptide component, an RNA molecule or a polypeptide. In a preferredembodiment, a binding agent is an antibody or an antigen-bindingfragment thereof. Antibodies may be prepared by any of a variety oftechniques known to those of ordinary skill in the art. See, e.g.,Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring HarborLaboratory, 1988. In general, antibodies can be produced by cell culturetechniques, including the generation of monoclonal antibodies asdescribed herein, or via transfection of antibody genes into suitablebacterial or mammalian cell hosts, in order to allow for the productionof recombinant antibodies. In one technique, an immunogen comprising thepolypeptide is initially injected into any of a wide variety of mammals(e.g., mice, rats, rabbits, sheep or goats). In this step, thepolypeptides of this invention may serve as the immunogen withoutmodification. Alternatively, particularly for relatively shortpolypeptides, a superior immune response may be elicited if thepolypeptide is joined to a carrier protein, such as bovine serum albuminor keyhole limpet hemocyanin. The immunogen is injected into the animalhost, preferably according to a predetermined schedule incorporating oneor more booster immunizations, and the animals are bled periodically.Polyclonal antibodies specific for the polypeptide may then be purifiedfrom such antisera by, for example, affinity chromatography using thepolypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interestmay be prepared, for example, using the technique of Kohler andMilstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto.Briefly, these methods involve the preparation of immortal cell linescapable of producing antibodies having the desired specificity (i.e.,reactivity with the polypeptide of interest). Such cell lines may beproduced, for example, from spleen cells obtained from an animalimmunized as described above. The spleen cells are then immortalized by,for example, fusion with a myeloma cell fusion partner, preferably onethat is syngeneic with the immunized animal. A variety of fusiontechniques may be employed. For example, the spleen cells and myelomacells may be combined with a nonionic detergent for a few minutes andthen plated at low density on a selective medium that supports thegrowth of hybrid cells, but not myeloma cells. A preferred selectiontechnique uses HAT (hypoxanthine, aminopterin, thymidine) selection.After a sufficient time, usually about 1 to 2 weeks, colonies of hybridsare observed. Single colonies are selected and their culturesupernatants tested for binding activity against the polypeptide.Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growinghybridoma colonies. In addition, various techniques may be employed toenhance the yield, such as injection of the hybridoma cell line into theperitoneal cavity of a suitable vertebrate host, such as a mouse.Monoclonal antibodies may then be harvested from the ascites fluid orthe blood. Contaminants may be removed from the antibodies byconventional techniques, such as chromatography, gel filtration,precipitation, and extraction. The polypeptides of this invention may beused in the purification process in, for example, an affinitychromatography step.

Within certain embodiments, the use of antigen-binding fragments ofantibodies may be preferred. Such fragments include Fab fragments, whichmay be prepared using standard techniques. Briefly, immunoglobulins maybe purified from rabbit serum by affinity chromatography on Protein Abead columns (Harlow and Lane, Antibodies: A Laboratory Manual, ColdSpring Harbor Laboratory, 1988) and digested by papain to yield Fab andFc fragments. The Fab and Fc fragments may be separated by affinitychromatography on protein A bead columns.

Monoclonal antibodies of the present invention may be coupled to one ormore therapeutic agents. Suitable agents in this regard includeradionuclides, differentiation inducers, drugs, toxins, and derivativesthereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re,¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, andpyrimidine and purine analogs. Preferred differentiation inducersinclude phorbol esters and butyric acid. Preferred toxins include ricin,abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin,Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (e.g., covalently bonded) to asuitable monoclonal antibody either directly or indirectly (e.g., via alinker group). A direct reaction between an agent and an antibody ispossible when each possesses a substituent capable of reacting with theother. For example, a nucleophilic group, such as an amino or sulfhydrylgroup, on one may be capable of reacting with a carbonyl-containinggroup, such as an anhydride or an acid halide, or with an alkyl groupcontaining a good leaving group (e.g., a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and anantibody via a linker group. A linker group can function as a spacer todistance an antibody from an agent in order to avoid interference withbinding capabilities. A linker group can also serve to increase thechemical reactivity of a substituent on an agent or an antibody, andthus increase the coupling efficiency. An increase in chemicalreactivity may also facilitate the use of agents, or functional groupson agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety ofbifunctional or polyfunctional reagents, both homo- andhetero-functional (such as those described in the catalog of the PierceChemical Co., Rockford, Ill.), may be employed as the linker group.Coupling may be effected, for example, through amino groups, carboxylgroups, sulfhydryl groups or oxidized carbohydrate residues. There arenumerous references describing such methodology, e.g., U.S. Pat. No.4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibodyportion of the immunoconjugates of the present invention, it may bedesirable to use a linker group which is cleavable during or uponinternalization into a cell. A number of different cleavable linkergroups have been described. The mechanisms for the intracellular releaseof an agent from these linker groups include cleavage by reduction of adisulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spitler), byirradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, toSenter et al.), by hydrolysis of derivatized amino acid side chains(e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serumcomplement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, toRodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No.4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In oneembodiment, multiple molecules of an agent are coupled to one antibodymolecule. In another embodiment, more than one type of agent may becoupled to one antibody. Regardless of the particular embodiment,immunoconjugates with more than one agent may be prepared in a varietyof ways. For example, more than one agent may be coupled directly to anantibody molecule, or linkers which provide multiple sites forattachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalentbonding either directly or via a linker group. Suitable carriers includeproteins such as albumins (e.g., U.S. Pat. No. 4,507,234, to Kato etal.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat.No. 4,699,784, to Shih et al.). A carrier may also bear an agent bynoncovalent bonding or by encapsulation, such as within a liposomevesicle (e.g., U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriersspecific for radionuclide agents include radiohalogenated smallmolecules and chelating compounds. For example, U.S. Pat. No. 4,735,792discloses representative radiohalogenated small molecules and theirsynthesis. A radionuclide chelate may be formed from chelating compoundsthat include those containing nitrogen and sulfur atoms as the donoratoms for binding the metal, or metal oxide, radionuclide. For example,U.S. Pat. No. 4,673,562, to Davison et al. discloses representativechelating compounds and their synthesis.

A variety of routes of administration for the antibodies andimmunoconjugates may be used. Typically, administration will beintravenous, intramuscular, subcutaneous or in site-specific regions byappropriate methods. It will be evident that the precise dose of theantibody/immunoconjugate will vary depending upon the antibody used, theantigen density, and the rate of clearance of the antibody.

Antibodies may be used in diagnostic tests to detect the presence ofChlamydia antigens using assays similar to those detailed above andother techniques well known to those of skill in the art, therebyproviding a method for detecting Chlamydial infection in a patient.

Diagnostic reagents of the present invention may also comprise DNAsequences encoding one or more of the above polypeptides, or one or moreportions thereof. For example, at least two oligonucleotide primers maybe employed in a polymerase chain reaction (PCR) based assay to amplifyChlamydia-specific cDNA derived from a biological sample, wherein atleast one of the oligonucleotide primers is specific for a DNA moleculeencoding a polypeptide of the present invention. The presence of theamplified cDNA is then detected using techniques well known in the art,such as gel electrophoresis. Similarly, oligonucleotide probes specificfor a DNA molecule encoding a polypeptide of the present invention maybe used in a hybridization assay to detect the presence of an inventivepolypeptide in a biological sample.

As used herein, the term “oligonucleotide primer/probe specific for aDNA molecule” means an oligonucleotide sequence that has at least about80%, preferably at least about 90% and more preferably at least about95%, identity to the DNA molecule in question. Oligonucleotide primersand/or probes which may be usefully employed in the inventive diagnosticmethods preferably have at least about 10-40 nucleotides. In a preferredembodiment, the oligonucleotide primers comprise at least about 10contiguous nucleotides of a DNA molecule encoding one of thepolypeptides disclosed herein. Preferably, oligonucleotide probes foruse in the inventive diagnostic methods comprise at least about 15contiguous oligonucleotides of a DNA molecule encoding one of thepolypeptides disclosed herein. Techniques for both PCR based assays andhybridization assays are well known in the art (see, for example, Mulliset al. Ibid; Ehrlich, Ibid). Primers or probes may thus be used todetect Chlamydia-specific sequences in biological samples. DNA probes orprimers comprising oligonucleotide sequences described above may be usedalone or in combination with each other.

The following Examples are offered by way of illustration and not by wayof limitation.

EXAMPLE 1 Isolation of DNA Sequences Encoding Chlamydia Antigens

Chlamydia antigens of the present invention were isolated by expressioncloning of a genomic DNA library of Chlamydia trachomatis LGV IIessentially as described by Sanderson et al. (J. Exp. Med., 1995,182:1751-1757) and were shown to induce PBMC proliferation and IFN-γ inan immunoreactive T cell line.

A Chlamydia-specific T cell line was generated by stimulating PBMCs froma normal donor with no history of chlamydial genital tract infectionwith elementary bodies of Chlamydia trachomatis LGV II. This T cellline, referred to as TCL-8, was found to recognize both Chlamydiatrachomatis and Chlamydia pneumonia infected monocyte-derived dendriticcells.

A randomly sheared genomic library of Chlamydia trachomatis LGV II wasconstructed in Lambda ZAP (Stratagene, La Jolla, Calif.) and theamplified library plated out in 96 well microtiter plates at a densityof 30 clones/well. Bacteria were induced to express recombinant proteinin the presence of 2 mM IPTG for 3 h, then pelleted and resuspended in200 μl of RPMI 10% FBS. 10 μl of the induced bacterial suspension wastransferred to 96 well plates containing autologous monocyte-deriveddendritic cells. After a 2 h incubation, dendritic cells were washed toremove free E. coli and Chlamydia-specific T cells were added. PositiveE. coli pools were identified by determining IFN-γ production andproliferation of the T cells in response to the pools.

Four positive pools were identified, which were broken down to yieldfour pure clones (referred to as 1-B1-66, 4-D7-28, 3-G3-10 and10-C10-31), with insert sizes of 481 bp, 183 bp, 110 bp and 1400 bp,respectively. The determined DNA sequences for 1-B1-66, 4-D7-28, 3-G3-10and 10-C10⁻³¹ are provided in SEQ ID NO: 1-4, respectively. Clone1-B1-66 is approximately in region 536690 of the C. trachomatis genome(NCBI C. trachomatis database). Within clone 1-B1-66, an open readingframe (ORF) has been identified (nucleotides 115-375) that encodes apreviously identified 9 kDa protein (Stephens, et al. Genbank AccessionNo. AE001320), the sequence of which is provided in SEQ ID NO: 5). Clone4-D7-28 is a smaller region of the same ORF (amino acids 22-82 of1-B1-66). Clone 3-G3-10 is approximately in region 74559 of the C.trachomatis genome. The insert is cloned in the antisense orientationwith respect to its orientation in the genome. The clone 10-C10-31contains an open reading frame that corresponds to a previouslypublished sequence for S13 ribosomal protein from Chlamydia trachomatis(Gu, L. et al. J. Bacteriology, 177:2594-2601, 1995). The predictedprotein sequences for 4-D7-28 and 10-C10-31 are provided in SEQ ID NO: 6and 12, respectively. Predicted protein sequences for 3-G3-10 areprovided in SEQ ID NO: 7-11.

In a related series of screening studies, an additional T cell line wasused to screen the genomic DNA library of Chlamydia trachomatis LGV IIdescribed above. A Chlamydia-specific T cell line (TCT-1) was derivedfrom a patient with a chlamydial genital tract infection by stimulatingpatient PBMC with autologous monocyte-derived dendritic cells infectedwith elementary bodies of Chlamydia trachomatis LGV II. One clone,4C9-18 (SEQ ID NO: 21), containing a 1256 bp insert, elicited a specificimmune response, as measured by standard proliferation assays, from theChlamydia-specific T cell line TCT-1. Subsequent analysis revealed thisclone to contain three known sequences: lipoamide dehydrogenase (GenbankAccession No. AE001326), disclosed in SEQ ID NO: 22; a hypotheticalprotein CT429 (Genbank Accession No. AE001316), disclosed in SEQ ID NO:23; and part of an open reading frame of ubiquinone methyltransferaseCT428 (Genbank Accession No. AE001316), disclosed in SEQ ID NO: 24.

In further studies involving clone 4C9-18 (SEQ ID NO: 21), thefull-length amino acid sequence for lipoamide dehydrognase (SEQ ID NO:22) from C. trachomatis (LGV II) was expressed in clone CtL2-LPDA-FL, asdisclosed in SEQ ID NO: 90.

To further characterize the open reading frame containing the T cellstimulating epitope(s), a cDNA fragment containing nucleotides 1-695 ofclone 4C9-18 with a cDNA sequence encoding a 6×-Histidine tag on theamino terminus was subcloned into the NdeI/EcoRI site of the pET17bvector (Novagen, Madison, Wis.), referred to as clone 4C9-18#2 BL21pLysS (SEQ ID NO: 25, with the corresponding amino acid sequenceprovided in SEQ ID NO: 26) and transformed into E. coli. Selectiveinduction of the transformed E. coli with 2 mM IPTG for three hoursresulted in the expression of a 26 kDa protein from clone 4C9-18#2 BL21pLysS, as evidenced by standard Coomassie-stained SDS-PAGE. To determinethe immunogenicity of the protein encoded by clone 4C9-18#2 BL21 pLysS,E. coli expressing the 26 kDa protein were titered onto 1×10⁴monocyte-derived dendritic cells and incubated for two hours. Thedendritic cell cultures were washed and 2.5×10⁴ T cells (TCT-1) addedand allowed to incubate for an additional 72 hours, at which time thelevel of IFN-γ in the culture supernatant was determined by ELISA. Asshown in FIG. 1, the T-cell line TCT-1 was found to respond to inducedcultures as measured by IFN-g, indicating a Chlamydia-specific T-cellresponse against the lipoamide dehydrogenase sequence. Similarly, theprotein encoded by clone 4C9-18#2 BL21 pLysS was shown to stimulate theTCT-1 T-cell line by standard proliferation assays.

Subsequent studies to identify additional Chlamydia trachomatis antigensusing the above-described CD4+ T-cell expression cloning techniqueyielded additional clones. The TCT-1 and TCL-8 Chlamydia-specific T-celllines, as well as the TCP-21 T-cell line were utilized to screen theChlamydia trachomatis LGVII genomic library. The TCP-21 T-cell line wasderived from a patient having a humoral immune response to Chlamydiapneumoniae. The TCT-1 cell line identified 37 positive pools, the TCT-3cell line identified 41 positive pools and the TCP-21 cell lineidentified 2 positive pools. The following clones were derived from 10of these positive pools. Clone 11-A3-93 (SEQ ID NO: 64), identified bythe TCP-21 cell line, is a 1339 bp genomic fragment sharing homology tothe HAD superfamily (CT103). The second insert in the same clone shareshomology with the fab I gene (CT104) present on the complementarystrand. Clone 11-C12-91 (SEQ ID NO: 63), identified using the TCP-21cell line, has a 269 bp insert that is part of the OMP2 gene (CT443) andshares homology with the 60 kDa cysteine rich outer membrane protein ofC. pneumoniae.

Clone 11-G10-46, (SEQ ID NO: 62), identified using the TCT-3 cell line,contains a 688 bp insert that shares homology to the hypotheticalprotein CT610. Clone 11-G1-34, (SEQ ID NO: 61), identified using theTCT-3 cell line, has two partial open reading frames (ORF) with aninsert size of 1215 bp. One ORF shares homology to the malatedehydrogenase gene (CT376), and the other ORF shares homology to theglycogen hydrolase gene (CT042). Clone 1′-H3-68, (SEQ ID NO: 60),identified using the TCT-3 cell line, has two ORFs with a total insertsize of 1180 bp. One partial ORF encodes the plasmid-encoded PGP6-Dvirulence protein while the second ORF is a complete ORF for the L1ribosomal gene (CT318). Clone 11-H4-28, (SEQ ID NO: 59), identifiedusing the TCT-3 cell line, has an insert size of 552 bp and is part ofthe ORF for the dnaK gene (CT396). Clone 12-B3-95, (SEQ ID NO: 58),identified using the TCT-1 cell line, has an insert size of 463 bp andis a part of the ORF for the lipoamide dehydrogenase gene (CT557).Clones 15-G1-89 and 12-B3-95 are identical, (SEQ ID NO: 55 and 58,respectively), identified using the TCT-1 cell line, has an insert sizeof 463 bp and is part of the ORF for the lipoamide dehydrogenase gene(CT557). Clone 12-G3-83, (SEQ ID NO: 57), identified using the TCT-1cell line, has an insert size of 1537 bp and has part of the ORF for thehypothetical protein CT622.

Clone 23-G7-68, (SEQ ID NO: 79), identified using the TCT-3 cell line,contains a 950 bp insert and contains a small part of the L11 ribosomalORF, the entire ORF for L1 ribosomal protein and a part of the ORF forL10 ribosomal protein. In addition, this clone also identified thepatient lines CT4, CT5, CT11, CT 12, and CHH037. Clone 22-F8-91, (SEQ IDNO: 80), identified using the TCT-1 cell line, contains a 395 bp insertthat contains a part of the pmpC ORF on the complementary strand of theclone. Clone 21-E8-95, (SEQ ID NO: 81), identified using the TCT-3 cellline, contains a 2,085 bp insert which contains part of CT613 ORF, thecomplete ORF for CT612, the complete ORF for CT611 and part of the ORFfor CT610. Clone 19-F12-57, (SEQ ID NO: 82), identified using the TCT-3cell line, contains a 405 bp insert which contains part of the CT 858ORF and a small part of the recA ORF. Clone 19-F12-53, (SEQ ID NO: 83),identified using the TCT-3 cell line, contains a 379 bp insert that ispart of the ORF for CT455 encoding glutamyl tRNA synthetase. Clone19-A5-54, (SEQ ID NO: 84), identified using the TCT-3 cell line,contains a 715 bp insert that is part of the ORF3 (complementary strandof the clone) of the cryptic plasmid. Clone 17-E11-72, (SEQ ID NO: 85),identified using the TCT-1 cell line, contains a 476 bp insert that ispart of the ORF for Opp_(—)2 and pmpD. The pmpD region of this clone iscovered by the pmpD region of clone 15-H2-76. Clone 17-C1-77, (SEQ IDNO: 86), identified using the patient cell lines CT3, CT1, CT4, andCT12, contains a 1551 bp insert that is part of the CT857 ORF, as wellas part of the CT858 ORF. Clone 15-H2-76, (SEQ ID NO: 87), identifiedusing the TCT-1 cell line, contains a 3,031 bp insert that contains alarge part of the pmpD ORF, part of the CT089 ORF, as well as part ofthe ORF for SycE. Clone 15-A3-26, (SEQ ID NO: 88), contains a 976 bpinsert that contains part of the ORF for CT858. Clone 17-G4-36, (SEQ IDNO: 267), identified using the patient lines CL8, TCT-10, CT1, CT5,CT13, and CHH037, contains a 680 bp insert that is in frame withbeta-gal in the plasmid and shares homology to part of the ORF forDNA-directed RNA polymerase beta subunit (CT315 in SerD).

Several of the clones described above share homology to variouspolymorphic membrane proteins. The genomic sequence of Chlamydiatrachomatis contains a family of nine polymorphic membrane proteingenes, referred to as pmp. These genes are designated pmpA, pmpB, pmpC,pmpD, pmpE, pmpF, pmpG, pmpH and pmpI. Proteins expressed from thesegenes are believed to be of biological relevance in generating aprotective immune response to a Chlamydial infection. In particular,pmpC, pmpD, pmpE and pmpI contain predictable signal peptides,suggesting they are outer membrane proteins, and therefore, potentialimmunological targets.

Based on the Chlamydia trachomatis LGVII serovar sequence, primer pairswere designed to PCR amplify the full-length fragments of pmpC, pmpD,pmpE, pmpG, pmpH and pmpI. The resulting fragments were subcloned intothe DNA vaccine vector JA4304 or JAL, which is JA4304 with a modifiedlinker (SmithKline Beecham, London, England). Specifically, PmpC wassubcloned into the JAL vector using the 5′ oligo GAT AGG CGC GCC GCA ATCATG AAA TTT ATG TCA GCT ACT GCT G and the 3′ oligo CAG AAC GCG TTT AGAATG TCA TAC GAG CAC CGC A, as provided in SEQ ID NO: 197 and 198,respectively. PCR amplification of the gene under conditions well knownin the art and ligation into the 5′ ASCI/3′ MluI sites of the JAL vectorwas completed after inserting the short nucleotide sequence GCAATC (SEQID NO: 199) upstream of the ATG to create a Kozak-like sequence. Theresulting expression vector contained the full-length pmpC genecomprising 5325 nucleotides (SEQ ID NO: 173) containing the hypotheticalsignal sequence, which encodes a 187 kD protein (SEQ ID NO: 179). ThepmpD gene was subcloned into the JA4304 vaccine vector following PCRamplification of the gene using the following oligos: 5′ oligo-TGC AATCAT GAG TTC GCA GAA AGA TAT AAA AAG C (SEQ ID NO: 200) and 3′ oligo-CAGAGC TAG CTT AAA AGA TCA ATC GCA ATC CAG TAT TC (SEQ ID NO: 201). Thegene was ligated into the a 5′ blunted HIII/3′ MluI site of the JA4304vaccine vector using standard techniques well known in the art. TheCAATC (SEQ ID NO: 202) was inserted upstream of the ATG to create aKozak-like sequence. This clone is unique in that the last threonine ofthe HindIII site is missing due to the blunting procedure, as is thelast glycine of the Kozak-like sequence. The insert, a 4593 nucleotidefragment (SEQ ID NO: 172) is the full-length gene for pmpD containingthe hypothetical signal sequence, which encodes a 161 kD protein (SEQ IDNO: 178). PmpE was subcloned into the JA4304 vector using the 5′oligo-TGC AAT CAT GAA AAA AGC GTT TTT CTT TTT C (SEQ ID NO: 203), andthe 3′ oligo-CAG AAC GCG TCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 204).Following PCR amplification, the gene was ligated into the 5′ bluntedHIII/3′ MluI site of JA4304. To facilitate this, a short nucleotidesequence, TGCAATC (SEQ ID NO: 293), was added upstream of the initiationcodon for creating a Kozak-like sequence and reconstituting the HindIIIsite. The insert is the full-length pmpE gene (SEQ ID NO: 171)containing the hypothetical signal sequence. The pmpE gene encodes a 105kD protein (SEQ ID NO: 177). The pmpG gene was PCR amplified using the5′ oligo-GTG CAA TCA TGA TTC CTC AAG GAA TTT ACG (SEQ ID NO: 205), andthe 3′ oligo-CAG AAC GCG TTT AGA ACC GGA CTT TAC TTC C (SEQ ID NO: 206)and subcloned into the JA4304 vector. Similar cloning strategies werefollowed for the pmpI and pmpK genes. In addition, primer pairs weredesigned to PCR amplify the full-length or overlapping fragments of thepmp genes, which were then subcloned for protein expression in thepET17b vector (Novagen, Madison, Wis.) and transfected into E. coli BL21pLysS for expression and subsequent purification utilizing thehistidine-nickel chromatographic methodology provided by Novagen.Several of the genes encoding the recombinant proteins, as describedbelow, lack the native signal sequence to facilitate expression of theprotein. Full-length protein expression of pmpC was accomplished throughexpression of two overlapping fragments, representing the amino andcarboxy termini. Subcloning of the pmpC-amino terminal portion, whichlacks the signal sequence, (SEQ ID NO: 187, with the corresponding aminoacid sequence provided in SEQ ID NO: 195) used the 5′ oligo-CAG ACA TATGCA TCA CCA TCA CCA TCA CGA GGC GAG CTC GAT CCA AGA TC (SEQ ID NO: 207),and the 3′ oligo-CAG AGG TAC CTC AGA TAG CAC TCT CTC CTA TTA AAG TAG G(SEQ ID NO: 208) into the 5′ NdeI/3′ KPN cloning site of the vector. Thecarboxy terminus portion of the gene, pmpC-carboxy terminal fragment(SEQ ID NO: 186, with the corresponding amino acid sequence provided inSEQ ID NO: 194), was subcloned into the 5′ NheI/3′ KPN cloning site ofthe expression vector using the following primers: 5′ oligo-CAG AGC TAGCAT GCA TCA CCA TCA CCA TCA CGT TAA GAT TGA GAA CTT CTC TGG C (SEQ IDNO: 209), and 3′ oligo-CAG AGG TAC CTT AGA ATG TCA TAC GAG CAC CGC AG(SEQ ID NO: 210). PmpD was also expressed as two overlapping proteins.The pmpD-amino terminal portion, which lacks the signal sequence, (SEQID NO: 185, with the corresponding amino acid sequence provided in SEQID NO: 193) contains the initiating codon of the pET17b and is expressedas a 80 kD protein. For protein expression and purification purposes, asix-histidine tag follows the initiation codon and is fused at the28^(th) amino acid (nucleotide 84) of the gene. The following primerswere used, 5′ oligo, CAG ACA TAT GCA TCA CCA TCA CCA TCA CGG GTT AGC(SEQ ID NO: 211), and the 3′ oligo-CAG AGG TAC CTC AGC TCC TCC AGC ACACTC TCT TC (SEQ ID NO: 212), to splice into the 5′ NdeI/3′ KPN cloningsite of the vector. The pmpD-carboxy terminus portion (SEQ ID NO: 184)was expressed as a 92 kD protein (SEQ ID NO: 192). For expression andsubsequent purification, an additional methionine, alanine and serinewas included, which represent the initiation codon and the first twoamino acids from the pET17b vector. A six-histidine tag downstream ofthe methionine, alanine and serine is fused at the 691^(St) amino acid(nucleotide 2073) of the gene. The 5′ oligo-CAG AGC TAG CCA TCA CCA TCACCA TCA CGG TGC TAT TTC TTG CTT ACG TGG (SEQ ID NO: 213) and the 3′oligo-CAG AGG TAC TTn AAA AGA TCA ATC GCA ATC CAG TAT TCG (SEQ ID NO:214) were used to subclone the insert into the 5′ NheI/3′ KPN cloningsite of the expression vector. PmpE was expressed as a 106 kD protein(SEQ ID NO: 183 with the corresponding amino acid sequence provided inSEQ ID NO: 191). The pmpE insert also lacks the native signal sequence.PCR amplification of the gene under conditions well known in the art wasperformed using the following oligo primers: 5′ oligo-CAG AGG ATC CACATC ACC ATC ACC ATC ACG GAC TAG CTA GAG AGG TTC (SEQ ID NO: 215), andthe 3′ oligo-CAG AGA ATT CCT AGA ATC GCA GAG CAA TTT C (SEQ ID NO: 216),and the amplified insert was ligated into a 5′ BamHI/3′ EcoRI site ofJA4304. The short nucleotide sequence, as provided in SEQ ID NO: 217,was inserted upstream of the initiation codon for creating theKozak-like sequence and reconstituting the HindIII site. The expressedprotein contains the initiation codon and the downstream 21 amino acidsfrom the pET17b expression vector, i.e., MASMTGGQQMGRDSSLVPSSDP (SEQ IDNO: 218). In addition, a six-histidine tag is included upstream of thesequence described above and is fused at the 28^(th) amino acid(nucleotide 84) of the gene, which eliminates the hypothetical signalpeptide. The sequences provided in SEQ ID NO: 183 with the correspondingamino acid sequence provided in SEQ ID NO: 191 do not include theseadditional sequences. The pmpG gene (SEQ ID NO: 182, with thecorresponding amino acid sequence provided in SEQ ID No; 190) was PCRamplified under conditions well known in the art using the followingoligo primers: 5′ oligo-CAG AGG TAC CGC ATC ACC ATC ACC ATC ACA TGA TTCCTC AAG GAA TTT ACG (SEQ ID NO: 219), and the 3′ oligo-CAG AGC GGC CGCTTA GAA CCG GAC TTT ACT TCC (SEQ ID NO: 220), and ligated into the 5′KPN/3′ NotI cloning site of the expression vector. The expressed proteincontains an additional amino acid sequence at the amino end, namely,MASMTGGQQNGRDSSLVPHHHHHH (SEQ ID NO: 221), which comprises theinitiation codon and additional sequence from the pET17b expressionvector. The pmpI gene (SEQ ID NO: 181, with the corresponding amino acidsequence provided in SEQ ID No; 189) was PCR amplified under conditionswell known in the art using the following oligo primers: 5′ oligo-CAGAGC TAG CCA TCA CCA TCA CCA TCA CCT CTT TGG CCA GGA TCC C (SEQ ID NO:222), and the 3′ oligo-CAG AAC TAG TCT AGA ACC TGT AAG TGG TCC (SEQ IDNO: 223), and ligted into the expression vector at the 5′ NheI/3′ SpeIcloning site. The 95 kD expressed protein contains the initiation codonplus an additional alanine and serine from the pET17b vector at theamino end of the protein. In addition, a six-histidine tag is fused atthe 21 St amino acid of the gene, which eliminates the hypotheticalsignal peptide.

Clone 14H1-4, (SEQ ID NO: 56), identified using the TCT-3 cell line,contains a complete ORF for the TSA gene, thiol specific antioxidant—CT603 (the CT603 ORF is a homolog of CPn0778 from C. pneumoniae). TheTSA open reading frame in clone 14-H1-4 was amplified such that theexpressed protein possess an additional methionine and a 6× histidinetag (amino terminal end). This amplified insert was sub-cloned into theNde/EcoRI sites of the pET17b vector. Upon induction of this clone withIPTG, a 22.6 kDa protein was purified by Ni-NTA agarose affinitychromatography. The determined amino acid sequence for the 195 aminoacid ORF of clone 14-H1-4 encoding the TSA gene is provided in SEQ IDNO: 65. Further analysis yielded a full-length clone for the TSA gene,referred to as CTL2-TSA-FL, with the full-length amino acid sequenceprovided in SEQ ID NO: 92.

Further studies yielded 10 additional clones identified by the TCT-1 andTCT-3 T-cell lines, as described above. The clones identified by theTCT-1 line are: 16-D4-22, 17-C5-19, 18-C5-2, 20-G3-45 and 21-C7-66;clones identified by the TCT-3 cell line are: 17-C10-31, 17-E2-9,22-A1-49 and 22-B3-53. Clone 21-G12-60 was recognized by both the TCT-1and TCT-3 T cell lines. In addition, clone 20-G3-45, which containedsequence specific for pmpB, was identified against the patient lines CT1and CT4. Clone 16-D4-22 (SEQ ID NO: 119), identified using the TCT-1cell line contains a 953 bp insert that contains two genes, parts ofopen reading frame 3 (ORF3) and ORF4 of the C. trachomatis plasmid forgrowth within mammalian cells. Clone 17-C5-19 (SEQ ID NO: 118), containsa 951 bp insert that contains part of the ORF for DT431, encoding forclpP_(—)1 protease and part of the ORF for CT430 (diaminopimelateepimerase). Clone 18-C5-2 (SEQ ID NO: 117) is part of the ORF for SIribosomal protein with a 446 bp insert that was identified using theTCT-1 cell line. Clone 20-G3-45 (SEQ ID NO: 116), identified by theTCT-1 cell line, contains a 437 bp insert that is part of the pmpB gene(CT413). Clone 21-C7-8 (SEQ ID NO: 115), identified by the TCT-1 line,contains a 995 bp insert that encodes part of the dnaK like protein. Theinsert of this clone does not overlap with the insert of the TCT-3 clone11-H4-28 (SEQ ID NO: 59), which was shown to be part of the dnaK geneCT396. Clone 17-C10C-31 (SEQ ID NO: 114), identified by the TCT-3 cellline, contains a 976 bp insert. This clone contains part of the ORF forCT858, a protease containing IRBP and DHR domains. Clone 17-E2-9 (SEQ IDNO: 113) contains part of ORFs for two genes, CT611 and CT610, that spana 1142 bp insert. Clone 22-A1-49 (SEQ ID NO: 112), identified using theTCT-3 line, also contains two genes in a 698 bp insert. Part of the ORFfor CT660 (DNA gyrase{gyrA_(—)2}) is present on the top strand where asthe complete ORF for a hypothetical protein CT659 is present on thecomplementary strand. Clone 22-B3-53 (SEQ ID NO: III), identified by theTCT-1 line, has a 267 bp insert that encodes part of the ORF for GroEL(CT110). Clone 21-G12-60 (SEQ ID NO: 110), identified by both the TCT-1and TCT-3 cell lines contains a 1461 bp insert that contains partialORFs for hypothetical proteins CT875, CT229 and CT228.

Additional Chlamydia antigens were obtained by screening a genomicexpression library of Chlamydia trachomatis (LGV II serovar) in LambdaScreen-1 vector (Novagen, Madison, Wis.) with sera pooled from severalChlamydia-infected individuals using techniques well known in the art.The following immuno-reactive clones were identified and the insertscontaining Chlamydia genes sequenced: CTL2#1 (SEQ ID NO: 71); CTL2#2(SEQ ID NO: 70); CTL2#3-5′ (SEQ ID NO: 72, a first determined genomicsequence representing the 5′ end); CTL2#3-3′ (SEQ ID NO: 73, a seconddetermined genomic sequence representing the 3′ end); CTL2#4 (SEQ ID NO:53); CTL2#5 (SEQ ID NO: 69); CTL2#6 (SEQ ID NO: 68); CTL2#7 (SEQ ID NO:67); CTL2#8b (SEQ ID NO: 54); CTL2#9 (SEQ ID NO: 66); CTL2#10-5′ (SEQ IDNO: 74, a first determined genomic sequence representing the 5′ end);CTL2#10-3′ (SEQ ID NO: 75, a second determined genomic sequencerepresenting the 3′ end); CTL2#11-5′ (SEQ ID NO: 45, a first determinedgenomic sequence representing the 5′ end); CTL2#11-3′ (SEQ ID NO: 44, asecond determined genomic sequence representing the 3′ end); CTL2#12(SEQ ID NO: 46); CTL2#16-5′ (SEQ ID NO: 47); CTL2#18-5′ (SEQ ID NO: 49,a first determined genomic sequence representing the 5′ end); CTL2#18-3′(SEQ ID NO: 48, a second determined genomic sequence representing the 3′end); CTL2#19-5′ (SEQ ID NO: 76, the determined genomic sequencerepresenting the 5′ end); CTL2#21 (SEQ ID NO: 50); CTL2#23 (SEQ ID NO:51; and CTL2#24 (SEQ ID NO: 52).

Additional Chlamydia trachomatis antigens were identified by serologicalexpression cloning. These studies used sera pooled from severalChlamydia-infected individuals, as described above, but, IgA, and IgMantibodies were used in addition to IgG as a secondary antibody. Clonesscreened by this method enhance detection of antigens recognized by anearly immune response to a Chlamydial infection, that is a mucosalhumoral immune response. The following immunoreactive clones werecharacterized and the inserts containing Chlamydia genes sequenced:CTL2gam-1 (SEQ ID NO: 290), CTL2gam-2 (SEQ ID NO: 289), CTL2gam-5 (SEQID NO: 288), CTL2gam-6-3′ (SEQ ID NO: 287, a second determined genomicsequence representing the 3′ end), CTL2gam-6-5′ (SEQ ID NO: 286, a firstdetermined genomic sequence representing the 5′ end), CTL2gam-8 (SEQ IDNO: 285), CTL2gam-10 (SEQ ID NO: 284), CTL2gam-13 (SEQ ID NO: 283),CTL2gam-15-3′ (SEQ ID NO: 282, a second determined genomic sequencerepresenting the 3′ end), CTL2gam-15-5′ (SEQ ID NO: 281, a firstdetermined genomic sequence representing the 5′ end), CTL2gam-17 (SEQ IDNO: 280), CTL2gam-18 (SEQ ID NO: 279), CTL2gam-21 (SEQ ID NO: 278),CTL2gam-23 (SEQ ID NO: 277), CTL2gam-24 (SEQ ID NO: 276), CTL2gam-26(SEQ ID NO: 275), CTL2gam-27 (SEQ ID NO: 274), CTL2gam-28 (SEQ ID NO:273), CTL2gam-30-3′ (SEQ ID NO: 272, a second determined genomicsequence representing the 3′ end) and CTL2gam-30-5′ (SEQ ID NO: 271, afirst determined genomic sequence representing the 5′ end).

EXAMPLE 2 Induction of T Cell Proliferation and Interferon-γ Productionby Chlamydia Trachomatis Antigens

The ability of recombinant Chlamydia trachomatis antigens to induce Tcell proliferation and interferon-γ production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinitychromatograph (Webb et al., J. Immunology 157:5034-5041, 1996). Thepurified polypeptides are then screened for the ability to induce T-cellproliferation in PBMC preparations. PBMCs from C. trachomatis patientsas well as from normal donors whose T-cells are known to proliferate inresponse to Chlamydia antigens, are cultured in medium comprising RPMI1640 supplemented with 10% pooled human serum and 50 μg/ml gentamicin.Purified polypeptides are added in duplicate at concentrations of 0.5 to10 μg/mL. After six days of culture in 96-well round-bottom plates in avolume of 200 μl, 50 μl of medium is removed from each well fordetermination of IFN-γ levels, as described below. The plates are thenpulsed with 1 μCi/well of tritiated thymidine for a further 18 hours,harvested and tritium uptake determined using a gas scintillationcounter. Fractions that result in proliferation in both replicates threefold greater than the proliferation observed in cells cultured in mediumalone are considered positive.

IFN-γ is measured using an enzyme-linked immunosorbent assay (ELISA).ELISA plates are coated with a mouse monoclonal antibody directed tohuman IFN-γ (PharMingen, San Diego, Calif.) in PBS for four hours atroom temperature. Wells are then blocked with PBS containing 5% (W/V)non-fat dried milk for 1 hour at room temperature. The plates are washedsix times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture mediumin the ELISA plates are incubated overnight at room temperature. Theplates are again washed and a polyclonal rabbit anti-human IFN-γ serumdiluted 1:3000 in PBS/10% normal goat serum is added to each well. Theplates are then incubated for two hours at room temperature, washed andhorseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical So., St.Louis, Mo.) is added at a 1:2000 dilution in PBS/5% non-fat dried milk.After a further two hour incubation at room temperature, the plates arewashed and TMB substrate added. The reaction is stopped after 20 minwith 1 N sulfuric acid. Optical density is determined at 450 nm using570 nm as a reference wavelength. Fractions that result in bothreplicates giving an OD two fold greater than the mean OD from cellscultured in medium alone, plus 3 standard deviations, are consideredpositive.

Using the above methodology, recombinant 1B 1-66 protein (SEQ ID NO: 5)as well as two synthetic peptides corresponding to amino acid residues48-67 (SEQ ID NO: 13; referred to as 1-B1-66/48-67) and 58-77 (SEQ IDNO: 14, referred to as 1B1-66/58-77), respectively, of SEQ ID NO: 5,were found to induce a proliferative response and IFN-γ production in aChlamydia-specific T cell line used to screen a genomic library of C.trachomatis LGV II.

Further studies have identified a C. trachomatis-specific T-cell epitopein the ribosomal S13 protein. Employing standard epitope mappingtechniques well known in the art, two T-cell epitopes in the ribosomalS13 protein (rS13) were identified with a Chlamydia-specific T-cell linefrom donor CL-8 (T-cell line TCL-8 EB/DC). FIG. 8 illustrates that thefirst peptide, rS13 1-20 (SEQ ID NO: 106), is 100% identical with thecorresponding C. pneumoniae sequence, explaining the cross-reactivity ofthe T-cell line to recombinant C. trachomatis- and C. pneumoniae-rS13.The response to the second peptide rS13 56-75 (SEQ ID NO: 108) is C.trachomatis-specific, indicating that the rS13 response in this healthyasymptomatic donor was elicited by exposure to C. trachomatis and not toC. pneumoniae, or any other microbial infection.

As described in Example 1, Clone 11-C12-91 (SEQ ID NO: 63), identifiedusing the TCP-21 cell line, has a 269 bp insert that is part of the OMP2gene (CT443) and shares homology with the 60 kDa cysteine rich outermembrane protein of C. pneumoniae, referred to as OMCB. To furtherdefine the reactive epitope(s), epitope mapping was performed using aseries of overlapping peptides and the immunoassay previously described.Briefly, proliferative responses were determined by stimulating 2.5×¹⁰⁴TCP-21 T-cells in the presence of 1×¹⁰⁴ monocyte-derived dendritic cellswith either non-infectious elementary bodies derived from C. trachomatisand C. pneumoniae, or peptides derived from the protein sequence of C.trachomatis or C. pneumoniae OMCB protein (0.1 μg/ml). The TCP-21T-cells responded to epitopes CT-OMCB #167-186, CT-OMCB #171-190,CT-OMCB #171-186, and to a lesser extent, CT-OMCB #175-186 (SEQ ID NO:249-252, respectively). Notably, the TCP-21 T-cell line also gave aproliferative response to the homologous C. pneumoniae peptide CP-OMCB#171-186 (SEQ ID NO: 253), which was equal to or greater than theresponse to the C. trachomatis peptides. The amino acid substitutions inposition two (i.e., Asp for Glu) and position four (i.e., Cys for Ser)did not alter the proliferative response of the T-cells and thereforedemonstrating this epitope to be a cross-reactive epitope between C.trachomatis and C. pneumoniae.

To further define the epitope described above, an additional T-cellline, TCT-3, was used in epitope mapping experiments. The immunoassayswere performed as described above, except that only peptides from C.trachomatis were tested. The T-cells gave a proliferative response totwo peptides, CT-OMCB #152-171 and CT-OMCB #157-176 (SEQ ID NO: 246 and247, respectively), thereby defining an additional immunogenic epitopein the cysteine rich outer membrane protein of C. trachomatis.

Clone 14H1-4, (SEQ ID NO: 56, with the corresponding full-length aminoacid sequence provided in SEQ ID NO: 92), was identified using the TCT-3cell line in the CD4 T-cell expression cloning system previouslydescribed, and was shown to contain a complete ORF for the, thiolspecific antioxidant gene (CT603), referred to as TSA. Epitope mappingimmunoassays were performed, as described above, to further define theepitope. The TCT-3 T-cells line exhibited a strong proliferativeresponse to the overlapping peptides CT-TSA #96-115, CT-TSA #101-120 andCT-TSA #106-125 (SEQ ID NO: 254-256, respectively) demonstrating animmunoreactive epitope in the thiol specific antioxidant gene of C.trachomatis serovar LGVII.

EXAMPLE 3 Preparation of Synthetic Polypeptides

Polypeptides may be synthesized on a Millipore 9050 peptide synthesizerusing FMOC chemistry with HPTU(O-Benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate)activation. A Gly-Cys-Gly sequence may be attached to the amino terminusof the peptide to provide a method of conjugating or labeling of thepeptide. Cleavage of the peptides from the solid support may be carriedout using the following cleavage mixture: trifluoroaceticacid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleavingfor 2 hours, the peptides may be precipitated in coldmethyl-t-butyl-ether. The peptide pellets may then be dissolved in watercontaining 0.1% trifluoroacetic acid (TFA) and lyophilized prior topurification by C18 reverse phase HPLC. A gradient of 0-60% acetonitrile(containing 0.1% TFA) in water (containing 0.1% TFA) may be used toelute the peptides. Following lyophilization of the pure fractions, thepeptides may be characterized using electrospray mass spectrometry andby amino acid analysis.

EXAMPLE 4 Isolation and Characterization of DNA Sequences EncodingChlamydia Antigens Using Retroviral Expression Vector Systems andSubsequent Immunological Analysis

A genomic library of Chlamydia trachomatis LGV II was constructed bylimited digests using BamHI, BglII, BstYi and MboI restriction enzymes.The restriction digest fragments were subsequently ligated into theBamHI site of the retroviral vectors pBIB-KS1,2,3. This vector set wasmodified to contain a Kosak translation initiation site and stop codonsin order to allow expression of proteins from short DNA genomicfragments, as shown in FIG. 2. DNA pools of 80 clones were prepared andtransfected into the retroviral packaging line Phoenix-Ampho, asdescribed in Pear, W. S., Scott, M. L. and Nolan, G. P., Generation ofHigh Titre, Helper-free Retroviruses by Transient Transfection. Methodsin Molecular Medicine: Gene Therapy Protocols, Humana Press, Totowa,N.J., pp. 41-57. The Chlamydia library in retroviral form was thentransduced into H2-Ld expressing P815 cells, which were then used astarget cells to stimulate an antigen specific T-cell line.

A Chlamydia-specific, murine H2^(d) restricted CD8+ T-cell line wasexpanded in culture by repeated rounds of stimulation with irradiated C.trachomatis-infected J774 cells and irradiated syngeneic spleen cells,as described by Stambach, M., in J. Immunol., 153:5183, 1994. ThisChlamydia-specific T-cell line was used to screen the above Chlamydiagenomic library expressed by the retrovirally-transduced P815 cells.Positive DNA pools were identified by detection of IFN-γ productionusing Elispot analysis (SEE Lalvani et al., J. Experimental Medicine186:859-865, 1997).

Two positive pools, referred to as 2C7 and 2E10, were identified byIFN-γ Elispot assays. Stable transductants of P815 cells from pool 2C7were cloned by limiting dilution and individual clones were selectedbased upon their capacity to elicit IFN-γ production from theChlamydia-specific CTL line. From this screening process, four positiveclones were selected, referred to as 2C7-8, 2C7-9, 2C7-19 and 2C7-21.Similarly, the positive pool 2E10 was further screened, resulting in anadditional positive clone, which contains three inserts. The threeinserts are fragments of the CT016, tRNA syntase and clpX genes (SEQ IDNO: 268-270, respectively).

Transgenic DNA from these four positive 2C7 clones were PCR amplifiedusing pBIB-KS specific primers to selectively amplify the Chlamydia DNAinsert. Amplified inserts were gel purified and sequenced. Oneimmunoreactive clone, 2C7-8 (SEQ ID NO: 15, with the predicted aminoacid sequence provided in SEQ ID NO: 32), is a 160 bp fragment withhomology to nucleotides 597304-597145 of Chlamydia trachomatis, serovarD (NCBI, BLASTN search; SEQ ID NO: 33, with the predicted amino acidsequence provided in SEQ ID NO: 34). The sequence of clone 2C7-8 mapswithin two putative open reading frames from the region of high homologydescribed immediately above, and in particular, one of these putativeopen reading frames, consisting of a 298 amino acid fragment (SEQ ID NO:16, with the predicted amino acid sequence provided in SEQ ID NO: 17),was demonstrated to exhibit immunological activity.

Full-length cloning of the 298 amino acid fragment (referred to as CT529and/or the Cap1 gene) from serovar L2 was obtained by PCR amplificationusing 5′-ttttgaagcaggtaggtgaatatg (forward) (SEQ ID NO: 159) and5′-ttaagaaatttaaaaaatccctta (reverse) (SEQ ID NO: 160) primers, usingpurified C. trachomatis L2 genomic DNA as template. This PCR product wasgel-purified, cloned into pCRBlunt (Invitrogen, Carlsbad, Calif.) forsequencing, and then subcloned into the EcoRI site of pBIB-KMS, aderivative of pBIB-KS for expression. The Chlamydia pneumoniae homlogueof CT529 is provided in SEQ ID NO: 291, with the corresponding aminoacid sequence provided in SEQ ID NO: 292.

Full-length DNA encoding various CT529 serovars were amplified by PCRfrom bacterial lysates containing 10⁵ IFU, essentially as described(Denamur, E., C. Sayada, A. Souriau, J. Orfila, A. Rodolakis and J.Elion. 1991. J. Gen. Microbiol. 137: 2525). The following serovars wereamplified as described: Ba (SEQ ID NO: 134, with the correspondingpredicted amino acid sequence provided in SEQ ID NO: 135); E (BOUR) andE (MTW447) (SEQ ID NO: 122, with the corresponding predicted amino acidsequence provided in SEQ ID NO: 123); F (N11) (SEQ ID NO: 128, with thecorresponding predicted amino acid sequence provided in SEQ ID NO: 129);G; (SEQ ID NO: 126, with the corresponding predicted amino acid sequenceprovided in SEQ ID NO: 127); Ia (SEQ ID NO: 124, with the correspondingpredicted amino acid sequence provided in SEQ ID NO: 125); L1 (SEQ IDNO: 130, with the corresponding predicted amino acid sequence providedin SEQ ID NO: 131); L3 (SEQ ID NO: 132, with the corresponding predictedamino acid sequence provided in SEQ ID NO: 133); I (SEQ ID NO: 263, withthe corresponding predicted amino acid sequence provided in SEQ ID NO:264); K (SEQ ID NO: 265, with the corresponding predicted amino acidsequence provided in SEQ ID NO: 266); and MoPn (SEQ ID NO: 136, with thecorresponding predicted amino acid sequence provided in SEQ ID NO: 137).PCR reactions were performed with Advantage Genomic PCR Kit (Clontech,Palo Alto, Calif.) using primers specific for serovar L2 DNA (externalto the ORF). Primers sequences were 5′-ggtataatatctctctaaattttg(forward-SEQ ID NO: 161) and 5‘-agataaaaaaggctgtttc’ (reverse-SEQ ID NO:162) except for MoPn which required 5′-ttttgaagcaggtaggtgaatatg(forward-SEQ ID NO: 163) and 5′-tttacaataagaaaagctaagcactttgt(reverse-SEQ ID NO: 164). PCR amplified DNA was purified with QIAquickPCR purification kit (Qiagen, Valencia, Calif.) and cloned in pCR2.1(Invitrogen, Carlsbad, Calif.) for sequencing.

Sequencing of DNA derived from PCR amplified inserts of immunoreactiveclones was done on an automated sequencer (ABI 377) using both a pBIB-KSspecific forward primer 5′-ccttacacagtcctgctgac (SEQ ID NO: 165) and areverse primer 3′-gtttccgggccctcacattg (SEQ ID NO: 166). PCRBlunt clonedDNA coding for CT529 serovar L2 and pCR2.1 cloned DNA coding for CT529serovar Ba, E (BOUR), E (MTW447), F (NI1), G, Ia, K, L1, L3 and MoPnwere sequenced using T7 promoter primer and universal M13 forward andM13 reverse primers.

To determine if these two putative open reading frames (SEQ ID NO: 16and 20) encoded a protein with an associated immunological function,overlapping peptides (17-20 amino acid lengths) spanning the lengths ofthe two open reading frames were synthesized, as described in Example 3.A standard chromium release assay was utilized to determine the percentspecific lysis of peptide-pulsed H2^(d) restricted target cells. In thisassay, aliquots of P815 cells (H2^(d)) were labeled at 37° C. for onehour with 100 μCi of ⁵¹Cr in the presence or absence of 1 μg/ml of theindicated peptides. Following this incubation, labeled P815 cells werewashed to remove excess ⁵¹Cr and peptide, and subsequently plated induplicate in microculture plates at a concentration of 1,000 cells/well.Effector CTL (Chlamydia-specific CD8 T cells) were added at theindicated effector:target ratios. Following a 4 hour incubation,supernatants were harvested and measured by gamma-counter for release of⁵¹Cr into the supernatant. Two overlapping peptides from the 298 aminoacid open reading frame did specifically stimulate the CTL line. Thepeptides represented in SEQ ID NO: 138-156 were synthesized,representing the translation of the L2 homologue of the serovar D openreading frame for CT529 (Cap1 gene) and 216 amino acid open readingframe. As shown in FIG. 3, peptides CtC7.8-12 (SEQ ID NO: 18, alsoreferred to as Cap1#132-147, SEQ ID NO: 139) and CtC7.8-13 (SEQ ID NO:19, also referred to as Cap1#138-155, SEQ ID NO: 140) were able toelicit 38 to 52% specific lysis, respectively, at an effector to targetratio of 10:1. Notably, the overlap between these two peptides containeda predicted H2^(d) (K^(d) and L^(d)) binding peptide. A 10 amino acidpeptide was synthesized to correspond to this overlapping sequence (SEQID NO: 31) and was found to generate a strong immune response from theanti-Chlamydia CTL line by elispot assay. Significantly, a search of themost recent Genbank database revealed no proteins have previously beendescribed for this gene. Therefore, the putative open reading frameencoding clone 2C7-8 (SEQ ID NO: 15) defines a gene which encompasses anantigen from Chlamydia capable of stimulating antigen-specific CD8+T-cells in a MHC-I restricted manner, demonstrating this antigen couldbe used to develop a vaccine against Chlamydia.

To confirm these results and to further map the epitope, truncatedpeptides (SEQ ID NO: 138-156) were made and tested for recognition bythe T-cells in an IFN-g ELISPOT assay. Truncations of either Ser139(Cap1#140-147, SEQ ID NO: 146) or Leu147 (Cap1#138-146, SEQ ID NO: 147)abrogate T-cell recognition. These results indicate that the 9-merpeptide Cap1#139-147 (SFIGGITYL, SEQ ID NO: 145) is the minimal epitoperecognized by the Chlamydia-specific T-cells.

Sequence alignments of Cap1 (CT529) from selected serovars of C.trachomatis (SEQ ID NO: 121, 123, 125, 127, 129, 131, 133, 135, 137 and139) shows one of the amino acid differences is found in position 2 ofthe proposed epitope. The homologous serovar D peptide is SIIGGITYL (SEQID NO: 168). The ability of SFIGGITYL and SIIGGITYL to target cells forrecognition by the Chlamydia specific T-cells was compared. Serialdilutions of each peptide were incubated with P815 cells and tested forrecognition by the T-cells in a ⁵¹Cr release assay, as described above.The Chlamydia-specific T-cells recognize the serovar L2 peptide at aminimum concentration of 1 nM and the serovar D peptide at a minimumconcentration of 10 nM.

Further studies have shown that a Cap1#139-147-specific T-cell clonerecognizes C. trachomatis infected cells. To confirm that Cap1#139-147is presented on the surface of Chlamydia infected cells, Balb-3T3(H-2^(d)) cells were infected with C. trachomatis serovar L2 and testedto determine whether these cells are recognized by a CD8+ T-cell clonespecific for Cap1#139-147 epitope (SEQ ID NO: 145). The T-cell clonespecific for Cap I#139-147 epitope was obtained by limiting dilution ofthe line 69 T-cells. The T-cell clone specifically recognized theChlamydia infected cells. In these experiments, target cells were C.trachomatis infected (positive control) or uninfected Balb/3T3 cells,showing 45%, 36% and 30% specific lysis at 30:1, 10:1 and 3:1 effectorto target ratios, respectively; or Cap1#139-147 epitope (SEQ ID NO: 145)coated, or untreated P815 cells, showing 83%, 75% and 58% specific lysisat 30:1, 10:1 and 3:1 effector to target ratios, respectively (negativecontrols having less than 5% lysis in all cases). This data suggeststhat the epitope is presented during infection.

In vivo studies show Cap1#139-147 epitope-specific T-cells are primedduring murine infection with C. trachomatis. To determine if infectionwith C. trachomatis primes a Cap1#139-147 epitope-specific T-cellresponse, mice were infected i.p. with 10⁸ IFU of C. trachomatis serovarL2. Two weeks after infection, the mice were sacrificed and spleen cellswere stimulated on irradiated syngeneic spleen cells pulsed withCap1#139-147 epitope peptide. After 5 days of stimulation, the cultureswere used in a standard ⁵¹Cr release assay to determine if there wereCap1#139-147 epitope-specific T-cells present in the culture.Specifically, spleen cells from a C. trachomatis serovar L2 immunizedmouse or a control mouse injected with PBS after a 5 days culture withCap1#139-147 peptide-coated syngeneic spleen cells and CD8+ T-cells ableto specifically recognize Cap1#139-147 epitope gave 73%, 60% and 32%specific lysis at a30:1, 10:1 and 3:1 effector to target ratios,respectively. The control mice had a percent lysis of approximately 10%at a 30:1 effector to target ratio, and steadily declining with loweringE:T ratios. Target cells were Cap1#139-147 peptide-coated, or untreatedP815 cells. These data suggest that Cap1#139-147 peptide-specificT-cells are primed during murine infection with C. trachomatis.

Ct529 Localization

Studies were performed demonstrating that Ct529 (referred to herein asCap-1) localizes to the inclusion membrane of C. trachomatis-infectedcells and is not associated with elementary bodies or reticulate bodies.As described above, Cap-1 was identified as a product from Chlamydiathat stimulates CD8+ CTL. These CTL are protective in a murine model ofinfection, thus making Cap-1 a good vaccine candidate. Further, sincethese CTL are MHC-I restricted, the Cap-1 gene must have access to thecytosol of infected cells, which may be a unique characteristic ofspecific Chlamydial gene products. Therefore, determination of thecellular localization of the gene products would be useful incharacterizing Cap-1 as a vaccine candidate. To detect the intracellularlocalization of Cap-1, rabbit polyclonal antibodies directed against arecombinant polypeptide encompassing the N-terminal 125 amino acids ofCap-1 (SEQ ID NO: 305, with the amino acid sequence including theN-terminal 6-His tag provided in SEQ ID NO: 304) were used to stainMcCoy cells infected with Chlamydiae.

Rabbit-anti-Cap-1 polyclonal antibodies were obtained byhyper-immunization of rabbits with a recombinant polypeptide,rCt529c1-125 (SEQ ID NO: 305) encompassing the N-terminal portion ofCap-1. Recombinant rCt529e1-125 protein was obtained from E. colitransformed with a pET expression plasmid (as described above) encodingthe nucleotides 1-375 encoding the N-terminal 1-125 amino acids ofCap-1. Recombinant protein was purified by Ni-NTA using techniques wellknown in the art. For a positive control antiserum, polyclonal antiseradirected against elementary bodies were made by immunization of rabbitswith purified C. trachomatis elementary bodies (Biodesign, Sacco, Me.).Pre-immune sera derived from rabbits prior to immunization with theCap-1 polypeptide was used as a negative control.

Immunocytochemistry was performed on McCoy cell monolayers grown onglass coverslips inoculated with either C. trachomatis serovar L2 or C.psitacci, strain 6BC, at a concentration of 10⁶ IFU (Inclusion FormingUnits) per ml. After 2 hours, medium was aspirated and replaced withfresh RP-10 medium supplemented with cycloheximide (1.0 μg/ml). Infectedcells were incubated at in 7% CO₂ for 24 hours and fixed by aspiratingmedium, rinsing cells once with PBS and methanol fixation for 5 minutes.For antigen staining, fixed cell monolayers were washed with PBS andincubated at 37° C. for 2 hours with 1:100 dilutions of specific orcontrol antisera. Cells were rinsed with PBS and incubated for 1 hourwith fluorescein isothiocyanate (FITC)-labeled, anti-rabbit IgG (KPL,Gaithersburg) and stained with Evans blue (0.05%) in PBS. Fluorescencewas observed with a 100× objective (Zeiss epifluorescence microscope),and photographed (Nikon UFX-11A camera).

Results from this study show Cap-1 localizes to the inclusion membraneof C. trachomatis-infected cells. Cap-1 specific antibody labeled theinclusion membranes of C. trachomatis-infected cells, but not Chlamydialelementary bodies contained in these inclusions or released by thefixation process. Conversely, the anti-elementary body antibody clearlylabeled the bacterial bodies, not only within the inclusions, but thosereleased by the fixation process. Specificity of the anti-Cap-1 antibodyis demonstrated by the fact that it does not stain C. psittaci-infectedcells. Specificity of the Cap-1 labeling is also shown by the absence ofreactivity in pre-immune sera. These results suggest that Cap-1 isreleased from the bacteria and becomes associated with the Chlamydialinclusion membrane. Therefore, Cap-1 is a gene product which may beuseful for stimulating CD8+ T cells in the development of a vaccineagainst infections caused by Chlamydia.

The relevance of the Cap-1 gene as a potential CTL antigen in a vaccineagainst Chlamydia infection is further illustrated by two additionalseries of studies. First, CTL specific for the MHC-I epitope of Cap-1CT529 #138-147 peptide of C. trachomatis (SEQ ID NO: 144) have beenshown to be primed to a high frequency during natural infection.Specifically, Balb/C mice were inoculated with 10⁶ I.F.U. of C.trachomatis, serova L2. After 2 weeks, spleens were harvested andquantified by Elispot analysis for the number of IFN-γ secreting cellsin response to Cap-1 #138-147 peptide-pulsed antigen presenting cells.In two experiments, the number of IFN-γ-secreting cells in 10⁵splenocytes was about 1% of all CD8+ T-cells. This high frequency ofresponding CD8+ CTL to the MHC-1 epitope (Cap-1 CT529 #138-147 peptide)suggest that Cap-1 is highly immunogenic in infections.

Results from a second series of studies have shown that the Cap-1protein is almost immediately accessible to the cytosol of the host cellupon infection. This is shown in a time-course of Cap-1 CT529 #138-147peptide presentation. Briefly, 3T3 cells were infected with C.trachomatis serovar L2 for various lengths of time, and then tested forrecognition by Cap-1 CT529 #138-147 peptide-specific CTL. The resultsshow that C. trachomatis-infected 3T3 cells are targeted for recognitionby the antigen-specific CTL after only 2 hours of infection. Theseresults suggest that Cap-1 is an early protein synthesized in thedevelopment of C. trachomatis elementary bodies to reticulate bodies. ACD8+ CTL immune response directed against a gene product expressed earlyin infection may be particularly efficacious in a vaccine againstChlamydia infection.

EXAMPLE 5 Generation of Antibody and T-Cell Responses in Mice Immunizedwith Chlamydia Antigens

Immunogenicity studies were conducted to determine the antibody and CD4+T cell responses in mice immunized with either purified SWIB or S13proteins formulated with Montanide adjuvant, or DNA-based immunizationswith pcDNA-3 expression vectors containing the DNA sequences for SWIB orS13. SWIB is also referred to as clone 1-B1-66 (SEQ ID NO: 1, with thecorresponding amino acid sequence provided in SEQ ID NO: 5), and S13ribosomal protein is also referred to as clone 10-C10-31 (SEQ ID NO: 4,with the corresponding amino acid sequence provided in SEQ ID NO: 12).In the first experiment, groups of three C57BL/6 mice were immunizedtwice and monitored for antibody and CD4+ T-cell responses. DNAimmunizations were intradermal at the base of the tail and polypeptideimmunizations were administered by subcutaneous route. Results fromstandard ³H-incorporation assays of spleen cells from immunized miceshows a strong proliferative response from the group immunized withpurified recombinant SWIB polypeptide (SEQ ID NO: 5). Further analysisby cytokine induction assays, as previously described, demonstrated thatthe group immunized with SWIB polypeptide produced a measurable IFN-γand IL-4 response. Subsequent ELISA-based assays to determine thepredominant antibody isotype response in the experimental groupimmunized with the SWIB polypeptide were performed. FIG. 4 illustratesthe SWIB-immunized group gave a humoral response that was predominantlyIgG1.

In a second experiment, C3H mice were immunized three times with 10 μgpurified SWIB protein (also referred to as clone 1-B1-66, SEQ ID NO: 5)formulated in either PBS or Montanide at three week intervals andharvested two weeks after the third immunization. Antibody titersdirected against the SWIB protein were determined by standardELISA-based techniques well known in the art, demonstrating the SWIBprotein formulated with Montanide adjuvant induced a strong humoralimmune response. T-cell proliferative responses were determined by aXTT-based assay (Scudiero, et al, Cancer Research, 1988, 48:4827). Asshown in FIG. 5, splenocytes from mice immunized with the SWIBpolypeptide plus Montanide elicited an antigen specific proliferativeresponse. In addition, the capacity of splenocytes from immunizedanimals to secrete IFN-γ in response to soluble recombinant SWIBpolypeptide was determined using the cytokine induction assay previouslydescribed. The splenocytes from all animals in the group immunized withSWIB polypeptide formulated with montanide adjuvant secreted IFN-γ inresponse to exposure to the SWIB Chlamydia antigen, demonstrating anChlamydia-specific immune response.

In a further experiment, C3H mice were immunized at three separate timepoints at the base of the tail with 10 μg of purified SWIB or S13protein (C. trachomatis, SWIB protein, clone 1-B1-66, SEQ ID NO: 5, andS13 protein, clone 10-C10-31, SEQ ID NO: 4) formulated with the SBAS2adjuvant (SmithKline Beecham, London, England). Antigen-specificantibody titers were measured by ELISA, showing both polypeptidesinduced a strong IgG response, ranging in titers from 1×10⁻⁴ to 1×10⁻⁵.The IgG1 and IgG2a components of this response were present in fairlyequal amounts. Antigen-specific T-cell proliferative responses,determined by standard ³H-incorporation assays on spleen cells isolatedfrom immunized mice, were quite strong for SWIB (50,000 cpm above thenegative control) and even stronger for s13 (100,000 cpm above thenegative control). The IFNγ production was assayed by standard ELISAtechniques from supernatant from the proliferating culture. In vitrorestimulation of the culture with S13 protein induced high levels ofIFNγ production, approximately 25 ng/ml versus 2 ng/ml for the negativecontrol. Restimulation with the SWIB protein also induced IFNγ, althoughto a lesser extent.

In a related experiment, C3H mice were immunized at three separate timepoints with 10 μg of purified SWIB or S13 protein (C. trachomatis, SWIBprotein, clone 1-B1-66, SEQ ID NO: 5, and S13 protein, clone 10-C10-31,SEQ ID NO: 4) mixed with 10 μg of Cholera Toxin. Mucosal immunizationwas through intranasal inoculation. Antigen-specific antibody responseswere determined by standard ELISA techniques. Antigen-specific IgGantibodies were present in the blood of SWIB-immunized mice, with titersranging from 1×10⁻³ to 1×10⁻⁴, but non-detectable in the S13-immunizedanimals. Antigen-specific T-cell responses from isolated splenocytes, asmeasured by IFNγ production, gave similar results to those describedimmediately above for systemic immunization.

An animal study was conducted to determine the immunogenicity of theCT529 serovar LGVII CTL epitope, defined by the CT529 10mer consensuspeptide (CSFIGGITYL—SEQ ID NO: 31), which was identified as an H2-Kdrestricted CTL epitope. BALB/c mice (3 mice per group) were immunizedthree times with 25 μg of peptide combined with various adjuvants. Thepeptide was administered systemically at the base of the tail in eitherSKB Adjuvant System SBAS-2″, SBAS-7 (SmithKline Beecham, London,England) or Montanide. The peptide was also administered intranasallymixed with 10 ug of Cholera Toxin (CT). Naive mice were used as acontrol. Four weeks after the 3rd immunization, spleen cells wererestimulated with LPS-blasts pulsed with 10 ug/ml CT529 10 mer consensuspeptide at three different effector to LPS-blasts ratios: 6, 1.5 and 0.4at 1×10⁶ cell/ml. After 2 restimulations, effector cells were tested fortheir ability to lyse peptide pulsed P815 cells using a standardchromium release assay. A non-relevant peptide from chicken eggovalbumin was used as a negative control. The results demonstrate that asignificant immune response was elicited towards the CT529 10merconsensus peptide and that antigen-specific T-cells capable of lysingpeptide-pulsed targets were elicited in response to immunization withthe peptide. Specifically, antigen-specific lytic activities were foundin the SBAS-7 and CT adjuvanted group while Montanide and SBAS-2″ failedto adjuvant the CTL epitope immunization.

EXAMPLE 6 Expression and Characterization of Chlamydia Pneumoniae Genes

The human T-cell line, TCL-8, described in Example 1, recognizesChlamydia trachomatis as well as Chlamydia pneumonia infectedmonocyte-derived dendritic cells, suggesting Chlamydia trachomatis andpneumonia may encode cross-reactive T-cell epitopes. To isolate theChlamydia pneumonia genes homologous to Chlamydia trachomatis LGV IIclones 1B1-66, also referred to as SWIB (SEQ ID NO: 1) and clone10C10-31, also referred to as S13 ribosomal protein (SEQ ID NO: 4), HeLa229 cells were infected with C. pneumonia strain TWAR(CDC/CWL-029).After three days incubation, the C. pneumonia-infected HeLa cells wereharvested, washed and resuspended in 200 μl water and heated in aboiling water bath for 20 minutes. Ten microliters of the disrupted cellsuspension was used as the PCR template.

C. pneumonia specific primers were designed for clones 1B1-66 and10C10-31 such that the 5′ end had a 6×-Histidine tag and a Nde I siteinserted, and the 3′ end had a stop codon and a BamHI site included(FIG. 6). The PCR products were amplified and sequenced by standardtechniques well known in the art. The C. pneumonia-specific PCR productswere cloned into expression vector pET17B (Novagen, Madison, Wis.) andtransfected into E. coli BL21 pLysS for expression and subsequentpurification utilizing the histidine-nickel chromatographic methodologyprovided by Novagen. Two proteins from C. pneumonia were thus generated,a 10-11 kDa protein referred to as CpSWIB (SEQ ID NO: 27, and SEQ ID NO:78 having a 6×His tag, with the corresponding amino acid sequenceprovided in SEQ ID NO: 28, respectively), a 15 kDa protein referred toas CpS13 (SEQ ID NO: 29, and SEQ ID NO: 77, having a 6×His tag, with thecorresponding amino acid sequence provided in SEQ ID NO: 30 and 91,respectively).

EXAMPLE 7 Induction of T Cell Proliferation and Interferon-γ Productionby Chlamydia Pneumoniae Antigens

The ability of recombinant Chlamydia pneumoniae antigens to induce Tcell proliferation and interferon-γ production is determined as follows.

Proteins are induced by IPTG and purified by Ni-NTA agarose affinitychromatography (Webb et al., J. Immunology 157:5034-5041, 1996). Thepurified polypeptides are then screened for the ability to induce T-cellproliferation in PBMC preparations. PBMCs from C. pneumoniae patients aswell as from normal donors whose T-cells are known to proliferate inresponse to Chlamydia antigens, are cultured in medium comprising RPMI1640 supplemented with 10% pooled human serum and 50 μg/ml gentamicin.Purified polypeptides are added in duplicate at concentrations of 0.5 to10 μg/mL. After six days of culture in 96-well round-bottom plates in avolume of 200 μl, 50 μl of medium is removed from each well fordetermination of IFN-γ levels, as described below. The plates are thenpulsed with 1 μCi/well of tritiated thymidine for a further 18 hours,harvested and tritium uptake determined using a gas scintillationcounter. Fractions that result in proliferation in both replicates threefold greater than the proliferation observed in cells cultured in mediumalone are considered positive.

IFN-γ was measured using an enzyme-linked immunosorbent assay (ELISA).ELISA plates are coated with a mouse monoclonal antibody directed tohuman IFN-γ (PharMingen, San Diego, Calif.) in PBS for four hours atroom temperature. Wells are then blocked with PBS containing 5% (W/V)non-fat dried milk for 1 hour at room temperature. The plates are washedsix times in PBS/0.2% TWEEN-20 and samples diluted 1:2 in culture mediumin the ELISA plates are incubated overnight at room temperature. Theplates are again washed and a polyclonal rabbit anti-human IFN-γ serumdiluted 1:3000 in PBS/10% normal goat serum is added to each well. Theplates are then incubated for two hours at room temperature, washed andhorseradish peroxidase-coupled anti-rabbit IgG (Sigma Chemical So., St.Louis, Mo.) is added at a 1:2000 dilution in PBS/5% non-fat dried milk.After a further two hour incubation at room temperature, the plates arewashed and TMB substrate added. The reaction is stopped after 20 minwith 1 N sulfuric acid. Optical density is determined at 450 nm using570 nm as a reference wavelength. Fractions that result in bothreplicates giving an OD two fold greater than the mean OD from cellscultured in medium alone, plus 3 standard deviations, are consideredpositive.

A human anti-Chlamydia T-cell line (TCL-8) capable of cross-reacting toC. trachomatis and C. pneumonia was used to determine whether theexpressed proteins described in the example above, (i.e., CpSWIB, SEQ IDNO: 27, and SEQ ID NO: 78 having a 6×His tag, with the correspondingamino acid sequence provided in SEQ ID NO: 28, respectively, and the 15kDa protein referred to as CpS13 SEQ ID NO: 29, and SEQ ID NO: 77,having a 6×His tag, with the corresponding amino acid sequence providedin SEQ ID NO: 30 and 91, respectively), possessed T-cell epitopes commonto both C. trachomatis and C. pneumonia. Briefly, E. coli expressingChlamydial proteins were titered on 1×10⁴ monocyte-derived dendriticcells. After two hours, the dendritic_cells cultures were washed and2.5×10⁴ T cells (TCL-8) added and allowed to incubate for an additional72 hours. The amount of INF-γ in the culture supernatant was thendetermined by ELISA. As shown in FIGS. 7A and 7B, the TCL-8 T-cell linespecifically recognized the S13 ribosomal protein from both C.trachomatis and C. pneumonia as demonstrated by the antigen-specificinduction of IFN-γ, whereas only the SWIB protein from C. trachomatiswas recognized by the T-cell line. To validate these results, the T cellepitope of C. trachomatis SWIB was identified by epitope mapping usingtarget cells pulsed with a series of overlapping peptides and the T-cellline TCL-8. 3H-thymidine incorporation assays demonstrated that thepeptide, referred to as C.t.SWIB 52-67, of SEQ ID NO: 39 gave thestrongest proliferation of the TCL-8 line. The homologous peptidescorresponding to the SWIB of C. pneumoniae sequence (SEQ ID NO: 40), thetopoisomerase-SWIB fusion of C. pneumoniae (SEQ ID NO: 43) and C.trachomatis (SEQ ID NO: 42) as well as the human SWI domain (SEQ ID NO:41) were synthesized and tested in the above assay. The T-cell lineTCL-8 only recognized the C. trachomatis peptide of SEQ ID NO: 39 andnot the corresponding C. pneumoniae peptide (SEQ ID NO: 40), or theother corresponding peptides described above (SEQ ID NO; 41-43).

Chlamydia-specific T cell lines were generated from donor CP-21 with apositive serum titer against C. pneumoniae by stimulating donor PBMCwith either C. trachomatis or C. pneumoniae-infected monocyte-deriveddendritic cells, respectively. T-cells generated against C. pneumoniaeresponded to recombinant C. pneumoniae-SWIB but not C. trachomatis-SWIB,whereas the T-cell line generated against C. trachomatis did not respondto either C. trachomatis- or C. pneumoniae-SWIB (see FIG. 9). The C.pneumoniae-SWIB specific immune response of donor CP-21 confirms the C.pneumoniae infection and indicates the elicitation of C. pneumoniae-SWIBspecific T-cells during in vivo C. pneumoniae infection.

Epitope mapping of the T-cell response to C. pneumoniae-SWIB has shownthat Cp-SWIB-specific T-cells responded to the overlapping peptidesCp-SWIB 32-51 (SEQ ID NO: 101) and Cp-SWIB 37-56 (SEQ ID NO: 102),indicating a C. pneumoniae-SWIB-specific T-cell epitope Cp-SWIB 37-51(SEQ ID NO: 100).

In additional experiments, T-cell lines were generated from donor CP1,also a C. pneumoniae seropositive donor, by stimulating PBMC withnon-infectious elementary bodies from C. trachomatis and C. pneumoniae,respectively. In particular, proliferative responses were determined bystimulating 2.5×10⁴ T-cells in the presence of 1×10⁴ monocyte-deriveddendritic cells and non-infectious elementary bodies derived from C.trachomatis and C. pneumoniae, or either recombinant C. trachomatis orC. pneumoniae SWIB protein. The T-cell response against SWIB resembledthe data obtained with T-cell lines from CP-21 in that C.pneumoniae-SWIB, but not C. trachomatis-SWIB elicited a response by theC. pneumoniae T-cell line. In addition, the C. trachomatis T-cell linedid not proliferate in response to either C. trachomatis or C.pneumoniae SWIB, though it did proliferate in response to both CT and CPelementary bodies. As described in Example 1, Clone 11-C12-91 (SEQ IDNO: 63), identified using the TCP-21 cell line, has a 269 bp insert thatis part of the OMP2 gene (CT443) and shares homology with the 60 kDacysteine rich outer membrane protein of C. pneumoniae, referred to asOMCB. To further define the reactive epitope(s), epitope mapping wasperformed using a series of overlapping peptides and the immunoassaypreviously described. Briefly, proliferative responses were determinedby stimulating 2.5×10⁴ TCP-21 T-cells in the presence of 1×10⁴monocyte-derived dendritic cells with either non-infectious elementarybodies derived from C. trachomatis and C. pneumoniae, or peptidesderived from the protein sequence of C. trachomatis or C. pneumoniaeOMCB protein (0.1 μg/ml). The TCP-21 T-cells responded to epitopesCT-OMCB #167-186, CT-OMCB #171-190, CT-OMCB #171-186, and to a lesserextent, CT-OMCB #175-186 (SEQ ID NO: 249-252, respectively). Notably,the TCP-21 T-cell line also gave a proliferative response to thehomologous C. pneumoniae peptide CP-OMCB #171-186 (SEQ ID NO: 253),which was equal to or greater than the response to the to the C.trachomatis peptides. The amino acid substitutions in position two(i.e., Asp for Glu) and position four (i.e., Cys for Ser) did not alterthe proliferative response of the T-cells and therefore demonstratingthis epitope to be a cross-reactive epitope between C. trachomatis andC. pneumoniae.

EXAMPLE 8 Immune Responses of Human PBMC and T-Cell Lines AgainstChlamydia Antigens

The examples provided herein suggest that there is a population ofhealthy donors among the general population that have been infected withC. trachomatis and generated a protective immune response controllingthe C. trachomatis infection. These donors remained clinicallyasymptomatic and seronegative for C. trachomatis. To characterize theimmune responses of normal donors against chlamydial antigens which hadbeen identified by CD4 expression cloning, PBMC obtained from 12 healthydonors were tested against a panel of recombinant chlamydial antigensincluding C. trachomatis-, C. pneumoniae-SWIB and C. trachomatis-, C.pneumoniae-S13. The data are summarized in Table I below. All donorswere seronegative for C. trachomatis, whereas 6/12 had a positive C.pneumoniae titer. Using a stimulation index of >4 as a positiveresponse, 11/12 of the subjects responded to C. trachomatis elementarybodies and 12/12 responded to C. pneumoniae elementary bodies. Onedonor, AD104, responded to recombinant C. pneumoniae-S13 protein, butnot to recombinant C. trachomatis-S13 protein, indicating a C.pneumoniae-specific response. Three out of 12 donors had a C.trachomatis-SWIB, but not a C. pneumoniae-SWIB specific response,confirming a C. trachomatis infection. C. trachomatis and C.pneumoniae-S13 elicited a response in 8/12 donors suggesting achlamydial infection. These data demonstrate the ability of SWIB and S13to elicit a T-cell response in PBMC of normal study subjects.

TABLE I Immune response of normal study subjects against ChlamydiaChlamydia CT CP CT CP CT CP CT CT Donor Sex IgGtiter EB EB Swib Swib S13S13 lpdA TSA AD100 male negative ++ +++ + − ++ ++ − n.t. AD104 femalenegative +++ ++ − − − ++ − n.t. AD108 male CP 1:256 ++ ++ + +/− + + +n.t. AD112 female negative ++ ++ + − + − +/− n.t. AD120 male negative− + − − − − − n.t. AD124 female CP 1:128 ++ ++ − − − − − n.t. AD128 maleCP 1:512 + ++ − − ++ + ++ − AD132 female negative ++ ++ − − + + − −AD136 female CP 1:128 + ++ − − +/− − − − AD140 male CP 1:256 ++ ++ −− + + − − AD142 female CP 1:512 ++ ++ − − + + + − AD146 female negative++ ++ − − ++ + + − CT = Chlamydia trachomatis; CP = Chlamydiapneumoniae; EB = Chlamydia elementary bodies; Swib = recombinantChlamydia Swib protein; S13 = recombinant Chlamydia S13 protein; lpdA =recombinant Chlamydia lpdA protein; TSA = recombinant Chlamydia TSAprotein. Values represent results from standard proliferation assays.Proliferative responses were determined by stimulating 3 × 10⁵ PBMC with1 × 10⁴ monocyte-derived dendritic cells pre-incubated with therespective recombinant antigens or elementary bodies (EB). Assays wereharvested after 6 days with a ³H-thymidine pulse for the last 18 h. SI:Stimulation index +/−: SI ~4 +: SI > 4 ++: SI 10-30 +++: SI > 30

In a first series of experiments, T-cell lines were generated from ahealthy female individual (CT-10) with a history of genital exposure toC. trachomatis by stimulating T-cells with C. trachomatis LGV IIelementary bodies as previously described. Although the study subjectwas exposed to C. trachomatis, she did not seroconvert and did notdevelop clinical symptoms, suggesting donor CT-10 may have developed aprotective immune response against C. trachomatis. As shown in FIG. 10,a primary Chlamydia-specific T-cell line derived from donor CT-10responded to C. trachomatis-SWIB, but not C. pneumoniae-SWIB recombinantproteins, confirming the exposure of CT-10 to C. trachomatis. Epitopemapping of the T-cell response to C. trachomatis-SWIB showed that thisdonor responded to the same epitope Ct-SWIB 52-67 (SEQ ID NO: 39) asT-cell line TCL-8, as shown in FIG. 11.

Additional T-cell lines were generated as described above for various C.trachomatis patients. A summary of the patients' clinical profile andproliferative responses to various C. trachomatis and C. pneumoniaeelementary bodies and recombinant proteins are summarized in Table II asfollows:

Proliferative response of C. trachomatis patients Clinical CT CP CT CPCT CP CT CT Patients manifestation IgG titer EB EB Swib Swib S13 S13lpdA TSA CT-1 NGU negative + + − − ++ ++ ++ + CT-2 NGU negative ++ ++ −− + +/− − − CT-3 asymptomatic Ct 1:512 + + − − + − + − shed Eb Cp 1:1024Dx was HPV Cps 1:256 CT-4 asymptomatic Ct 1:1024 + + − − − − − − shed EbCT-5 BV Ct 1:256 ++ ++ − − + − − − Cp 1:256 CT-6 perinial rash Cp1:1024 + + − − − − − − discharge CT-7 BV Ct 1:512 + + − − + + + −genital ulcer Cp 1:1024 CT-8 Not known Not tested ++ ++ − − − − − − CT-9asymptomatic Ct 1:128 +++ ++ − − ++ + + − Cp 1:128 CT-10 Itch mildvulvar negative ++ ++ − − − − − − CT-11 BV, Ct 1:512 +++ +++ − − +++ +/−++ + abnormal pap CT-12 asymptomatic Cp 1:512 ++ ++ − − ++ + + − NGU =Non-Gonococcal Urethritis; BV = Bacterial Vaginosis; CT = Chlamydiatrachomatis; CP = Chlamydia pneumoniae; EB = Chlamydia elementarybodies; Swib = recombinant Chlamydia Swib protein; S13 = recombinantChlamydia S13 protein; lpdA = recombinant Chlamydia lpdA protein; TSA =recombinant Chlamydia TSA protein Values represent results from standardproliferation assays. Proliferative responses were determined bystimulating 3 × 10⁵ PBMC with the respective recombinant antigens orelementary bodies (EB). Assays were harvested after 6 days with a³H-thymidine pulse for the last 18 hours. SI: Stimulation index +/−: SI~4 +: SI > 4 ++: SI 10-30 +++: SI > 30

Using the panel of asymptomatic (as defined above) study subjects and C.trachomatis patients, as summarized in Tables I and TI, a comprehensivestudy of the immune responses of PBMC derived from the two groups wasconducted. Briefly, PBMCs from C. pneumoniae patients as well as fromnormal donors are cultured in medium comprising RPMI 1640 supplementedwith 10% pooled human serum and 50 μg/ml gentamicin. Purifiedpolypeptides, a panel of recombinant chlamydial antigens including C.trachomatis-, C. pneumoniae-SWIB and S13, as well as. C. trachomatislpdA and TSA are added in duplicate at concentrations of 0.5 to 10μg/mL. After six days of culture in 96-well round-bottom plates in avolume of 200 μl, 50 μl of medium is removed from each well fordetermination of IFN-γ levels, as described below. The plates are thenpulsed with 1 μCi/well of tritiated thymidine for a further 18 hours,harvested and tritium uptake determined using a gas scintillationcounter. Fractions that result in proliferation in both replicates threefold greater than the proliferation observed in cells cultured in mediumalone are considered positive.

Proliferative responses to the recombinant Chlamydiae antigensdemonstrated that the majority of asymptomatic donors and C. trachomatispatients recognized the C. trachomatis S13 antigen (8/12) and a majorityof the C. trachomatis patients recognized the C. pneumonia S13 antigen(8/12), with 4/12 asymptomatic donors also recognizing the C. pneumoniaS13 antigen. Also, six out of twelve of the C. trachomatis patients andfour out of twelve of the asymptomatic donors gave a proliferativeresponse to the lpdA antigen of C. trachomatis. These resultsdemonstrate that the C. trachomatis and C. pneumonia S13 antigen, C.trachomatis Swib antigen and the C. trachomatis lpdA antigen arerecognized by the asymptomatic donors, indicating these antigens wererecognized during exposure to Chlamydia and an immune response elicitedagainst them. This implies these antigens may play a role in conferringprotective immunity in a human host. In addition, the C. trachomatis andC. pneumonia S13 antigen is recognized equally well among the C.trachomatis patients, therefore indicating there may be epitopes sharedbetween C. trachomatis and C. pneumonia in the S13 protein. Table IIIsummarizes the results of these studies.

TABLE III Antigen Normal Donors C.t. Patients C.t.-Swib 3/12 0/12C.p.-Swib 0/12 0/12 C.t.-S13 8/12 8/12 C.p.-S13 4/12 8/12 lpdA 4/12 6/12TSA 0/12 2/12

A series of studies were initiated to determine the cellular immuneresponse to short-term T-cell lines generated from asymptomatic donorsand C. trachomatis patients. Cellular immune responses were measured bystandard proliferation assays and IFN-γ, as described in Example 7.Specifically, the majority of the antigens were in the form of single E.coli clones expressing Chlamydial antigens, although some recombinantproteins were also used in the assays. The single E. coli clones weretitered on 1×¹⁰⁴ monocyte-derived dendritic cells and after two hours,the culture was washed and 2.5×¹⁰⁴ T-cells were added. The assay usingthe recombinant proteins were performed as previously described.Proliferation was determined after four days with a standard³H-thymidine pulse for the last 18 hours. Induction of IFN-γ wasdetermined from culture supernatants harvested after four days usingstandard ELISA assays, as described above. The results show that all theC. trachomatis antigens tested, except for C.T. Swib, elicited aproliferative response from one or more different T-cell lines derivedform C. trachomatis patients. In addition, proliferative responses wereelicited from both the C. trachomatis patients and asymptomatic donorsfor the following Chlamydia genes, CT622, groEL, pmpD, CT610 and rS13.

The 12G3-83 clone also contains sequences to CT734 and CT764 in additionto CT622, and therefore these gene sequence may also have immunoreactiveepitopes. Similarly, clone 21G12-60 contains sequences to thehypothetical protein genes CT229 and CT228 in addition to CT875; and15H2-76 also contains sequences from CT812 and CT088, as well as sharinghomology to the sycE gene. Clone 11H3-61 also contains sequences sharinghomology to the PGP6-D virulence protein.

TABLE IV C. t. TCL from TCL from Antigen Asymp. C. t. Clone (putative*)Donors Patients SEQ ID NO: 1B1-66 (E. coli) Swib 2/2 0/4 5 1B1-66(protein) Swib 2/2 0/4 5 12G3-83 (E. coli) CT622* 2/2 4/4 57 22B3-53 (E.coli) groEL ½ 4/4 111 22B3-53 (protein) groEL ½ 4/4 111 15H2-76 (E.coli) PmpD* ½ 3/4 87 11H3-61 (E. coli) rL1* 0/2 3/4 60 14H1-4 (E. coli)TSA 0/2 3/4 56 14H1-4 (protein) TSA 0/2 3/4 56 11G10-46 (E. coli) CT610½ 1/4 62 10C10-17 (E. coli) rS13 ½ 1/4 62 10C10-17 (protein) rS13 ½ 1/462 21G12-60 (E. coli) CT875* 0/2 2/4 110 11H4-32 (E. coli) dnaK 0/2 2/459 21C7-8 (E. coli) dnaK 0/2 2/4 115 17C10-31 (E. coli) CT858 0/2 2/4114

EXAMPLE 9 Protection Studies Using Chlamydia Antigens

1. SWIB

Protection studies were conducted in mice to determine whetherimmunization with chlamydial antigens can impact on the genital tractdisease resulting from chlamydial inoculation. Two models were utilized;a model of intravaginal inoculation that uses a human isolate containinga strain of Chlamydia psittaci (MTW447), and a model of intrauterineinoculation that involves a human isolate identified as Chlamydiatrachomatis, serovar F (strain NI1). Both strains induce inflammation inthe upper genital tract, which resemble endometritis and salpingitiscaused by Chlamydia trachomatis in women. In the first experiment, C3Hmice (4 mice per group) were immunized three times with 100 μg ofpcDNA-3 expression vector containing C. trachomatis SWIB DNA (SEQ ID NO:1, with the corresponding amino acid sequence provided in SEQ ID NO: 5).Inoculations were at the base of the tail for systemic immunization. Twoweeks after the last immunization, animals were progesterone treated andinfected, either thru the vagina or by injection of the inoculum in theuterus. Two weeks after infection, the mice were sacrificed and genitaltracts sectioned, stained and examined for histopathology. Inflammationlevel was scored (from + for very mild, to +++++ for very severe).Scores attributed to each single oviduct/ovary were summed and dividedby the number of organs examined to get a mean score of inflammation forthe group. In the model of uterine inoculation, negativecontrol-immunized animals receiving empty vector showed consistentinflammation with an ovary/oviduct mean inflammation score of 6.12, incontrast to 2.62 for the DNA-immunized group. In the model of vaginalinoculation and ascending infection, negative control-immunized mice hadan ovary/oviduct mean inflammation score of 8.37, versus 5.00 for theDNA-immunized group. Also, in the later model, vaccinated mice showed nosigns of tubal occlusion while negative control vaccinated groups hadinflammatory cells in the lumen of the oviduct

In a second experiment, C3H mice (4 mice per group) were immunized threetimes with 50 μg of pcDNA-3 expression vector containing C. trachomatisSWIB DNA (SEQ ID NO: 1, with the corresponding amino acid sequenceprovided in SEQ ID NO: 5) encapsulated in Poly Lactide co-Glycolidemicrospheres (PLG); immunizations were made intra-peritoneally. Twoweeks after the last immunization, animal were progesterone treated andinfected by inoculation of C. psittaci in the vagina. Two weeks afterinfection, mice were sacrificed and genital tracts sectioned, stainedand examined for histopathology. Inflammation level was scored aspreviously described. Scores attributed to each single oviduct/ovarywere summed and divided by the number of examined organs to get a meanof inflammation for the group. Negative control-immunized animalsreceiving PLG-encapsulated empty vector showed consistent inflammationwith an ovary/oviduct mean inflammation score of 7.28, versus 5.71 forthe PLG-encapsulated DNA immunized group. Inflammation in the peritoneumwas 1.75 for the vaccinated group versus 3.75 for the control.

In a third experiment, C3H mice (4 per group) were immunized three timeswith 10 μg of purified recombinant protein, either SWIB (SEQ ID NO: 1,with the corresponding amino acid sequence provided in SEQ ID NO: 5, orS13 (SEQ ID NO: 4, with the corresponding amino acid sequence providedin SEQ ID NO: 12) mixed with Cholera Toxin (CT); the preparation wasadministered intranasally upon anaesthesia in a 20 uL volume. Two weeksafter the last immunization, animal were progesterone treated andinfected, either by vaginal inoculation of C. psittaci or by injectionof C. trachomatis serovar F in the uterus. Two weeks after infection,the mice were sacrificed and genital tracts sectioned, stained andexamined for histopathology. The degree of inflammation was scored asdescribed above. Scores attributed to each single oviduct/ovary weresummed and divided by the number of examined organs to get a mean scoreof inflammation for the group. In the model of uterine inoculation,negative control-immunized animals receiving cholera toxin alone showedan ovary/oviduct mean inflammation score of 4.25 (only 2 mice analyzed;2 other died) versus 5.00 for the s13 plus cholera toxin-immunizedgroup, and 1.00 for the SWIB plus cholera toxin. Untreated infectedanimals had an ovary/oviduct mean inflammation score of 7. In the modelof vaginal inoculation and ascending infection, negativecontrol-immunized mice had an ovary/oviduct mean inflammation score of7.37 versus 6.75 for the s13 plus cholera toxin-immunized group and 5.37for the SWIB plus cholera toxin-immunized group. Untreated infectedanimals had an ovary/oviduct mean inflammation score of 8.

The three experiments described above suggest that SWIB-specificprotection is obtainable. This protective effect is more marked in themodel of homologous infection but is still present when in aheterologous challenge infection with C. psittaci.

2. CT529/Cap1

CT529/Cap1 was identified earlier as a product from Chlamydia thatstimulates CD8+ CTL. In this example, we sought to confirm thatimmunization with Cap1 would be protective in an animal model ofchlamydia infection.

To generate recombinant vaccinia virus for delivery of a Cap1immunogenic fragment, a DNA fragment containing a modified Kozaksequence and base pairs 319-530 of the cap1 gene (CT529) was amplifiedfrom C. trachomatis L2 genomic DNA using PCR™ and ligated into pSC11ss(Earl P L, Koenig S, Moss B (1991) Biological and immunologicalproperties of human immunodeficiency virus type 1 envelope glycoprotein:analysis of proteins with truncations and deletions expressed byrecombinant vaccinia viruses. J. Virol. 65:31-41). DNA digested withSalI and StuI. The portion of the cap1 gene ligated into pSC11ss encodesamino acids 107-176 of Cap1 protein, containing the previouslyidentified CTL epitope of amino acids 139-147. The resulting plasmid wasused to transfect CV-1 cells (ATCC# CCL-70; Jensen F C et al. (1964)Infection of human and simian tissue cultures with Rous Sarcoma Virus.Proc. Natl. Acad. Sci. USA 52: 53-59.) which were subsequently infectedwith wild-type vaccinia virus. Homologous recombination between thewild-type virus and plasmid DNA generated recombinant vaccinia viruseswhich were selected on the basis of both beta-galactosidase expressionand the inactivation of thymidine kinase, as described previously(Chakrabarti et al, Mol Cell Biol. 1985, 5(12):3403-9). Recombinantvirus was plaque purified three times and titered after growth in humanTK-143B cells. Virus preparations were treated with equal volume of 0.25mg/ml trypsin for 30 mins. at 37° C. and diluted in PBS prior toimmunization of mice. Groups of 5 mice were used for all experimentaland control groups. The data presented below are representative of threeindependent experiments.

A group of mice was immunized with 10⁶ of the recombinant vaccinia i.p.and was allowed to recover for 3 weeks. Negative control groups wereimmunized with either buffer alone or wild-type vaccinia. As a positivecontrol, a group of mice was infected i.v. with 10⁶ i.f.u. of C.trachomatis. The number of organisms given to the positive control grouphas been previously shown to be cleared within 2 weeks. After 3 weeks,animals in each of the groups were challenged i.v. with 106 i.f.u. of C.trachomatis. Three days after challenge the mice were sacrificed and thenumber of i.f.u. per spleen was determined.

The mean number of organisms found in the spleens of animals immunizedwith the vaccinia virus expressing Cap1 (7.1×10⁴) was 2.6-fold fewer(p<0.01; Wilcoxon's-Rank Sum analysis) than animals in the controlgroups immunized with either buffer (1.8×10⁵) or wild-type vaccinia(1.9×10⁵). Animals in the positive group had 77-fold fewer organisms(2.4×103) per spleen than animals in the negative control groups(p<0.01; Wilcoxon's-Rank Sum analysis). These data demonstrate thatimmunization with an immunogenic fragment of Cap1 can afford astatistically significant level of protection against C. trachomatisinfection.

EXAMPLE 10 Pmp/Ra12 Fusion Proteins

Various Pmp/Ra12 fusion constructs were generated by first synthesizingPCR fragments of a Pmp gene using primers containing a Not I restrictionsite. Each PCR fragment was then ligated into the NotI restriction siteof pCRX1. The pCRX1 vector contains the 6HisRa12 portion of the fusion.The Ra12 portion of the fusion construct encodes a polypeptidecorresponding to amino acid residues 192-323 of Mycobacteriumtuberculosis MTB32A, as described in U.S. Patent Application 60/158,585,the disclosure of which is incorporated herein by reference. The correctorientation of each insert was determined by its restriction enzymepattern and its sequence was verified. Multiple fusion constructs weremade for PmpA, PmpB, PmpC, PmpF and PmpH, as described further below:

PmpA Fusion Proteins

PmpA is 107 kD protein containing 982 aa and was cloned from serovar E.The PmpA protein was divided into 2 overlapping fragments, thePmpA(N-terminal) and (C-terminal) portions.

PmpA(N-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 306) GAGAGCGGCCGCTCATGTTTATAACAAAGGAACTTATG (SEQ ID NO: 307)GAGAGCGGCCGCTTACTTAGGTGAGAAGAAGGGAGTTTCrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 308, encoding a 66 kD protein (619aa) expressing thesegment 1-473 aa of PmpA. The amino acid sequence of the fusion proteinis set forth in SEQ ID NO: 309.

PmpA(C-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 310) GAGAGCGGCCGCTCCATTCTATTCATTTCTTTGATCCTG (SEQ ID NO:311) GAGAGCGGCCGCTTAGAAGCCAACATAGCCTCCrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 312, encoding a 74 kD protein (691aa) expressing thesegment 438-982 aa of PmpA. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 313.

PmpF Fusion Proteins

PmpF is 112 kD protein containing 1034 aa and was cloned from theserovar E. PmpF protein was divided into 2 overlapping fragments, thePmpF(N-term) and (C-term) portions.

PmpF(N-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 314) GAGAGCGGCCGCTCATGATTAAAAGAACTTCTCTATCC (SEQ ID NO: 315)GAGAGCGGCCGCTTATAATTCTGCATCATCTTCTATGGCrespectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 316, encoding a 69 kD protein (646aa) expressing the segment1-499 aa of PmpF. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 317.

PmpF(C-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 318) GAGAGCGGCCGCTCGACATACGAACTCTGATGGG (SEQ ID NO: 319)GAGAGCGGCCGCTTAAAAGACCAGAGCTCCTCC

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 320, encoding a 77 kD protein (715aa) expressing the segment466-1034aa of PmpF. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 321.

PmpH Fusion Proteins

PmpH is 108 kD protein containing 1016 aa and was cloned from theserovar E. PmpH protein was divided into 2 overlapping fragments, thePmpH(N-term) and (C-term) portions.

PmpH(N-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 322) GAGAGCGGCCGCTCATGCCTTTTTCTTTGAGATCTAC (SEQ ID NO: 323)GAGAGCGGCCGCTTACACAGATCCATTACCGGACTG

respectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 324, encoding a 64 kD protein (631aa) expressing the segment1-484 aa of PmpH. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 325. The donor line CHH037 was found to be reactiveagainst this protein.

PmpH(C-term) was amplified by the sense and antisense primers:

(SEQ ID NO: 326) GAGAGCGGCCGCTCGATCCTGTAGTACAAAATAATTCAGC (SEQ ID NO:327) GAGAGCGGCCGCTTAAAAGATTCTATTCAAGCCrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 328, encoding a 77 kD protein (715aa) expressing thesegment 449-1016aa of PmpH. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 329. The patient line CT12 was foundto be reactive in response to this protein.

PmpB Fusion Proteins

PmpB is 183 kD protein containing 1750 aa and was cloned from theserovar E. PmpB protein was divided into 4 overlapping fragments,PmpB(1), (2), (3) and (4).

PmpB(1) was amplified by the sense and antisense primers:

(SEQ ID NO: 330) GAGAGCGGCCGCTCATGAAATGGCTGTCAGCTACTGCG (SEQ ID NO: 331)GAGAGCGGCCGCTTACTTAATGCGAATTTCTTCAAGrespectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 332, and encodes is a 53 kD protein (518aa) expressing thesegment 1-372 aa of PmpB. The amino acid sequence of the fusion proteinis set forth in SEQ ID NO: 333.

PmpB(2) was amplified by the sense and antisense primers:

(SEQ ID NO: 334) GAGAGCGGCCGCTCGGTGACCTCTCAATTCAATCTTC (SEQ ID NO: 335)GAGAGCGGCCGCTTAGTTCTCTGTTACAGATAAGGAGACrespectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 336 and encodes a 60 kD protein (585aa) expressing the segment330-767 aa of PmpB. The amino acid sequence of the fusion protein is setforth in SEQ ID NO: 337. Cell lines derived from patient lines CT1, CT3,CT4 responded to this recombinant pmpB protein.

PmpB(3) was amplified by the sense and antisense primers:

(SEQ ID NO: 338) GAGAGCGGCCGCTCGACCAACTGAATATCTCTGAGAAC (SEQ ID NO: 339)GAGCGGCCGCTTAAGAGACTACGTGGAGTTCTGrespectively. The resulting fusion has a DNA sequence set forth in SEQID NO: 340 encodes a 67 kD protein (654aa) expressing the segment732-1236 aa of PmpB. The amino acid sequence of the fusion protein isset forth in SEQ ID NO: 341 PmpB(4) was amplified by the sense andantisense primers:

(SEQ ID NO: 342) GAGAGCGGCCGCTCGGAACTATTGTGTTCTCTTCTG (SEQ ID NO: 343)GAGAGCGGCCGCTTAGAAGATCATGCGAGCACCGCrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 344 encodes a 76 kD protein (700aa) expressing thesegment 1160-1750 of PmpB. The amino acid sequence of the fusion proteinis set forth in SEQ ID NO: 345.

PmpC Fusion Proteins

PmpC is 187 kD protein containing 1774 aa and was cloned from theserovar E/L2. PmpC protein was divided into 3 overlapping fragments,PmpC(1), (2) and (3).

PmpC(1) was amplified by the sense and antisense primers:

(SEQ ID NO: 346) GAGAGCGGCCGCTCATGAAATTTATGTCAGCTACTGC (SEQ ID NO: 347)GAGAGCGGCCGCTTACCCTGTAATTCCAGTGATGGTCrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 348 and encodes a 51 kD protein (487aa) expressingthe segment 1-340 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 349.

PmpC(2) was amplified by the sense and antisense primers:

(SEQ ID NO: 350) GAGAGCGGCCGCTCGATACACAAGTATCAGAATCACC (SEQ ID NO: 351)GAGAGCGGCCGCTTAAGAGGACGATGAGACACTCTCGrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 352 and encodes a 60 kD protein (583aa) expressingthe segment 305-741 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 353.

PmpC(3) was amplified by the sense and antisense primers:

(SEQ ID NO: 354) GAGAGCGGCCGCTCGATCAATCTAACGAAAACACAGACG (SEQ ID NO:355) GAGAGCGGCCGCTTAGACCAAAGCTCCATCAGCAACrespectively. The resulting fusion construct has a DNA sequence setforth in SEQ ID NO: 356 and encodes a 70 kD protein (683aa) expressingthe segment 714-1250 aa of PmpC. The amino acid sequence of the fusionprotein is set forth in SEQ ID NO: 357.

EXAMPLE 11 Immunogenicity of CT622

Chlamydia-specific T cells lines were generated from two patients withChlamydia infections and the lines were designated CT1 and CT13. The Tcell lines were either generated against monocyte-derived dendriticcells infected C. trachomatis serovar E for 72 hours (CT1-ERB) oragainst killed serovar E elementary bodies (EB) (CT13-EEB). Oncegenerated, the lines were tested against the recombinantChlamydia-specific protein, CT622 in a proliferation assay.Proliferation assays were performed by stimulating 2.5×10⁴ T cells inthe presence of 1×10⁴ monocyte-derived dendritic cells with eitherrecombinant CT antigens (2 μg/ml) or Chlamydia EBs (1 g/ml). The assaywas incubated for 4 days with a ³H-thymidine pulse for the last 18hours.

The cell line CT1-ERB demonstrated proliferative responses significantlyabove the media controls when stimulated with CT622, CT875, and CT EB.The cell line CT13-EEB demonstrated a proliferative responsesignificantly above media controls when stimulated with CT622, CT875,and CT EB (see FIG. 12).

EXAMPLE 12 Cloning and Expression of Full Length Chlamydia TrachomatisGenes CT611, ORF3 and OppA1

Recombinant protein expression of the full-length open reading frameswas performed for clones containing genes CT611, ORF-3, and oppA1. Theclones that contained the genes of interest were CtL2-8 (SEQ ID NO:285)which encoded 4 ORFs (CT474, CT473, CT060, and CT139), CtL2-10 (SEQ IDNO:284) which encoded the ORFs of CT610 and CT611, and clones 16CtL2-16(SEQ ID NO:47), 16-D4-22 (SEQ ID NO: 119) and 19-A5-54 (SEQ ID NO:84)which all contained sequences related to ORF-3. Sequences within CtL2-10(Ct-610) and CtL2-16 (ORF-3) were also independently identified by theT-cell expression cloning approach. The clone CtL2-8 was furtherinvestigated as this clone had stimulated the proliferative responsesand IFN-gamma production by two T cell lines generated against serovarE.

Cloning and expression of clone sequences:

CtL2-10 was found to encode two open reading frames (ORFs), CT610 andCT611, and these were found organized adjacent to each other within thegenomic clone. The full length ORF of CT610 (containing a PQQ synthesisdomain) was previously expressed and demonstrated to stimulate theproliferative responses of T cell lines generated against Chlamydia. Todetermine whether the second ORF, CT611, was also recognized by T cells,the full-length sequence of CT611 was PCR amplified and engineered forprotein expression. The nucleotide sequence is disclosed in SEQ IDNO:361 with the corresponding amino acid sequence disclosed in SEQ IDNO:365.

The second serological clone, CtL2-8, was found to contain 4 ORFs(CT474, CT473, CT060, and CT139). Overlapping peptides to the threesmallest predicted ORFs (CT474, CT473, and CT060) did not stimulate theproliferative responses of T cell lines. This suggested that theimmunostimulatory antigen resides in the fourth ORF, CT139. The ORF ofCT139 is approximately 450 nucleotides. The full-length nucleotidesequence is disclosed in SEQ ID NO:359 and the full-length amino acidsequence is disclosed in SEQ ID NO:363. Amino acid sequence comparisonfrom Genbank revealed that it is an oligo-peptide binding protein(oppA1) as well as belonging to the peptide ABC transporter family. Thisprotein is 462 amino acids long with a predicted size of 48.3 kDa andappears to contain 2 trans-membrane regions.

To express the full-length sequence of oppA1, oligonucleotides weredesigned which specifically amplified sequences starting from amino acidresidue 22 (devoid of the first transmembrane domain), the nucleotidesequence for which is disclosed in SEQ ID NO:358 and, the amino acidsequence of which is disclosed in SEQ ID NO:362. This was shown toexpress the protein in E. coli.

The full-length cloning and recombinant protein expression of ORF-3 wasalso achieved. The nucleotide and amino acid sequences are disclosed inSEQ ID NOs:360 and 364, respectively.

EXAMPLE 13 Recombinant Chlamydial Antigens Recognized by T Cell Lines

Patient T cell lines were generated from the following donors: CT1, CT2,CT3, CT4, CT5, CT6, CT7, CT8, CT9, CT10, CT11, CT12, CT13, CT14, CT15,and CT16, some of which were discussed above. A summary of their detailsis included in Table V.

TABLE V C. trachomatis patients Gen- Clinical IgG Multiple Patients derAge Manifestation Serovar titer Infections CT1 M 27 NGU LCR Negative NoCT2 M 24 NGU D Negative E CT3 M 43 Asymptomatic J Ct 1:512 No Shed Eb CpDx was HPV 1:1024 Cps 1:256 CT4 F 25 Asymptomatic J Ct Y Shed Eb 1:1024CT5 F 27 BV LCR Ct 1:256 F/F Cp 1:256 CT6 M 26 Perinial rash G Cp NDischarge, 1:1024 dysuria CT7 F 29 BV E Ct 1:512 N Genital ulcer Cp1:1024 CT8 F 24 Not Known LCR Not NA tested CT9 M 24 asymptomatic LCR Ct1:128 N Cp 1:128 CT10 F 20 Mild itch negative negative 12/1/98 vulvarCT11 F 21 BV J Ct 1:512 F/F/J/E/E Abnormal pap PID June smear 6/96 CT12M 20 asymptomatic LCR Cp N 1:512 CT13 F 18 BV, gonorrhea, G Ct N Ctvaginal 1:1024 discharge, dysuria CT14 M 24 NGU LCR Ct 1:256 N Cp 1:256CT15 F 21 Muco-purulint culture Ct 1:256 N cervicitis Ct IgM Vaginal1:320 discharge Cp 1:64 CT16 M 26 Asymptomatic/ LCR NA N contact CL8 M38 No clinical negative negative N history of disease NGU =Non-Gonococcal Urethritis; BV = Bacterial Vaginosis; CT = Chlamydiatrachomatis; Cp = Chlamydia pneumoniae; Eb = Chlamydia elementarybodies; HPV = human papiloma virus; Dx = diagnosis; PID = pelvicinflammatory disease; LCR = Ligase chain reaction.

PBMC were collected from a second series of donors and T cell lines havebeen generated from a sub-set of these. A summary of the details forthree such T cell lines is listed in the table below.

TABLE III Normal Donors Donor Gender Age CT IgG Titer CP IgG TiterCHH011 F 49 1:64 1:16 CHH037 F 22 0 0 CHH042 F 25 0 1:16

Donor CHH011 is a healthy 49 year old female donor sero-negative for C.trachomatis. PBMC produced higher quantities of IFN-gamma in response toC. trachomatis elementary bodies as compared to C. pneumoniae elementarybodies, indicating a C. trachomatis-specific response. Donor CHH037 is a22 year old healthy female donor sero-negative for C. trachomatis. PBMCproduced higher quantities of IFN-gamma in response to C. trachomatiselementary bodies as compared to C. pneumoniae elementary bodies,indicating a C. trachomatis-specific response. CHH042 is a 25 year oldhealthy female donor with an IgG titer of 1:16 to C. pneumoniae. PBMCproduced higher quantities of IFN-gamma in response to C. trachomatiselementary bodies as compared to C. pneumoniae elementary bodies,indicating a C. trachomatis-specific response.

Recombinant proteins for several Chlamydia trachomatis genes weregenerated as described above. Sequences for MOMP was derived fromserovar F. The genes CT875, CT622, pmp-B-2, pmpA, and CT529 were derivedfrom serovar E and sequences for the genes gro-EL, Swib, pmpD, pmpG,TSA, CT610, pmpC, pmpE, S13, lpdA, pmpI, and pmpH-C were derived fromLII.

Several of the patient and donor lines described above were testedagainst the recombinant Chlamydia proteins. Table IV summarizes theresults of the T cell responses to these recombinant Chlamydia proteins.

TABLE VII Recombinant Chlamydia Antigens Recognized By T Cell Lines #ofCHH011 CHH037 Antigen Serovar hits CL8L2 CT10 E CT1 E CT3 E CT4L2 CT5 ECT11 E CT12 E CT13 E E E gro-EL L2 10 − + + + + + + + + + + (CT110)MompF F 10 − + + + + + + + + + + (CT681) CT875 E 8 − + + − + + + + + − +SWIB L2 8 + + − + − + − + + + + (CT460) pmpD L2 5 − + + + + − − + + − −(CT812) pmpG L2 6 − + + − + + nt − + + − (CT871) TSA L2 6 − − + + + + −− + − + (CT603) CT622 E 3 − − + − + − − − + − − CT610 L2 3 − + − + − −− + − − − pmpB-2 E 3 − − + + + − − − − − − (CT413) pmpC L2 4 − − − + − +− + − − + (CT414) pmpE L2 3 − + + − − − − − + − − (CT869) S13 L2 2 + − −− + − − − − − − (CT509) lpdA L2 3 − − + + − − − − − + − (CT557) pmpI L22 − − + − − − − − − + − (CT874) pmpH-C L2 1 − − − − − − − + − − −(CT872) pmpA E 0 − − − − − − − − − − − (CT412) CT529 E 0 − − − − − − − −− − −

From the foregoing it will be appreciated that, although specificembodiments of the invention have been described herein for purposes ofillustration, various modifications may be made without deviating fromthe spirit and scope of the invention. Accordingly, the invention is notlimited except as by the appended claims.

1. An isolated polynucleotide comprising a sequence selected from thegroup consisting of: (a) sequences provided in SEQ ID NOs: 1-4, 15-16,21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120, 122, 124, 126, 128,130, 132, 134, 136, 169-174, 181-187, 263, 267-290, 291, 292, 358-361,366-385, 406-430, 455-489, 516, 517, 523, 524, 525-559, 582-594, 595,and 596; (b) complements of the sequences provided in SEQ ID NOs: 1-4,15-16, 21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120, 122, 124, 126,128, 130, 132, 134, 136, 169-174, 181-187, 263, 267-290, 291, 292,358-361, 366-385, 406-430, 455-489, 516, 517, 523, 524, 525-559,582-594, 595, and 596; (c) sequences consisting of at least 20contiguous residues of a sequence provided in SEQ ID NOs: 1-4, 15-16,21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120, 122, 124, 126, 128,130, 132, 134, 136, 169-174, 181-187, 263, 267-290, 291, 292, 358-361,366-385, 406-430, 455-489, 516, 517, 523, 524, 525-559, 582-594, 595,and 596; (d) sequences that hybridize to a sequence provided in SEQ IDNOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120, 122,124, 126, 128, 130, 132, 134, 136, 169-174, 181-187, 263, 267-290, 291,292, 358-361, 366-385, 406-430, 455-489, 516, 517, 523, 524, 525-559,582-594, 595, and 596, under highly stringent conditions; (e) sequenceshaving at least 95% identity to a sequence of SEQ ID NOs: 1-4, 15-16,21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120, 122, 124, 126, 128,130, 132, 134, 136, 169-174, 181-187, 263, 267-290, 291, 292, 358-361,366-385, 406-430, 455-489, 516, 517, 523, 524, 525-559, 582-594, 595,and 596; (f) sequences having at least 99% identity to a sequence of SEQID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76, 77, 78, 79-88, 110-120,122, 124, 126, 128, 130, 132, 134, 136, 169-174, 181-187, 263, 267-290,291, 292, 358-361, 366-385, 406-430, 455-489, 516, 517, 523, 524,525-559, 582-594, 595, and 596; and (g) degenerate variants of asequence provided in SEQ ID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76,77, 78, 79-88, 110-120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174,181-187, 263, 267-290, 291, 292, 358-361, 366-385, 406-430, 455-489,516, 517, 523, 524, 525-559, 582-594, 595, and
 596. 2. An isolatedpolypeptide comprising an amino acid sequence selected from the groupconsisting of: (a) sequences encoded by a polynucleotide of claim 1; (b)sequences having at least 95% identity to a sequence encoded by apolynucleotide of claim 1; and (c) sequences having at least 99%identity to a sequence encoded by a polynucleotide of claim
 1. 3. Anisolated polypeptide comprising at least an immunogenic fragment of apolypeptide sequence selected from the group consisting of: (a) apolypeptide sequence set forth in SEQ ID NOs: 5-14, 17-20, 26, 28, 30,31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91, 92-98, 99-102, 103-108, 109,121, 13, 125, 127, 129, 131, 133, 135, 137-158, 167, 168, 175-180,189-195, 224-235, 236-252, 253, 254-262, 264-266, 294-302, 305, 362-365,386-405, 431-454, 490-515, 518-522, 560-581, 597, 598, and 599; (b) apolypeptide sequence having at least 95% identity to a sequence setforth in SEQ ID NOs: 5-14, 17-20, 26, 28, 30, 31, 32, 34, 39, 40, 41,42, 43, 89, 90, 91, 92-98, 99-102, 103-108, 109, 121, 13, 125, 127, 129,131, 133, 135, 137-158, 167, 168, 175-180, 189-195, 224-235, 236-252,253, 254-262, 264-266, 294-302, 305, 362-365, 386-405, 431-454, 490-515,518-522, 560-581, 597, 598, and 599; and (c) a polypeptide sequencehaving at least 99% identity to a sequence set forth in SEQ ID NOs:5-14, 17-20, 26, 28, 30, 31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91,92-98, 99-102, 103-108, 109, 121, 13, 125, 127, 129, 131, 133, 135,137-158, 167, 168, 175-180, 189-195, 224-235, 236-252, 253, 254-262,264-266, 294-302, 305, 362-365, 386-405, 431-454, 490-515, 518-522,560-581, 597, 598, and
 599. 4. An expression vector comprising apolynucleotide of claim 1 operably linked to an expression controlsequence.
 5. A host cell transformed or transfected with an expressionvector according to claim
 4. 6. An isolated antibody, or antigen-bindingfragment thereof, that specifically binds to a polypeptide of any one ofclaims 2 or
 3. 7. A method for detecting the presence of Chlamydia in apatient, comprising the steps of: (a) obtaining a biological sample fromthe patient; (b) contacting the biological sample with a binding agentthat binds to a polypeptide of any one of claims 2 or 3; (c) detectingin the sample an amount of polypeptide that binds to the binding agent;and (d) comparing the amount of polypeptide to a predetermined cut-offvalue and therefrom determining the presence of Chlamydia in thepatient.
 8. A fusion protein comprising at least one polypeptideaccording to claim 2, claim 3, or any one of the polypeptide sequencesset forth in SEQ ID NOs: 309, 313, 317, 321, 325, 329, 333, 337, 341,345, 349, 353, and
 357. 9. An oligonucleotide that hybridizes to asequence recited in SEQ ID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76,77, 78, 79-88, 110-120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174,181-187, 263, 267-290, 291, 292, 358-361, 366-385, 406-430, 455-489,516, 517, 523, 524, 525-559, 582-594, 595, and 596 under highlystringent conditions.
 10. A method for stimulating and/or expanding Tcells specific for a Chlamydia protein, comprising contacting T cellswith at least one component selected from the group consisting of: (a) apolypeptide according to claim 2 or claim 3; (b) a polynucleotideaccording to claim 1; and (c) an antigen-presenting cell that expressesa polynucleotide according to claim 1, under conditions and for a timesufficient to permit the stimulation and/or expansion of T cells.
 11. Anisolated T cell population, comprising T cells prepared according to themethod of claim
 10. 12. A composition comprising a first componentselected from the group consisting of physiologically acceptablecarriers and immunostimulants, and a second component selected from thegroup consisting of: (a) a polypeptide according to claim 2 or claim 3;(b) a polynucleotide according to claim 1; (c) an antibody according toclaim 6; (d) a fusion protein according to claim 8; (e) a T cellpopulation according to claim 11; and (f) an antigen presenting cellthat expresses a polypeptide according to claim 2 or claim
 3. 13. Amethod for stimulating an immune response in a patient, comprisingadministering to the patient a composition selected from the groupconsisting of: (a) a composition of claim 12; (b) a polynucleotidesequence of any one of SEQ ID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76,77, 78, 79-88, 110-120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174,181-187, 263, 267-290, 291, 292, 358-361, 366-385, 406-430, 455-489,516, 517, 523, 524, 525-559, 582-594, 595, and 596; and (c) apolypeptide sequence of any one of SEQ ID NOs: 5-14, 17-20, 26, 28, 30,31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91, 92-98, 99-102, 103-108, 109,121, 13, 125, 127, 129, 131, 133, 135, 137-158, 167, 168, 175-180,189-195, 224-235, 236-252, 253, 254-262, 264-266, 294-302, 305, 362-365,386-405, 431-454, 490-515, 518-522, 560-581, 597, 598, and
 599. 14. Amethod for the treatment of Chlamydia infection in a patient, comprisingadministering to the patient a composition selected from the groupconsisting of; (a) a composition of claim 12; (b) a polynucleotidesequence of any one of SEQ ID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76,77, 78, 79-88, 110-120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174,181-187, 263, 267-290, 291, 292, 358-361, 366-385, 406-430, 455-489,516, 517, 523, 524, 525-559, 582-594, 595, and 596; and (d) apolypeptide sequence of any one of SEQ ID NOs: 5-14, 17-20, 26, 28, 30,31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91, 92-98, 99-102, 103-108, 109,121, 13, 125, 127, 129, 131, 133, 135, 137-158, 167, 168, 175-180,189-195, 224-235, 236-252, 253, 254-262, 264-266, 294-302, 305, 362-365,386-405, 431-454, 490-515, 518-522, 560-581, 597, 598, and
 599. 15. Amethod for determining the presence of Chlamydia in a patient,comprising the steps of: (a) obtaining a biological sample from thepatient; (b) contacting the biological sample with an oligonucleotideaccording to claim 9 or claim 19; (c) detecting in the sample an amountof a polynucleotide that hybridizes to the oligonucleotide; and (d)comparing the amount of polynucleotide that hybridizes to theoligonucleotide to a predetermined cut-off value, and thereforedetermining the presence of the cancer in the patient.
 16. A diagnostickit comprising at least one oligonucleotide according to claim
 9. 17. Adiagnostic kit comprising at least one antibody according to claim 6 anda detection reagent, wherein the detection reagent comprises a reportergroup.
 18. A method for the treatment of Chlamydia in a patient,comprising the steps of: (a) incubating CD4+ and/or CD8+ T cellsisolated from a patient with at least one component selected from thegroup consisting of: (i) a polypeptide according to any one of claims 2or 3; (ii) a polypeptide sequence of any one of SEQ ID NOs: 5-14, 17-20,26, 28, 30, 31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91, 92-98, 99-102,103-108, 109, 121, 13, 125, 127, 129, 131, 133, 135, 137-158, 167, 168,175-180, 189-195, 224-235, 236-252, 253, 254-262, 264-266, 294-302, 305,362-365, 386-405, 431-454, 490-515, 518-522, 560-581, 597, 598, and 599;(iii) a polynucleotide according to claim 1; (iv) a polynucleotidesequence of any one of SEQ ID NOs: 1-4, 15-16, 21-25, 27, 29, 33, 44-76,77, 78, 79-88, 110-120, 122, 124, 126, 128, 130, 132, 134, 136, 169-174,181-187, 263, 267-290, 291, 292, 358-361, 366-385, 406-430, 455-489,516, 517, 523, 524, 525-559, 582-594, 595, and 596; (v) an antigenpresenting cell that expresses a polypeptide sequence set forth in anyone of claims 2 or 3; (vi) an antigen presenting cell that expresses apolypeptide sequence of any one of SEQ ID NOs: 5-14, 17-20, 26, 28, 30,31, 32, 34, 39, 40, 41, 42, 43, 89, 90, 91, 92-98, 99-102, 103-108, 109,121, 13, 125, 127, 129, 131, 133, 135, 137-158, 167, 168, 175-180,189-195, 224-235, 236-252, 253, 254-262, 264-266, 294-302, 305, 362-365,386-405, 431-454, 490-515, 518-522, 560-581, 597, 598, and 599 such thatthe T cells proliferate; and (b) administering to the patient aneffective amount of the proliferated T cells.